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SUMMARY
Portasystemic shunting is an important consequence 
of all diseases that lead to portal hypertension. The 
clinical-pathological problems associated with 
portasystemic shunting, such as hepatic encephalopathy 
and oesophageal varices, remain a potent cause of much 
morbidity and mortality. The aetiology of hepatic 
encephalopathy remains poorly understood, but it is 
thought that the more subtle sequallae of portasystemic 
shunting, such as hormonal (Fischer et al, 1974), and 
nutritional (Phear et al, 1955; Fischer and 
Baldessarini, 1971) changes contribute in varying
degrees to the onset and progression of the condition. 
Quantitation of the magnitude of portasystemic shunting 
is thus potentially most useful in the study of hepatic 
encephalopathy.
Up to now it has not been practical to measure on a 
routine basis the fraction of portal blood that 
bypasses functioning hepatocytes to reach the systemic 
circulation. The available methods are either highly 
invasive (Okuda et al, 1977), time consuming (McLean et 
al, 1979), or suffer from known measurement 
inaccuracies (Porchet and Bircher, 1982; Cavanna et al, 
1987), and their applications have been limited to a 
few studies. The purpose of this thesis is to describe 
and assess a novel, non-invasive procedure that
18
approaches quantitative assessement of portasystemic 
shunting.
The principle of the method consists of a comparison of 
the systemic availability of an oral and intravenous 
dose of galactose. The ability of galactose to 
quantitate the magnitude of portasystemic shunting 
associated with portal hypertension has been examined 
in patients with documented oesophageal varices and in 
a rat model of prehepatic portal hypertension using 
partial portal vein ligation. The rat model had been 
established and characterised previously in the 
University Department of Surgery, Glasgow Royal 
Infirmary (Geraghty et al, 1989).
Data from the studies described in this thesis has 
shown a marked difference in the systemic availability 
of galactose between control patients and patients with 
liver disease and/or portal hypertension. In the former 
group only 14 percent of the oral dose appeared in the 
systemic circulation, whereas in portal hypertensive 
patients an average of 72 percent (range 38% to 108%) 
was detected systemically. The absence of a gold 
standard for portasystemic shunting measurements, and 
ambiguity in the definition of portasystemic shunting 
itself, preclude direct validation of the measurements 
in man. However, the key assumptions about galactose 
elimination kinetics underlying the measurement 
technique were tested independently and found to be
19
satisfied.
The initial application of the technique in the rat 
model of prehepatic portal hypertension, in which 
independent measurements of portasystemic shunting 
could be performed using a radioactive microsphere 
technique, failed to show a difference in the systemic 
availability of oral galactose between control and 
portal hypertensive rats. Further studies showed this 
was largely due to erratic and incomplete absorption of 
galactose from the gastrointestinal tract.
A more comprehensive investigation was carried out and 
the kinetics of hepatic galactose elimination in the 
rat was studied by direct infusion of galactose into 
the portal vein. From this it was shown that, in 
contrast to man, hepatic extraction efficiency in this 
animal model had a high dependence on circulating blood 
galactose concentrations. This compromised the accuracy 
of the technique for quantitation of portasystemic 
shunting in individual animals because of the 
variability in kinetic parameters. However, there was 
a highly significant correlation between the systemic 
availability of intraportally administered galactose in 
rats and portasystemic shunting as measured with 
radioactive microspheres.
The galactose technique described in this thesis may 
thus be regarded as a tool to assess the magitude of 
portasystemic shunting, and may have a role in the
20
study of the associated complications of 
hypertension and liver disease.
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INTRODUCTION
Portal hypertension is described as an elevation 
of pressure in the portal venous system, and is 
secondary to various disease processes which affect the 
liver and/or the portal vein. The elevation of pressure 
in the portal venous system precipitates the opening of 
venous channels which carry portal venous blood away 
from the liver directly into the systemic circulation. 
The development of portasystemic shunts, as they are 
known, are responsible for the eventual clinical 
manifestations of portal hypertension, as well as 
various other problems. Oesophageal vaices and hepatic 
encephalopathy are by far the most clinically 
significant complications of portasystemic shunting and 
both are a potent cause of much morbidity and 
mortality. Various other problems associated with 
portasystemic shunting are septicemia,
hypergammaglobulinemia, and drug toxicity.
Oesophageal varices are one of the many channels by 
which portal venous blood can be diverted into the 
systemic circulation and their rupture has been linked 
to the height of pressure in the portal venous system 
(Orloff et al, 1963). The more subtle sequellae of 
portasystemic shunting such as the diversion of gut- 
derived compounds, for example ammonia (Bollman, 1961) , 
and gastrointestinal hormones (Fischer et al, 1974)
23
into the systemic circulation are thought to explain, 
at least in part, the onset and development of hepatic 
encephalopathy. The aetiology of the condition, 
however, remains poorly understood. The possibility of 
gaining a fuller understanding into the onset and 
development of hepatic encephalopathy may be realised 
if a means of quantitating the magnitude of 
portasystemic shunting could be developed. Up to now it 
has not been practical on a routine basis to measure 
the amount of portal blood that bypasses functioning 
hepatocytes to enter the systemic circulation. Methods 
currently available are either highly invasive (Okuda 
et al, 1977) and time consuming (McLean et al, 1979). 
The aim of this thesis is to develop and assess a 
novel, non-invasive method by which the degree of 
diversion of portal blood into the systemic circulation 
can be quantitated. The method, described in a 
subsequent chapter, is assessed in control subjects and 
patients with portal hypertension, and in a rat model 
of prehepatic portal hypertension.
This review of the literature is aimed at describing 
the development of portasystemic shunting, discussing 
the consequences of a developed collateral 
circulation and its contribution to the maintenance of 
portal hypertension, and describing the attempts that 
have been made at quantitating the magnitude of 
portasystemic shunting.
24
The review is divided into five sections. The first two 
sections describe the circulation of blood in the 
normal liver and portal vein and detail the 
morphological changes that occur to both the portal 
vein and the liver with the development of portal 
hypertension. This is linked to the development of a 
collateral circulation.
The third section discusses the pathophysiology of 
portal hypertension emphasising that the maintenance of 
a chronically elevated portal venous pressure in the 
face of a developed collateral circulation 
may be the result of an increased splanchnic inflow. 
This increase in splanchnic blood flow appears to be 
linked to the diversion of vasoactive substances 
derived from the gastrointestinal tract and normally 
metabolised by the liver through portasystemic shunts. 
The consequences of portasystemic shunting are 
described in the fourth section of this review and 
emphasis is placed on the development of hepatic 
encephalopathy through nutritional and hormonal 
abberations. Also stressed is the fact that the 
potential clinical usefulness of quantitating 
portasystemic shunting is in the study of hepatic 
encephalopathy.
The final section of the historical review describes 
methods which have been used to quantitate the 
magnitude of portasystemic shunting. The relative
25
merits and drawbacks of these techniques are discussed 
and emphasised.
PORTAL AND LIVER CIRCULATION
The dual supply of blood to the liver is provided 
through the portal vein and the hepatic artery. The 
portal vein itself is composed of four large veins 
which collect the venous blood from the viscera of 
digestion i.e. the stomach, intestine and pancreas, and 
from the spleen. The hepatic artery in turn carries 
blood directly to the liver from the heart. Both 
vessels seperately enter the liver through the porta 
hepatis, wherein the portal vein and the hepatic artery 
divide into branches to the right and left lobes of the 
liver (Rappaport, 1976). Both the portal vein and the 
hepatic artery branch extensively until both the high 
pressure of the hepatic arterial stream (120mmHg) and 
the low pressure portal venous stream (9mmHg) are 
united at the inlets of the hepatic sinusoids, which 
are thought to be controlled by inlet sphincters 
(Rappaport, 1976). In addition to these principal blood 
flow conduits, there are presinusoidal intrahepatic 
connections between the hepatic arterial and portal 
venous branches, though which it is estimated that 3 0% 
of the hepatic arterial blood is shunted into the 
portal venous system before reaching the sinusoids 
(Rabinovici and Vardi, 1965). At this level the 
circulation to the hepatic acinus (a microvascular unit 
of the liver) consists of terminal branches of the
hepatic arteriole and portal venule. A cluster of 
parenchymal cells are grouped around this 
microcirculation, together with terminal branches of 
the hepatic venule, which eventually unite to form the 
hepatic vein and so return blood to the vena cava 
(Rappaport, 1973) .
The liver receives 25 percent of the cardiac output. Of 
the total hepatic blood flow 20 to 33 percent is 
supplied by the hepatic vein, the remaining two-thirds 
of the hepatic blood supply is portal venous blood 
(Lautt and Greenway, 1987). Liver blood flow 
measurements based upon the rate of disappearance of 
colloidal particles from peripheral blood, and 
bromsuphalein, indocyanine green, and galactose 
clearance have shown hepatic blood flow to range from 
1,200 to 1,663 ml/min (Keiding, 1988; Caesar et al, 
1961; Shaldon et al, 1961; Bradley et al, 1945). With 
the advent of more modern techniques, such as pulsed 
doppler flowmetry, it is now possible to continuously 
measure blood flows in the portal vein and the hepatic 
artery (Braillon and Brody, 1988).
Studies carried out in animals have suggested that 
blood flow in the portal vein may be streamlined 
(Copher and Dick, 1928). Three distinct and seperate
t
currents have been identified in dogs arising from 
three sources, namely, the splenic vein, the superior 
mesenteric vein and its branches and the inferior
28
mesenteric vein. More recent work in patients has 
produced similar findings (Sherlock, 1978), although 
variability of the streamlines in the portal vein 
appear to be commonly observed.
In comparison to the extrahepatic studies on the 
vessels supplying the liver, intrahepatic blood flow 
distribution studies are comparatively sparse. However, 
studies carried out in which microspheres were injected 
into either the portal vein or hepatic artery (Greenway 
and Stark, 1971) suggest that there are no gross 
differences between the lobes of the liver in the 
proportion of either arterial or portal venous blood 
received. Futher, elevation in venous pressure, 
reduction of portal venous flow and stimulation of 
hepatic nerves or noradrenaline infusion do not result 
in flow redistribution within the liver (Gumucio, 1983; 
Greenway et al, 1972; Cousineau et al, 1985).
As flow in any vessel is a function of both pressure 
and resistance to flow, then liver blood flow can be 
influenced by hepatic arterial vascular resistance, the 
vascular resistance of the intestine, which governs the 
inflow of blood into the portal vein and intrahepatic 
portal vascular resistance.
Portal blood flow is exclusively determined by events 
in the splenic and gastrointestinal beds and not by 
events occuring in the liver (Greenway and Stark, 
1971). Indeed the resistance that the splanchnic organs
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offer to blood flow by far exceeds that offered by the 
liver, hence the resistance by the splanchnic organs to 
blood entering the portal vein has the dominant 
influence on portal blood flow. The only control of 
blood flow within the liver is via the hepatic artery. 
The factors which influence hepatic arterial resistance 
are thought to be both intrinsic and extrinsic in 
nature. However, as yet these factors have not been 
completely clarified (Greenway and Stark, 1971; Lautt 
and Greenway, 1987).
The inter-relationship of both the portal vein and the 
hepatic artery further serves to regulate blood flow. 
Ternberg and Butcher (1965) measured hepatic arterial 
and portal venous blood flows in the dog using
electromagnetic flow meters, and demonstrated that a 
decrease in portal venous blood flow was associated
with an increase in the hepatic arterial blood flow. 
The reciprocal relationship between portal and hepatic 
arterial flow is not only maintained but is enhanced in 
portal hypertension (Baker et al, 1974; Zimmon and 
Kessler, 1980). The mechanism behind the reciprocity 
however, is not yet understood, but it is thought that
the hepatic artery may serve as a buffer for flow
changes in the portal vein in a manner that tends to 
maintain a haemostatic environment within the liver, 
however, the hepatic artery cannot compemsate 
quantitatively for altered portal flow (Greenway and
30
Stark, 1971) .
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PORTAL VEIN AND LIVER MORPHOLOGY IN PORTAL HYPERTENSION
The fundamental mechanism underlying the 
pathophysiology of portal hypertension has been widely 
accepted for numerous years as an increased resistance 
to portal venous flow (Herrick, 1907). The rise in 
portal venous pressure is secondary to the 
morphological alterations occuring within the liver and 
the portal vein under varying disease conditions. The 
most frequently observed conditions precipitating 
portal hypertension are cirrhosis, alcoholic hepatitis, 
liver carcinomas, and parasitic invasion of the liver 
(Reynolds, 1969). Extrahepatic portal hypertension 
occurs if the portal or splenic veins are partly or 
completely occluded (Reynolds, 1969). Hepatic cirrhosis 
is primarily the cause of portal hypertension in the 
western world, but extrahepatic obstruction of the 
portal vein also produces equivalent pressure increases 
(Rousselot et al, 1959).
Mclndoe (1928) and Epplen (1922) in examining vascular 
lesions in liver cirrhosis noted obvious superficial 
alterations in the liver. A marked diminution in liver 
size was frequently observed. However, on occasions the 
converse occurs, and the liver is observed to undergo 
an increase in size (Herrick, 1907). Further the liver 
appeared hobnailed, and stiff with an increased 
consistancy.
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Intrahepatic vascular transformations occuring within a 
cirrhotic liver were examined by use of celloidin casts 
of the portal venous pathways. From such casts, Mclndoe 
(1928) and Popper et al (1952) were able to demonstrate 
in patients and rats (Popper et al, 1952) a marked 
reduction in the total vascular bed together with a
stenosis and attenuation of the main portal trunks and
numerous portahepatic anastomoses (intrahepatic 
shunts). Portograms performed by Rousselot et al
(1959) on patients and cirrhotic rats showed clearly 
the portal circulatory derangement observed in 
cirrhosis of the liver, including the development of an 
extrahepatic collateral circulation.
Histological and serial sectioning of the liver have 
provided an explanation for the altered vascular
pattern in the liver together with the liver's 
hobnailed appearance. Comprehensive reviews of the 
liver by Rappaport (1976) and Sherlock (1981) detail 
the necrosis of the parenchymal cells, the collapse of 
hepatic lobules, formation of diffuse septa, and the 
nodular regrowth of liver cells. It is the 
regeneration of these nodular liver cells, which 
explains the hobnailed appearance of the liver together 
with the distortion of the hepatic vascular tree.
In contrast, portal hypertension resulting from 
extrahepatic occlusion of the portal vein does not 
result in notable morphological changes in the liver
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(Simonds, 1936), indeed complete occulsion of the 
portal vein as performed in the monkey by Child and 
associates (1950) failed to demonstrate at hepatic 
biopsy any evidence of morphological change. The portal 
vein itself, however, can undergo various degrees of 
occlusion which give rise to a range of transformations 
in the appearance of the portal vein (Philips, 1988). 
Turner et al (1957) showed by use of venograms and 
autopsy studies on patients a dramatic transformation
of the portal vein into a cavernous mass of small
tortuous vessels. By contrast, Simonds (1936) and 
Whipple (1945) showed from hepatic autopsy studies the 
more subtle changes of the portal vein, which involve 
replacement of the vein or its main tributaries with
fibrous tissue or scar tissue with little or no
canalization. However, whichever morphological form the 
portal vein assumes, the resultant increase in portal 
venous pressure inevitably precipitates the formation 
of extrahepatic shunts (Rousselot et al, 1959).
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THE PATHOPHYSIOLOGY OF PORTAL HYPERTENSION
In an attempt to understand the fundamental cause
of the chronic increase in portal pressure two opposing
theories have developed. The first, and the most
obvious theory, is the "obstruction" or "backward flow"
»
theory, which was first proposed -£>y Whipple (1945) and 
was based upon the suggestion by Herrick (1907) that 
intrahepatic fibrosis was the precipitating factor in 
the elevation of portal venous pressure. The opposing 
theory, the "forward flow" theory, was suggested 
initially by Banti's comments on his patients with 
congestive splenomegaly in 1894 (Banti, 1894).
1. "Backward flow" theory
The "backward flow" theory of portal hypertension 
is based upon the concept of a raised portal venous 
pressure secondary to an increased resistance to portal 
venous flow. The term does not necessarily imply a 
reversal in direction of blood flow.
Supportive evidence for the "backward flow" theory has 
arisen from abundant clinical and pathological data 
(Popper et al, 1952) together with evidence of a 
decreased hepatic sinusoidal and venular drainage 
capacity (Friedman and Weiner, 1951; Ketly et al, 
1950).
Prehepatic portal hypertension secondary to portal
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vein obstruction has also been shown to increase 
resistance in the portal venous system (Halvorsen and 
Myking, 1979), and increased rat stomach weights in the 
face of obstructed venous outflow (Baronofsky et al, 
1945), together with dilation of the gastric veins 
(Rousselot et al, 1959) has been cited as evidence 
of the stasis in the circulation in portally 
hypertensive splanchnic organs. Such observations have 
led to a frequent analogy being made between 
"congestive splanchnic failure" in portal hypertension 
and "congestive cardiac failure". A reduced hepatic 
blood flow in patients with cirrhosis of the liver 
(Bradley et al, 1952) has also been considered 
indicative of a reduced splanchnic inflow, and 
measurements of a reduced blood flow in the portal vein 
by means of electromagnetic flowmeters (Ferguson, 1963; 
Moreno et al, 1967) would appear to substantiate 
hepatic blood flow findings. However, since neither 
total liver nor portal venous blood flow necessarily 
includes flow in the portasystemic shunts, these direct 
flow measurements may not reflect accurately the level 
of splanchnic inflow in portal hypertension. Despite 
this, a wealth of evidence exists which appears to 
corroborate the backward flow theory, thus it has been 
generally accepted for numerous years, that a reduced 
splanchnic circulatory flow exists in both intrahepatic 
and extrahepatic portal hypertension.
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2. "Forward flow11 theory
fa) Systemic haemodvnamics in portal hypertension
Evidence of an alternative hypothesis underlying
the pathophysiology of portal hypertension was first
provided by Kowalski and Abelmann in 1953.
The existence of a hyperkinetic state was found 
indirectly by both investigators when they demonstrated 
an increase in resting cardiac output in one third of 
patients suffering with hepatic cirrhosis. This 
observation was later confirmed by investigators Murray 
et al (1958), who further suggested that the elevated 
cardiac output was one of the factors responsible for 
the frequent occurence of warm extremities and 
peripheral pulsations observed in patients with hepatic 
cirrhosis. This elevated cardiac output, or
hyperkinetic haemodynamic state in cirrhotic patients 
was found to closely resemble the "shunt circulation" 
occuring in patients with arterio-venous (A-V) fistulae 
(Johnson et al, 1969) and further reports of 
arteriovenous fistulae in the spleen, stomach and lower 
oesophagus (Peters and Womack, 1961) and lung (Rydell 
and Hoffbauer, 1956) of patients with hepatic cirrhosis 
has led to the suggestion that the elevated cardiac 
output is secondary to the development of A-V fistulae. 
In conjunction with the raised cardiac output, Kowalski 
and Abelmann (1953) and Murray et al (1958) were also
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able to demonstrate a reduction in peripheral systemic 
vascular resistance in patients with elevated cardiac 
output, and attributed this fall to the increased 
presence of a "vasodilator material" normally 
metabolised by the liver (Shorr et al, 1951). This 
finding has also been supported by the failure to 
demonstrate an increased cardiac output in patients 
with extrahepatic portal hypertension and normal liver 
function (Murray et al, 1958). Subsequent studies have 
focused on organ blood flow in cirrhosis and work 
carried out by Kontos et al (1964) demonstrated an 
increased blood flow to the upper limb and a reduced 
arteriovenous oxygen difference.
(b) Splanchnic haemodvnamics in portal hypertension
It is generally accepted that increased resistance 
to flow in the portal vein and liver will raise portal 
pressure (Halvorsen and Myking, 1979; Popper et al, 
1952) , but the maintenance of such an elevated portal 
pressure in the presence of extensive collateral 
communications between the portal venous system and the 
systemic circulation could not by means of the 
"backward flow" theory be rationally explained. Over 
the last 20 years various investigators have proposed 
that portal hypertension is maintained after the
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development of portasystemic shunts as a result of an 
increased splanchnic inflow.
Indirect evidence of an elevated splanchnic blood flow 
was provided by Williams et al (1968) and later by 
Gitlin et al (1970) and Witte et al (1972). All three 
investigators showed an increase in total splenic blood 
flow in cirrhotic patients as compared to controls, and 
suggested that an elevated splenic blood flow would 
contribute to the elevation in portal venous pressure. 
Demonstration that portal blood is highly oxygenated 
(Womack and Peters, 1961; Witte et al, 1969) a feature 
which is in direct contrast to the stagnant circulation 
of congestive heart failure, often used as a 
comparative description to that of the splanchnic 
circulation, is also suggestive of an elevated 
splanchnic inflow.
The first direct evidence of an elevated splanchnic 
blood flow was, however provided by Kotelanski et al 
(1972), who demonstrated that the mean transit time of 
radiolabelled albumin from the superior mesenteric and 
hepatic arteries to the hepatic veins was significantly 
reduced in patients with hepatic cirrhosis. Since 
portal venous pressure is the result of the interplay 
between portal venous blood flow and the vascular 
resistance offered to that flow, then such evidence 
from Kotelanski et al (1972) and Williams et al (1968) 
has suggested that increases in splanchnic blood flow
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may be an important factor in the pathogenesis of 
portal hypertension. Subsequent studies were,
therefore aimed at splanchnic blood flow and its 
relationship to portal pressure. Witte et al (1974) 
measured, in dogs, superior mesenteric artery flow and 
portal venous pressure following intravenous infusion 
of glucagon. Glucagon simulated a hyperdynamic 
splanchnic blood flow causing a two fold increase in 
flow in the superior mesenteric artery without any rise 
in portal venous pressure. In contrast, constriction of 
the portal vein produced an increase in pressure, and 
in seperate animals both glucagon infusion and portal 
vein constriction produced a much greater rise. Thus 
it was proposed that a combined effect of elevated 
splanchnic inflow and resistance to portal venous flow 
was responsible for the level of portal pressure and 
the production of active congestion. Later work by 
Witte et al (1976) substantiated earlier findings and 
demonstrated that the sequential rise in portal venous 
pressure secondary to increasing constriction of the 
portal vein is enhanced during increasing arterial 
infusions of glucagon. Thus, together with the finding 
that blood volume was increased in patients with 
cirrhosis (Zimmon and Kessler, 1974) , subsequent 
studies have focused on the role of elevated splanchnic 
inflow rather than increased resistance to portal 
venous flow in the pathogenesis of portal hypertension
40
(Vorobioff et al, 1983; Vorobioff et al, 1984). 
Subsequent studies in rat models of cirrhosis and 
chronic extrahepatic portal hypertension have shown 
conclusively that portal venous inflow is increased in 
these models although there remains a conflict of 
evidence about whether increased downstream resistance 
also contributes to elevated portal venous pressure 
(Blanchet and Lebrec, 1982; Benoit et al, 1985; Sikuler 
et al, 1985).
As discussed earlier, the development of a hyperdynamic 
systemic circulation has been attributed to the 
presence of a "vasodilator material" normally 
metabolised by the liver (Shorr et al, 1951). The same 
"vasodilator material" is also thought to be 
responsible for the increase in portal venous inflow. 
Theories about the mediator of the increased portal 
venous inflow proposed by the "forward flow" theory 
abound and at present the gastrointestinal hormone 
glucagon seems the most likely candidate as the 
mediator of this process (Sherwin et al, 1974; Sikuler 
et al, 1984; Benoit et al, 1984). Glucagon is known to 
induce a significant reduction of mean arterial 
pressure, total vascular resistance and splanchnic 
resistance and an increase intestinal and arterial 
hepatic blood flow (Feruglio et al, 1966; Farah, 1983). 
Glucagon concentrations are elevated in cirrhotic 
patients particularly in association with portasystemic
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shunting (Sherwin et al, 1974) mainly as a consequence 
of pancreatic hypersecretion (Sherwin et al, 1978). 
However, correlation to hepatocellular injury has also 
been reported (Smith-Laing et al, 1980).
Benoit et al (1984) have found increased concentrations 
of glucagon in portal vein constricted rats and intra- 
arterial infusions of glucagon produced a 20% reduction 
of intestinal vascular resistance. Sikuler et al 
(1984) have observed similar increased concentrations 
of glucagon in portal vein ligated rats, however no 
correlation was found between the hyperdynamic 
circulation and glucagon blood levels.
While the initial mechanism of increased portal 
pressure may be related to a distorted intrahepatic 
vascular bed with subsequent increased resistance, the 
development of a collateral circulation acts to reduce 
resistance to portal blood flow. It is at this stage 
that the increased portal venous inflow might play an 
important role in the maintenance of portal 
hypertension. Thus the development of portasystemic 
shunting itself may contribute, by diverting humoral 
vasodilator factors released from the gastrointestinal 
tract into the systemic circulation, to the maintenance 
of portal hypertension.
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CONSEQUENCES OF PORTASYSTEMIC SHUNTING
Both portasystemic encephalopathy (Sherlock et al, 
1954) and oesophageal variceal haemorrhage (Teres et 
al, 1976) have been described as the most important 
complications of portasystemic shunting.
Despite their clinical significance, oesophageal 
varices constitute only a part of the extrahepatic 
collateral circulation, and since the method described 
in this thesis quantitates the total amount of blood 
bypassing functioning hepatocytes, be it through 
extrahepatic and intrahepatic shunts, they have little 
relevance in the context of this thesis. Thus they will 
be dealt with only briefly. Hepatic encephalopathy 
however, is thought to be in part the result of the 
diversion of gut derived compounds and gastrointesinal 
hormones around functioning hepatocytes. The 
quantitation of portasystemic shunting is therefore 
potentially most useful in examining hepatic 
encephalopathy, in as much as an increase or change in 
portasystemic shunting may parallel the appearance and 
progression of hepatic encephalopathy.
(a) Oesophageal varices
One of the major complication of portasystemic 
shunting is haemorrhage from oesophagogastric varices. 
Oesophagogastric varices due to cirrhosis of the liver
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has been known and documented for many years (Preble, 
1900). Portal hypertension induces the development of 
various types of portasystemic collaterals, although 
usually a single type of collateral circulation is 
predominant (Jackson, 1963), thus the diversion of 
blood into the diaphragmo-oesophageal veins of the 
caval system leads to varicosities in the submucous 
layer of the lower end of the oesophagus and upper part 
of the stomach.
Tamiya and Thai (1960) created oesophageal varices in 
dogs only when portal or splenic obstruction was 
associated with an increased flow into the portal 
system produced by an arteriovenous shunt. Such 
findings suggest that an increased portal venous flow 
may be equally as important as the obstructive factor 
in the pathogenesis of oesophageal varices.
Endoscopy has been predominately used to evaluate the 
origin of bleeding (Conn and Brodoff, 1964) and 
numerous techniques allow visualisation of the portal 
venous system and so the varices (Rousselot and 
Burchell, 1969).
Contradictory reports however, have been published 
regarding the relationship between portal hypertension 
and the severity of the oesophageal varices. Willoughby 
et al (1964) utilising hepatic vein catherterization 
found a correlation between the size of oesophageal 
varices and the severity of portal hypertension. Joly
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et al (1971) by transumbilical catheterization of the 
portal vein, demonstrated as similar relationship. In 
contrast, Lebrec et al (1980) demonstrated that the 
presence and size of oesophageal varices were not 
related to the degree of portal hypertension, an 
observation further corroberated by splenic pulp 
manometry (Greene et al, 1965; Palmer, 1953). Although 
the mechanism of variceal rupture is unclear, it would 
appear that the height of the portal blood pressure is 
important (Orloff et al, 1963), and indeed bleeding 
varices have only been observed if significant portal 
hypertension exists (Viallet et al, 1975). Further, 
overall risk of gastrointestinal bleeding was much 
higher in patients with large sized oesophageal varices 
than those with no visible or small sized varices 
(Lebrec et al, 1980), a finding which is in accordance 
with observations made by Baker et al (1959).
(b) Hepatic encephalopathy
Hepatic encephalopathy and the factors 
precipitating its development are of particular 
relevance to this thesis, therefore a comprehesive 
discussion on hepatic encephalopathy is given. 
Portasystemic encephalopathy is to a large extent 
secondary to the more subtle consequences of the 
altered circulation which present in the form of
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hormonal, nutritional, immunological and
pharmacological disorders. The condition is thus 
thought to be the product of cerebral intoxication 
secondary to the metabolic changes arising in patients 
with cirrhosis (Sherlock et al, 1954) or in patients 
with portacaval anastomosis (McDermott and Adams,
1954), and resulting in behaviour, personality and mood 
disorders before progressing to coma (Hoyumpa et al, 
1979). Immunological and pharamacological disorders do 
not appear to play a role in the development of hepatic 
encephalopathy, but they do, however, give rise to 
humoral and cell mediated immunity abnormalities and 
enhanced drug bioavailabiltiy.
The combination of both nutritional and hormonal 
disorders and the onset of portasystemic encephalopathy 
are extensively interrelated.
(i) Nutritional disorders
Elevated levels of ammonia secondary to an altered 
nitrogen metabolism have been described in humans with 
cirrhosis (Bessman et al, 1955), rats with portacaval 
shunt (Masland, 1964) and cirrhosis (Yamamoto et al, 
1987) and patients with portasystemic encephalopathy 
(Sherlock et al, 1954). Other species have also been 
observed to develop diffuse neurological abnormalities 
either spontaneously or when challenged with high 
protein, orally administered ammonium chloride, or
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ammonium-releasing resin (Bollman, 1961). 
Pharmacologically active amines have also been 
implicated in hepatic coma. Raised blood mercaptan 
levels produced by intestinal methionine metabolism are 
found in portasystemic encephalopathy, but not in all 
patients (McLain et al, 1980) and tryptophan is 
increased in the brain in experimental hepatic coma as 
well as the cerebrospinal fluid of patients with 
hepatic coma (Ono et al, 1978). Its metabolism to 
serotonin has profound effects on the central nervous 
system. A similar picture to ammonia and amine 
intoxication can be induced in patients with a high 
protein diet or when challenged with urea (Phear et al,
1955), or methionine (Phillips et al, 1952; Phear et 
al, 1956).
Further nutritional aberrations present in the form of 
elevated tyrosine levels, which are further accentuated 
by abnormalities in plasma amino acid concentrations 
arising from hormonal alterations. In 1978 Faraj et 
al, demonstrated an impaired tyrosine metabolism in 
dogs with portacaval shunt, elevated tyrosine levels 
becoming more pronounced as they manifested symptoms of 
hepatic encephalopathy. Similar results were reported 
by Ali et al (1980), who attributed decreased tyrosine 
metabolism to a reduced nutrient hepatic flow, rather 
than a loss of the liver catabolising enzyme. Such 
elevated tyrosine levels have been hypothesised to
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produce false neurological transmitters, thus 
interfering with normal synaptic transmission, and so 
contributing to the symptoms of hepatic encephalopathy 
(Fischer and Baldessarini, 1971).
Alterations in fatty acid metabolism, shown by elevated 
concentrations of short and long chain fatty acids have 
been found in hepatic coma and are believed to act 
synergistically with ammonia, although a direct 
association between encephalopathy and fatty acids has 
not been established (Wilcox et al, 1978).
(ii) Hormonal disorders
The inter-relationship between hormonal
alterations and hepatic encephalopathy occurs via 
abnormalities in plasma amino acid concentrations which 
have been reported in humans (Fischer et al, 1974 and 
1976; Morgan et al, 1978), dogs (Aguirre et al, 1974; 
Fischer et al, 1975) and rats (Cummings et al, 1976; 
Rosen et al, 1978) with hepatic cirrhosis or after 
portacaval shunt.
These abnormalities are characterised by elevated 
levels of aromatic amino acids, tyrosine, phenylamine 
and tryptophan as well as methionine and histidine and 
depressed levels of the branched amino acids, leucine, 
valine and isoleucine. Such alterations have been 
attributed to initial hormonal changes, particularly 
those of the hormone insulin. Hyperinsulinemia together
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with glucose intolerance and insulin resistance has 
been found in patients with cirrhosis (Collins et al, 
1969) and in patients after portacaval shunt (Johnson 
et al, 1977). Hyperinsulinemia is thought to increase 
catabolism by skeletal muscle and kidney of branched 
chain amino acids, allowing excess aromatic amino acids 
to cross the blood brain barrier and so alter 
neurotransmitter synthesis (Munro et al, 1975), thus 
precipitating once again the signs and symptoms of 
hepatic encephalopathy.
Hormonal disturbances such as hyperinsulinemia have 
been attributed independently to both portasystemic 
shunting (Johnson et al, 1977) and parenchymal liver 
damage (Smith-Laing et al, 1979). The contribution of 
both to the development of hyperinsulinemia has not 
been assessed. Further, raised levels of glucagon have 
been evidenced in patients with cirrhosis and 
portacaval shunt (Alford et al, 1979), and as discussed 
in a previous section, are thought to be implicated in 
the increased portal venous inflow. However, the 
reason underlying the hypersecretion of pancreatic 
glucagon is as yet unknown.
The following consequences of portasystemic shunting, 
as already stated do not appear to contribute to the 
development of hepatic encephalopathy, but they are 
responsible for the more subtle problems encountered 
in patients with cirrhosis.
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(iii) Immunological disorders
Immunological alterations secondary to
portasystemic shunting and cirrhosis present in the 
form of humoral and cell mediated immunity 
abnormalities. Evidence of elevated immunoglobulin 
levels (Prytz et al, 1977) and serum antibodies to gut 
bacteria (Bjorneboe et al, 1972; Triger et al, 1972) 
have typified changes in humoral immunity, whereas 
defects in cell mediated immunity have been shown by 
diminished delayed hypersensitivity responces (Fox et 
al, 1969), reduction in peripheral T-cell 
concentrations (Bernstein et al, 1974) and diminished 
responses to phytohaemagglutinin (MacSween and Thomas, 
1973).
Hypergammaglobulinemia evidenced by electrophoretic 
studies in cirrhotic livers is the most prevalent 
raised immunoglobulin (Franklin et al, 1951). 
Comparable conditions have been created in the rat 
(Thomas et al, 1976) with the proposition that 
depressed defects in cell mediated immunity are related 
in part to the presence of a serum inhibitor (Willems 
et al, 1969), possibly produced by splenic suppressor 
cells stimulated by diversion of gut derived antigens 
through portasystemic shunts (Thomas et al, 1976). 
Raised immunoglobulin and antibody concentrations have
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been demonstrated both in the presence of patients with 
portacaval shunt (Galbraith et al, 1976) and rats 
(Keraan et al, 1974). In contrast, Thomas et al (1976) 
working on rats and Webb et al (1980) studying patients 
attributed hepatocellular damage, rather than 
extrahepatic portasystemic shunting as the influencing 
factor in the altered humoral immune response. 
Further, researchers have proposed that the presence of 
intrahepatic shunts (Prytz et al, 1977) as opposed to 
extrahepatic shunts are more significant in the 
causation of the elevated levels of the immunoglobulins 
and Pomier-Layrargues et al (1980) attributed 
alterations in kupffer cell uptake secondary to 
intrahepatic portasystemic shunting.
(iv) Pharmacological disorders
Pharmacological changes surface in patients with 
liver cirrhosis in the form of enhanced bioavailability 
of drugs, particularly those drugs which 
characteristically have a high first pass hepatic 
clearance (Blaschke and Rubin, 1979). Early on it was 
accepted that patients with hepatic disease had more 
central nervous system depression from analgesics and 
sedative agents than patients with normal liver 
function (Laidlaw et al, 1961; Schenker et al, 1975) 
and mounting evidence implied that increased 
sensitivity in patients with liver disease was due to
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altered drug disposition (Wilkinson et al, 1975; 
Pessayre et al, 1978). Shand and Rangno (1972) were 
one of the first to observe a marked increase in 
systemic availability of orally administered 
propranolol in a patient with a portacaval shunt and 
further studies by Gugler et al (1975) on dogs with a 
surgically constructed portacaval shunt resulted in 
enhanced bioavalability of drugs such as lidocaine and 
salicylamide. Neal et al (1979) further demonstrated 
decreased clearance of analgesics, and correlated 
enhanced bioavailability to drugs with highest hepatic 
clearances in cirrhotic patients with portasystemic 
shunting. However, Pessayre et al (1978) and Roberts 
et al (1978) attributed enhanced drug bioavailavility 
in cirrhotic patients to an impaired ability of the 
liver to primarily remove the drug from the blood due 
to liver damage and secondly to a reduced liver blood 
flow. It is now accepted that a reduced extraction in 
cirrhosis will be compounded by the development of 
mesenteric portacaval anastomoses (Shand, 1979).
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MEASUREMENT OF PORTASYSTEMIC SHUNTING
(a) Visualisation of portasystemic shunting
The methods available by which a patient with 
clinical liver disease could be studied was for many 
years limited to tests of hepatic function and tissue 
biopsy. The presence and site of extrahepatic 
obstruction was also not easily determined by available 
clinical methods, even at the time of exploratory 
laparotomy. The development and implementation of 
visual technology and splenic radiographic injection 
techniques in the middle of the 1940's (Whipple, 1945; 
Blakemore and Lord, 1945) allowed more indepth evidence 
to be gathered on the portal venous system, collateral 
circulation, and the level of portal venous pressure. 
During the 1950's and 1960's, portal venography, portal 
portography, retrograde portography, transcapillary 
portography and splenic portography were used to 
radiologically visualise the portal venous system by 
use of contrast medium injected at various areas 
depending on the technique being used (Rousselot et al, 
1953; Bahnson et al, 1953; Child et al, 1951 and 
Rousselot and Burchell, 1969). These techniques were 
used as a means of diagnostically assessing the 
anatomical location, caliber, patency and haemodynamic 
derangement of the portal vein and its collateral
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circulation, the knowledge of which was used to grade 
the collateral circulation.
(b) Measurement of portasystemic shunting
The first objective method designed to quantitate 
the portal venous collateral circulation in cirrhosis 
was described in 1960 by Iber and co-workers. The 
method, validated by Reichman et al (1958), was based 
upon indicator dilution techniques and the use of a 
radioactive indicator substance, human radioiodinated 
serum albumin. Collateral flow was estimated from the 
difference between the measured concentration of 
iodinated albumin injected into the spleen appearing at 
the hepatic vein and in the peripheral circulation. 
Values for portal collateral loss ranged from 0-100% in 
patients with various forms of liver disease. A similar 
study carried out two years later by Caesar et al 
(1962) produced comparable results.
The method used by Iber and colleagues (1960) to assess 
portasystemic collateral flow was, however, criticised 
by investigators Nakamura et al (1962). While 
themselves describing two methods in the measurement of 
extrahepatic shunted blood flow in liver cirrhosis, 
Nakamura et al (1962) claimed that calculation of 
extrahepatic collateral flow would be grossly
54
overestimated if the described method by Iber et al
(1960) was used. The methods used by Nakamura and 
colleagues (1962) to calculate extrahepatic shunted 
blood flow produced significantly lower values than 
those acheived by Iber et al (I960), and these values 
were claimed by the investigators to be a more 
realistic indication of shunted blood flow.
The methods used by Nakamura et al (1962) are in 
themselves, however, subject to critisism. Their first 
method involved determining continuously the 
radioactivity of brachial arterial blood after 
injection of radioactive iodinated serum albumin into 
the spleen. From the resultant curve of radioactivity 
the extrahepatic shunted blood flow was calculated as 
percent extrahepatic shunt. The method however, 
suffers from an inability to differentiate between 
curves produced by extrahepatic shunted blood flow and 
that caused by the blood flow through the liver in the 
radioactivity curve as well as a failure to record 
continuous arterial concentrations, thus extrahepatic 
shunted blood flow could not be quantitatively 
calculated. In their second method, indocyanine green 
and radioactive iodinated human serum albumin were 
injected into the peripheral vein and spleen, and 
percent extrahepatic shunt was calculated from the dye 
concentration curves recorded with an ear densitometer 
and from final concentrations of radioactive iodinated
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human serum albumin. The second method appeared to be 
more sensitive than the first but was still subject to 
theoretical problems and inaccuracies that beset all 
applications of indicator dilution techniques utilising 
splenic injection of a radioactive indicator. Such 
inaccuracies, as detailed below, have thus limited 
their application,
(1) The method provides an estimation only of shunting 
of splenic blood flow, since some or all of the 
injected label may escape through splenic vein 
collaterals before mixing with the intestinal flow. 
Thus independent shunting from the mesentery is 
disregarded and collateral flow is overestimated.
(2) The indicator injected into the spleen does not 
all gain quick access to the circulation and delayed 
absorption or inconstant residual at the injection site 
introduces a complication in calculating shunt flow 
(Reichman et al, 1958).
(3) Hepatocellular function must be adequate to allow 
measurement of hepatic blood flow by an independent 
clearance method (Reynolds, 1969) .
(4) Finally, splenic puncture is contraindicated in 
the presence of ascites or clotting disorders, both of 
which are common in patients with liver disease 
(Rousselot and Burchell, 1969) .
It was not until 1972 that a technique which allowed 
separate evaluation of collateral flow arising from the
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splenic and mesenteric portal inflow by means of 
selective percutaneous cathererization and single 
injections of i131 labelled human serum directly into 
the respective arteries was described by Groszmann and 
associates (1972). The technique, previously validated 
by Cohn et al (1972), allowed the fraction of portal 
venous inflow shunted through portasystemic collaterals 
to be computed by comparing the area of an isotope 
dilution curve recorded from the hepatic vein after 
injection into the superior mesenteric or splenic 
artery with that after injection into the hepatic 
artery. From such studies Groszmann et al (197 2) found 
that up to 62% of mesenteric and 80% of splenic blood 
flow may undergo extrahepatic shunting in patients with 
alcholic liver disease. Furthermore, it appeared that 
shunts developed independently in the mesenteric and 
splenic bed. However, on interpretating Groszmann et 
al's, data it must be remembered that shunting has been 
calculated as a percentage of splenic or mesenteric 
inflow and that the actual flow in the collateral 
channels cannot be quantitated because it is dependent 
on the total splenic and mesenteric flow.
Further studies carried out by Ueda et al (1967) and 
Okuda and colleagues (1977), attempted to quantitate 
seperately intra and extrahepatic shunts in one 
procedure. Previous techniques had allowed only for the 
seperate evaluation of both types of shunting within
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different procedures. Extrahepatic shunts being 
determined by methods already described and those 
arising within a diseased liver have been delineated by 
Shaldon et al, 1961 and Nakamura et al, 1961. However, 
the method by which an extrahepatic shunt index is 
calculated by Ueda et al (1967) and Okuda et al (1977) 
arises from the administration of I131-macroaggregated 
albumin and 99mTc-macroaggregated albumin respectively, 
into the splenic vein at the splenic hilum, which in 
itself is subect to the already mentioned model errors. 
Further, subsequent errors arise with the inhomogeneity 
of the macroaggregeted albumin, thus the technique 
suffers from several possible sources of error.
Despite the development of techniques to measure the 
proportion of portal blood that bypasses the liver to 
reach the systemic circulation, no single method has 
gained practical use due to their complexity, model 
restrictions and more importantly the fact that all 
techniques suffer from being highly invasive, (Okuda et 
al, 1977; Groszmann et al, 1972).
The first hypothetical non-invasive kinetic approach to 
the estimation of hepatic shunting in chronic liver 
disease was described in 1979 by McLean and coworkers. 
The method defines the relationship between the degree 
of shunting of total liver blood flow around the 
fraction of functional liver cell mass and develops 
pharmacokinetic equations to permit the estimation of
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both total hepatic blood flow and the extent to which 
this blood flow is shunted. The method requires 
determination of the systemic clearance of a high and 
low hepatic extraction ratio drug in the same patient, 
indocyanine and antipyrine being used respectively. By 
application of the developed equations to literature 
data obtained from patients with moderate or severe 
chronic liver disease and from patients with a
portacaval shunt, McLean et al (1979) were able to 
demostrate a significant degree of shunting, 27% in 
patients with moderate chronic liver disease and
extensive shunting, 72% in patients with severe chronic 
liver disease. The basis for the pharmacokinetic method 
however, requires adequately functioning hepatocytes, 
thus in a diseased liver deviations from this result, 
and in a given patient will introduce errors in the 
estimation of liver blood flow and the degree of 
shunting. Calculations by McLean et al (1979) have 
however, been consistent with published data (Bradley
et al, 1952; Caesar et al, 1961; Groszmann et al,
1972), thus the pharmacokinetic method appears to be a 
feasible technique. Its main fault lies in the fact 
that it is time consuming.
Porchet and Bircher in 1982 outlined the first attempt 
at a practical non-invasive procedure that approached 
quantitative assessment of portasystemic shunting. The 
authors proposed that the systemic availability of oral
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glyceryl trinitrate was a measure of the fraction of 
portal blood bypassing the liver through portasystemic 
shunts. It was assumed that at low oral doses 
intestinal absorption of glyceryl trinitrate was 
complete and hepatic extraction was almost 100 percent, 
therefore systemic spillover mainly depends on intra or 
extrahepatic shunting, thus the systemic clearance of 
glyceryl trinitrate should directly reflect the amount 
of blood flowing through functioning hepatic 
parenchyma, and glyceryl trinitrate bioavailability 
should indicate the fraction of portal blood bypassing 
it.
It must be stressed that the methods used by Porchet 
and Bircher (1982) and McLean et al (1979) to 
quantitate the magnitude of portasytemic shunting do 
not distinguish between anatomical shunting through 
large calibre extrahepatic and intrahepatic 
collaterals and functional shunting as a result of 
impaired hepatocyte function. The increased
bioavailability of gut derived agents thought to be 
responsible for hepatic encephalopathy arises not only 
because of the diversion of portal venous blood through 
major collateral channels, but also because functional 
damage to the liver reduces its capacity to eliminate 
these agents on passage through the sinusoids. Any 
attempt to relate the degree of shunting to the 
development of encephalopathy must therefore take into
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account the latter process i.e. functional shunting, as 
well as the former. The use of a test substance whose 
bioavailability reflects both potential types of 
shunting is therefore the most appropriate choice for 
this purpose.
In concurrence with the non-invasive principle of the 
method described by Porchet and Bircher (1982), blood 
sampling was replaced by digital plethysmography which 
assessed the pharmacological effects of glyceryl 
trinitrate, this in turn could be translated into a 
measure of the systemic availability of the drug. Dose- 
response curves resulting from graded intravenous 
infusions of glyceryl trinitrate were used as standard 
of comparison for the pharmacological response 
resulting from an oral dose of the drug. Small oral 
doses were used to achieve a practically complete 
elimination in normal subjects on first pass and avoid 
saturation kinetics. Therefore first-order kinetics 
were assumed. Results demonstrated that normal 
volunteers had a systemic availability of oral glyceryl 
trinitrate of 2-4 percent, while patients with 
cirrhosis of the liver showed variation between 15 
percent and 85 percent.
Problems within the method however arose relating to 
digital plethysmography which proved to be subject to 
large measurement errors. Also drug absorption through 
oral or oesophageal mucosa may also bypass the liver
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and simulate portasystemic shunting. Further, glyceryl 
trinitrate maybe subject to first-pass elimination in 
the intestine and retention within the tubing during 
the intravenous infusion, thereby installing errors 
into the calculation of infusion rates and systemic 
availabilities. More importantly glyceryl trinitrate 
may also modify the splanchnic circulation and thereby 
potentially change the degree of shunting.
More recently Cavanna et al (1987) used the compound 
sorbitol, already proven to have a high hepatic 
elimination (Molino et al, 1987) for non-invasive 
assessment of the magnitude of portasystmic shunting. 
First-order kinetics were again assumed and by arterial 
sampling and enzmymatic spectrophotometric analysis 
sorbitol concentration in plasma were determined. The 
ratio between the area under the curve from an 
intravenous infusion of sorbitol and that from orally 
administered sorbitol were used in the calculation of 
sorbitol bioavailability.
The bioavailability of sorbitol, as with glyceryl 
trinitrate, reflects both anatomical and functional 
shunting. Normal subjects exhibited zero sorbitol 
bioavailability whereas patients with cirrhosis and 
portacaval shunts demonstrated varying
bioavailabilities. Despite patients with portacaval 
shunt presumably having 100 percent shunting, sorbitol 
bioavailability was only able to demonstrate 38 percent
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shunting in such patients. The failure of sorbitol to 
measure accurately shunting may be due to its 
elimination across the intestinal wall during 
absorption.
The methods described by Porchet and Bircher (982) and 
Cavanna et al (1987), however were well accepted by 
patients with the minimum of inconvenience and 
demonstrated a realistic means of determining 
portasystemic shunting.
Indeed it is the theory behind these two techniques 
that underlies the method described in this thesis. 
The choice of galactose as a test substance, as 
discussed in the following section, lies in the fact 
that galactose does not undergo intestinal elimination 
and has a high hepatic elimination.
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AIMS OF THESIS
1. To develop a theoretical model to describe the 
behaviour of an oral test substance that could be used 
to quantify the magnitude of portasystemic shunting, 
which in this study represents anatomical and 
functional shunting combined.
2. To test the validity of the model using galactose 
as a test substance in humans and in a rat model of 
prehepatic portal hypertension. Independent
quantitation of the magnitude of portasystemic shunting 
by radioactive microspheres will also be carried out in 
the rat model.
3. To measure the systemic availability of oral 
galactose in control patients and patients with 
documented portal hypertension and portasystemic 
shunting.
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INTRODUCTION
Hepatic elimination of galactose from the body has 
been proposed as the basis of a test of liver function 
(Colcher et al, 1946; Tygstrup, 1964 and 1966), of a 
method of measuring liver blood flow (Henderson et al,
1982), and in this thesis of a means of assessing the 
magnitude of portasystemic shunting.
Galactose elimination from the circulation by the liver 
is an active metabolic process with a maximum limiting 
rate (Vmax) dependent upon the phosphorylation of 
galactose to galactose-l-phosphate by the enzyme 
galactokinase, one of several enzymes in the Leloir 
metabolic pathway responsible for the interconversion 
of galactose to glucose (Cohn and Segal, 1973: Goresky 
et al, 1973). It has been shown that galactose 
elimination may be described by a mathematical kinetic 
model based on the assumption that hepatocytes 
eliminate the substrate from the body by an 
irreversible process described by Michaelis-Menten 
kinetics (Keiding et al, 1976). The Michaelis-Menten 
equation V = VmaxCa/(Km+Ca) describes the elimination 
rate, V, of galactose at a given concentration Ca. The 
kinetic parameters, Vmax and Km can be estimated from 
the mathematical model providing a direct value of the 
maximum galactose elimination rate, and galactose 
concentrations which give half the maximum elimination
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rate respectively.
The knowledge of Vmax and Km can be applied in the 
design of methods of measuring liver function, liver 
blood flow and portasystemic shunting. A test of liver 
function can be made when the concentration of 
galactose, Ca, is greater than Km and the elimination 
rate of galactose is zero-order and approximates Vmax. 
Conversely, when the concentration of galactose is less 
than Km the elimination rate of galactose is first- 
order and equals VmaxCa/Km and conditions are suitable 
for measuring blood flow and portasystemic shunting. 
Michaelis-Menten kinetics are applicable not only at 
the cellular (hepatocyte) level but also to the liver 
as a whole (Keiding, 1973). In this chapter whole organ 
kinetics are considered in the hepatic elimination of 
galactose. A more detailed discussion of Michaelis- 
Menten kinetics at the cellular level will be given in 
a subsequent chapter.
This Chapter, which is divided into three sections, 
examines in detail the theory and assumptions 
underlying the techniques of applying galactose as a 
test of liver function, and a measure of hepatic blood 
flow. This theory is then extended to develop a 
theoretical model for a method of assessing 
portasystemic shunting non-invasively in man. This 
model in turn has been applied in man, the results of 
which are discussed in Chapter 4.
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SECTION A. GALACTOSE CLEARANCE AS A TEST OF
LIVER FUNCTION
THEORY
Before devising formulae to fit the theoretical 
model for clearance of blood galactose as a test of 
liver function, a number of assumptions must be made, 
these being;
1). Galactose is eliminated from blood by the liver via 
an active metabolic process which has a maximum 
limiting rate, Vmax, dependent on liver function. 
Saturation of this metabolic pathway occurs if blood 
galactose concentration (Ca) exceeds a certain 
threshold level, when the rate of hepatic elimination 
is independent of galactose concentration.
2). Exchange of galactose between blood and other body 
compartments is sufficiently rapid that blood galactose 
can be considered to be in continuous equilibrium with 
total body galactose, i.e. the rate of disappearance of 
galactose from blood accurately reflects the rate of 
elimination from the body as a whole.
3). Elimination of galactose from the body by other 
routes either is negligible or can be quantified.
From the above assumptions the following formulae 
can be derived, the application of which allow, Vmax, 
the maximum galactose elimination rate, to be 
determined experimentally.
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If extrahepatic elimination is for the moment neglected 
(assumption 3), then, following the intravenous 
administration of a large quantity of galactose (Qo), 
typically 500 mg/kg body weight (Tygstrup, 1964), the 
amount remaining in the body after time t is given by,
Q(t) = Qo - Vmax.t ...........................2.1
From the second assumption above it is implied 
that blood galactose concentration (Ca) is proportional 
to Q(t), and can be written,
Ca (t) = Q(t)/Vd = Cao - (Vmax/Vd).t .......... 2.2
where Vd is the volume of distribution of galactose, 
and Cao, the hypothetical concentration in blood 
immediately after injection, is given by,
Cao = Qo/Vd .....................................2.3
Schematically illustrated in Figure 1 is the typical 
form of the systemic blood galactose concentration time 
curve observed experimentally after a single, rapid 
injection of galactose (Tygstrup and Winkler, 1954). 
The rapid fall in concentration immediately after 
injection in part reflects diffusion of galactose out 
of the vascular bed. The gradual decline of the curve 
i.e. the linear clearance of galactose thereafter 
reflects the rate of hepatic elimination. As 
equilibration of galactose between blood and tissue is
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Figure 1
This shows the typical form of a galactose concentration 
time curve after a single, rapid intravenous injection 
of galactose. The rapid fall in concentration immediately 
after injection in part reflects diffusion of galactose 
out of the vascular bed. The gradual linear decline of 
the curve thereafter reflects the rate of hepatic 
elimination, and the non-linear tail of the curve 
reflects the fall in concentration below the level at 
which hepatic extraction is saturated.
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not in practise instantaneous, then Cao must be 
determined by extrapolation of the linear part of the 
curve that follows. Tygstrup (1963) suggested a time 
shift of the elimination curve of seven minutes as an 
empirical correction for non-uniform distribution of 
galactose in this early phase. The tail of the curve is 
non-linear, reflecting the fall in galactose 
concentration below the level at which hepatic 
extraction is saturated.
By measurement of the gradient of the linear phase of 
the clearance curve (-Vmax/Vd by equation 2.2), 
estimation of Cao, and knowledge of Qo, Vd, the volume 
of distribution, and Vmax, the galactose elimination 
capacity, can be calculated.
This treatment, as already stated, ignores extrahepatic 
removal of galactose, which is principally by renal 
excretion (Tygstrup, 1961: McNamara and Segal, 1972).
Typically, 10% of the injected dose is recovered in 
urine, most of it is excreted during the early, non­
linear phase of clearance (Tygstrup, 1964). Simple 
subtraction of the excreted galactose from the quantity 
injected is therefore an acceptable correction for 
extrahepatic clearance.
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DISCUSSION
Experiments on intravenous administration of 
galactose as a test of liver function have 
demonstrated that the amount of galactose eliminated 
per unit time is constant, independent of concentration 
within a certain range (Tygstrup and Winkler, 1954). 
The linear portion of the slope of the blood galactose 
clearance curve after a single, rapid intravenous 
injection has been taken as a measure of the maximum 
galactose elimination rate and measured values are 
typically in the range 300-600 mg galactose/min in 
control subjects, and 200-400 mg galactose/min in 
cirrhotic patients (Tygstrup, 1964; Lindskov et al, 
1983). With respect to this study, these values are 
chiefly of interest for comparison with the galactose 
infusion rates employed in the techniques to be 
discussed below (up to 100 mg galactose/min) which are 
required to be substantially below the maximum 
elimination rate (Henderson et al, 1982). Indeed, the 
model for galactose clearance in the measurement of 
hepatic blood flow is based upon infused galactose 
concentrations well below the maximum galactose 
elimination rate (Vmax).
Estimation of the maximum galactose elimination 
rate from the single injection curve rests on some 
assumptions which are idealizations of the actual
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conditions: the elimination curve in the selected
interval is a straight line, urinary loss may be 
corrected for by the average excretion rate, and uneven 
distribution of galactose is compensated for by a time 
shift of the elimination curve of seven minutes 
(Tygstrup, 1963). Deviations from these assumptions 
may affect the calculated maximum galactose elimination 
rate in a direction, and to an extent, which depends on 
several factors.
It has been suggested, that the maximum galactose 
elimination rate as estimated from the peripheral 
curve (Tygstrup, 1964) overestimates liver function as 
determined from splanchnic galactose uptake, estimated 
from arterio-hepatic venous difference and splanchnic 
blood flow following a single intravenous injection 
(Ranek et al, 1983). A difference of 40% in galactose 
elimination rate was found between the two methods in 
patients with cirrhosis (Ranek et al, 1983), and 
attributed to the redistribution of galactose in the 
body and elimination outside the splanchnic organs (and 
excretion by the kidneys, for which the standard 
equation has a correction) .
The existance of an unidentified extrahepatic, 
extrarenal glactose elimination pathway was challenged 
by Lindskov et al (1983), who employed a steady-state 
infusion technique to estimate splanchnic galactose 
uptake. The technique reduced the influence of
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distribution problems, but had its own limitations, for 
example, errors in methods for determining regional 
blood flow and the representativity of catheter 
sampling in the hepatic and renal veins. Lindskov et al 
(1983) found an almost identical galactose elimination 
rate to that of Ranek et al (1983), 319 and 313 mg
galactose/min respectively in patients with liver 
disease, but also found that the galactose elimination
rate overestimated the splanchnic galactose elmination 
rate by only 2 5 percent in patients with cirrhosis. 
Lindsov et al (1983) concluded that this difference 
could be accounted for in equal parts to uneven 
distribution and by elimination in the kidneys, which 
had previously been underestimated by the conventional 
correction for urinary loss. This elimination may be 
partly excretion in the urine, partly intrarenal 
conversion.
The large extrahepatic-extrarenal galactose
elimination pathway, as estimated after single 
injection in the study by Ranek et al (1983) can be
thus attributed to over estimation of the total body 
galactose elimination rate and underestimation of 
splanchnic galactose uptake due to distribution 
phenomena. However, extrahepatic-extrarenal conversion 
of galactose cannot be excluded, but is estimated by
Lindskov et al (1983) not to exceed 3 6 mg
galactose/min.
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It must be pointed out, that galactose elimination 
outside the splanchnic organs does not invalidate the 
galactose elimination rate as a quantitative liver 
function test, especially when used repeatedly in the 
same patient because the extrahepatic, extrarenal 
elimination tends to be constant.
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SECTION B. GALACTOSE CLEARANCE IN THE
MEASUREMENT OF LIVER BLOOD FLOW
THEORY
Experimental measurements of hepatic blood flow 
are based upon application of the Fick principle
(Bradley et al, 1945; Waldstein and Arcilla, 1958).
According to the Fick principle, the rate of extraction 
of any substance from blood by an organ is given by,
V = F. (Ca-Cv) .................................. 2.4
where V is the rate of extraction, F is organ blood 
flow, Ca is the concentration of the substance in 
arterial blood, and Cv the concentration in venous
blood draining from the organ. The liver is a special 
case because of its dual blood supply, but, if 
extraction of the substance by organs draining into the 
portal vein is negligible, portal venous concentration 
is equivalent to arterial or peripheral venous
concentration, and the Fick principle may be applied to 
the liver by equating F with total liver blood flow and 
Cv with hepatic venous concentration. Equation 2.4 has 
been widely used to measure hepatic blood flow via the 
clearance of circulating dyes such as indocyanine 
green, with sampling from peripheral blood and from the 
hepatic veins (Caesar et al, 1961? Leevy et al, 1962). 
In experiments with both peripheral and hepatic venous
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sampling of blood galactose, Ranek et al (1983) and 
Lindskov et al (1983) observed that, during the linear 
clearance phase described in the preceding section, a 
constant difference was maintained between Ca and Cv, 
in keeping with the assumption of constant (saturated) 
clearance. However, the linear phase ended with the 
falling of the hepatic venous concentration effectively 
to zero, after which the peripheral concentration 
declined exponentially (Figure 2). Clearance of 
galactose in this phase is described as a first-order 
process, the metabolic removal pathway for galactose in 
the liver is nolonger saturated and the exponential 
decline in blood concentration with time depends on 
liver blood flow.
The observation that, for sufficiently low values of 
galactose concentration (Ca), hepatic extraction of 
galactose was essentially complete was a crucial one, 
as it implied that galactose could be used for the 
measurement of liver blood flow without hepatic venous 
sampling (Tygstrup and Winkler, 1958). Later work, to 
be discussed below, has defined more clearly the 
limitations of the assumption of complete extraction 
it is manifestly invalid in the presence of liver 
disease, for example, as a result of an alteration in 
perfusion together with a reduced hepatocellular 
function - but we first continue on the basis that it 
is a good approximation.
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Figure 2
This shows both linear and exponential clearance phases of 
galactose following a single rapid intravenous injection of 
galactose. Linear clearance of galactose ends as hepatic 
venous concentration falls to zero, systemic galactose 
concentration thereafter declines exponentially. The 
observation that, for sufficiently low values of galactose 
concentration, hepatic extraction of galactose was essentially 
complete, implies that galactose could be used for the 
measurement of liver blood flow without hepatic venous 
sampling.
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One possible approach to the measurement of liver blood 
flow is through the analysis of the exponentially 
decaying peripheral galactose concentration curve. 
Adopting the notation of the previous section, together 
with the assumptions of "instantaneous" equilibration 
and negligible extrahepatic extraction, the rate of 
extraction (V) can be expressed as,
V = -dQ(t)/dt = -Vd.dCa(t)/dt ................. 2.5
where, Vd = volume of distribution
Ca(t) = peripheral galactose concentration at 
time t
Combining equations 2.4 and 2.5, and setting Cv to 
zero, gives,
dCa(t)/dt = -(F/Vd) .Ca(t) ................... 2.6
Equation 2.6 has the solution,
Ca(t) = Cao.exp(-F.t/Vd) .......................2.7
Where, Cao = peripheral galactose concentration
immediately after intravenous injection
Hepatic blood flow (F) can be determined by measurement 
of the exponential decay constant and estimation of Vd 
as described above. However, this approach has the 
disadvantages that it depends on (a) accurate 
measurement of a rapidly decaying concentration curve, 
(b) the assumption of tissue/blood equilibration on
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a short time scale, and (c) estimation of Vd.
The alternative approach, circumventing these problems, 
is to infuse galactose peripherally at a known, 
constant rate (I). Provided that I < Vmax 
(i.e. galactose elimination is first-order), blood 
galactose concentration will eventually reach an 
equilibrium level (Cae), at which the rate of 
elimination (V) from the body equals the rate of 
infusion (I). If extrahepatic elimination is 
negligible, and hepatic venous concentration is truly 
zero, equation 2.4 becomes,
I = F.Cae ....................................... 2.8
yielding hepatic blood flow (F) directly from known or 
easily-measured variables.
To take formal account of incomplete hepatic 
extraction, the extraction efficiency (E) is defined 
as,
E = (Ca - Cv)/Ca ............................... 2.9
and equation 2.4 becomes,
V = E.F.Ca ...................................... 2.10
The ratio V/Ca = E.F is termed hepatic clearance, and 
equals the volume of blood totally cleared of galactose 
by the liver per unit of time. Unless hepatic venous
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blood is sampled, or hepatic extraction efficiency (E) 
otherwise determined, only clearance can be measured, 
as an approximation to flow. If there is significant 
extrahepatic elimination of galactose, the rate of 
infusion at equilibrium equals the sum of the hepatic 
and extrahepatic elimination rates, and clearance can 
likewise be separated into hepatic and extrahapatic 
components.
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DISCUSSION
The most comprehensive study of galactose 
clearance in patients at a low concentration range and 
at a constant intravenous infusion rate has been 
performed by Henderson et al (1982). In their 
study galactose was infused at a rate of 50 mg 
galactose/min and 40 mg galactose/min in normal and 
cirrhotic patients respectively. This rate of infusion 
was well below the maximum hepatic elimination rate 
(Vmax) for galactose of 300-600 mg galactose/min and 
200-400 mg galactose/min, found in normal and cirrhotic 
patients as previously discussed in section A. A 
similar study was performed by Tygstrup and Winkler in 
1958 in which galactose was infused in control subjects 
and patients with liver disease at a rate no greater 
than 300 mg galactose/min. Galactose clearance was 
calculated by both investigators as the infusion rate 
divided by the mean galactose concentration in the 
peripheral venous blood during the measurement period. 
The mean galactose clearance values found by Tygstrup 
and Winkler (1958) in patients with and without liver 
disease was 1046 ml/min and 1420 ml/min respectively. 
Henderson et al (1982) found galactose clearance values 
in the range 1200-1600 ml/min in control subjects, and 
700-950 ml/min in cirrhotic patients. Tygstrup and 
Winker (1958) and Henderson and colleagues (1982) also
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measured hepatic extraction efficiency by hepatic 
venous sampling. Henderson et al (1982) found mean 
hepatic extraction efficiency values of 94% for normal 
subjects and 79% for cirrhotic patients, at infusion 
rates of 50 mg galactose/min and 40 mg galactose/min 
respectively. Correspondingly Tygstrup and Winkler 
(1958) found hepatic extraction efficiency values of 
88% and 69% in normal subjects and patients with liver 
disease respectively. Tygstrup and Winkler (1958) also 
found good correlation between galactose clearance and 
hepatic blood flow as measured by the bromsulfalein 
method in normal patients. From the study by Tygstrup 
and Winkler (1958) and Henderson et al (1982) it was 
not possible, however, to determine whether the lower 
extraction efficiency in cirrhotic patients was due to 
intrahepatic portasystemic shunts or to impaired 
hepatocyte function.
Further, Henderson et al (1982) measured urinary 
excretion and erythrocyte metabolism, and estimated 
each to contribute only 2% to total clearance. A 
similar study to that by Henderson et al (1982), 
carried out the following year (Henderson and Hanna,
1983) produced comparable results, and led both groups 
of investigators to conclude that galactose clearance 
at low concentrations was a useful estimate of 
functional liver blood flow. It must be borne in mind 
however, that hepatic galactose clearance is a measure
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of hepatic blood flow (F) only if hepatic extraction 
efficiency (E) is known i.e. Clearance = E.F. Unless 
hepatic venous blood is sampled, only clearance can be 
determined as an approximation to flow. A reduction in 
hepatic extraction efficiency will occur in liver 
disease but to what extent galactose clearance 
accurately reflects hepatic blood flow in the absence 
of a hepatic extraction efficiency measurement is 
debatable (Groszmann, 1983).
Galactose clearance as a measure of hepatic blood 
flow has been extended to dogs (Hanna, 1984) and to a 
procedure using a single injection technique and higher 
blood galactose concentrations in humans (Zaramella et 
al, 1985). Results by Zaramella et al (1985) were 
superimposible to values obtained for hepatic galactose 
clearance by Tygstrup and Winkler (1958), and a close 
correlation between galactose clearance and hepatic 
blood flow as determined by bromosulfalein infusion was 
found in patients with various degrees of hepatic 
function.
It has been argued however, by Keiding and Bass (1983) 
that the hepatic elimination capacity of galactose is 
not high enough to ensure satisfactory approximation of 
clearance to hepatic blood flow in subjects with liver 
impairment (Ranek et al, 1976), although in subjects 
with no liver disease hepatic clearance approximates 
liver blood flow. The view that galactose clearance is
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a useful measure of functional liver blood flow has 
also been challenged by Keiding (1988), who performed a 
comparative study of galactose and indocyanine green 
(ICG), which were infused simultaneously in normal 
subjects. Systemic clearance of galactose was found to 
overestimate by 33% the value of liver blood flow as 
measured with ICG by the Fick principle (equation 2.4), 
regarded by the author as the gold standard by which 
hepatic blood flow should be determined.
Hepatic extraction efficiency was 91%, in reasonable 
agreement with Henderson's value of 94%, and too high 
to account for the discrepancy between clearance and 
blood flow. Urinary excretion was found to be 
negligible, and Keiding (1988) concluded that there 
must be a further, unidentified extrahepatic clearance 
mechanism, possibly renal metabolism. However, Dahn et 
al (1988), who performed a similar study in septic 
patients and normal volunteers, found good agreement 
between galactose clearance and ICG measurements of 
liver blood flow in the latter group, and a discrepancy 
in sepsis that could be fully accounted for by reduced 
hepatic extraction efficiency for galactose in this 
group. The existence of a significant extrahepatic 
metabolic pathway for galactose, and the accuracy of 
galactose clearance as a measure of liver blood flow, 
therefore remain controversial questions at present.
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SECTION C. ORAL GALACTOSE AND THE ASSESSMENT
OF PORTASYSTEMIC SHUNTING
THEORY
The tests described so far are based on the 
introduction of galactose as a bolus injection or 
continuous infusion into the systemic circulation. It 
has been found by hepatic venous sampling that 
circulating galactose, below a certain concentration 
threshold, is almost completely extracted from blood
during a single passage through the normal liver 
(Henderson et al, 1982). This implies that if galactose 
were introduced directly into the portal vein, at a 
concentration which did not exceed the maximum 
elimination rate (Vmax, from the Michaelis-Menten 
equation) for galactose by the liver i.e the liver
threshold concentration, little would escape metabolism 
on its first passage through the liver to enter the 
systemic circulation. In a patient with portasystemic 
shunting, however, some portal venous galactose would 
bypass functioning liver tissue through collateral 
channels, and the remainder might be extracted by the
hepatocytes with reduced efficiency because of liver 
disease. The aim of the proposed technique is to
quantify the fraction of galactose that enters the 
systemic circulation after it is introduced indirectly
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into the portal vein by oral administration and 
absorption from the gastrointestinal tract. No 
distinction is made between "anatomical shunting" of 
galactose through large-calibre collateral vessels, and 
"functional shunting" through poorly functioning liver 
hepatocytes, as galactose is intended to model the 
behaviour of gut-derived agents whose bioavailability 
is increased in similar fashion by both mechanisms.
Two key assumptions are made in the model;
a). The oral dose of galactose is absorbed completely 
into portal venous blood over the measurement period, 
without retention or metabolism by the gut.
b). The rate of elimination of recirculating galactose 
at any instant is proportional to peripheral blood 
galactose concentration. Recirculating galactose is 
here distinguished from the galactose that is extracted 
on first pass through the liver, and its rate of 
elimination refers to all routes, whether hepatic or 
extrahepatic.
A schematic diagram of the typical form of a blood 
galactose concentration time curve recorded after 
administration of an oral dose of galactose to a 
patient with portasystemic shunting is shown in Figure
3. The return of the curve to baseline at time T 
reflects the completion of absorption and elimination, 
and the curve is assumed to be determined 
experimentally up to this point. Adopting the
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Figure 3
This shows the typical form of a galactose concentration time 
curve recorded after administration of an oral dose of galactose 
to a patient with portasystemic shunting. The return of the 
curve towards the baseline reflects the completion of absorption 
and elimination of galactose.
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notations of the previous section, and by the second 
assumption above, the rate of elimination of 
recirculating galactose (V) at any instant is given by,
V = K.Ca(t) ..................................... 2.11
where K is a constant equal to total systemic 
galactose clearance, and Ca(t) represents peripheral 
galactose concentration at time t. The total amount of 
recirculating galactose eliminated over time T must 
equal the quantity that enters the systemic circulation 
(Qs), and is given by the time integral of V;
f v . «  -  k J<QS = |V dt = K J Ca (t) . dt = K.AUC .............. 2.12
where, AUC =j~Ca(t).dt represents the area under the 
curve in Figure 3.
If the oral dose (Q) is completely absorbed, the 
fraction of portal venous galactose that enters the 
systemic circulation (SA = systemic availability of 
galactose) is thus,
SA = Qs/Q = Kjca(t).dt/Q ......................2.13
K is determined by infusing galactose peripherally at a
known rate (I) and measuring the equilibrium value of
Ca (Cae), which satisfies
I = K.Cae........................................ 2.14
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Hence, from equations 2.13 and 2.14,
SA = Qs/Q = I^CaCti.dt / Q.Cae ............... 2.15
The systemic availability of galactose in this study 
is attributable to both anatomical and functional 
shunting, i.e.
SA = S + (1-S) (1-E) ............................. 2.16
Where S represents anatomical shunting via large 
calibre collateral vessels, (1-S) represents that 
fraction of portal blood that enters the liver and (1- 
E) represents that proportion of galactose which on 
entering the liver is not extracted by hepatocytes i.e 
(1-S)(1-E) represents functional shunting. In this 
method no distinction can be made between the extent to 
which anatomical and functional shunting each 
contribute to the systemic availability of galactose. 
The systemic availability of galactose can thus be 
readily determined from easily measurable parameters 
in equation 2.15.
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DISCUSSION
In the above analysis, it should be noted that, no 
assumptions have been about equilibration between blood 
and tissue of the oral dose of galactose. We have 
assumed that its rate of elimination by organs of 
extraction (chiefly the liver and kidneys) is 
instantaneously proportional to its concentration in 
blood, but not that it is in equilibrium between blood 
and its extravascular distribution space. The 
alternative conceptual approach, that of relating 
peripheral blood concentration to an "equivalent 
infusion rate", would yield the same results, but would 
mask this independence of tissue/blood equilibration. 
It is necessary to attain equilibrium during the 
constant infusion of galactose, however, so that the 
infusion rate can be equated with the elimination rate. 
It is of no importance what fraction of recirculating 
galactose is cleared by extrahepatic routes, and 
therefore unnecessary to measure urinary excretion. 
However, there must be proportionality between the rate 
of clearance by all routes and the concentration in 
blood. Renal excretion of galactose is known to be 
proportional to concentration (Tygstrup, 1961), and 
metabolism by red blood cells, although possibly not 
proportional, is quantitatively negligible (Henderson 
et al, 1982). The kinetics of the unidentified
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extrahepatic route proposed by Keiding (1988) are 
unknown, but, as discussed above, there is conflicting 
evidence on the quantitative significance of this 
route.
If hepatic extraction is complete, proportionality is 
assured for this route of elimination, but otherwise it 
follows from equation 2.10 that hepatic extraction 
efficiency must be independent of blood galactose 
concentration. Hepatic extraction is a saturable 
process which has been shown experimentally to obey 
Michaelis-Menten kinetics (Keiding et al, 1976; Keiding 
and Chiarantini, 1978), and the extraction efficiency 
will in fact decrease with increasing concentration. 
However, there is good evidence that this decrease is 
small for concentrations within the range actually 
encountered. Henderson et al, (1982) investigated the 
effect of doubling the rate of infusion of galactose on 
measurements of galactose clearance performed as 
described in the preceding section. They found that, in 
both normal subjects and patients with cirrhosis of the 
liver, clearance was only reduced by 8% on average at 
the higher rate of infusion (50-100 mg galactose/min), 
implying that hepatic extraction efficiency varied 
relatively little over concentrations up to 100 mg/1,
and that galactose clearance was first-order process. 
The incomplete hepatic extraction observed in normal 
subjects implies that some oral galactose will enter
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the systemic circulation in the absence of liver 
disease and/or portal hypertension, and it is an 
acceptable limitation of the technique that the 
measured parameter cannot be equated with portasystemic 
shunting as generally understood. It is an index which 
is related to shunting, and which may predict the 
bioavailability of gut-derived agents which are partly 
or completely removed on first pass by the liver in the 
absence of shunting (Bjorneboe et al, 1972). In a 
later chapter we consider explicitly the Michaelis- 
Menten equation, and the variability of hepatic 
extraction efficiency, in the context of experimental 
studies on galactose elimination kinetics in portal 
hypertension. The development of the present 
theoretical framework has been guided by the objective 
of obtaining useful information from a practicable 
clinical test, in which simplicity of performance and 
analysis are at a premium, and which existing evidence 
suggests will yield acceptably accurate results.
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CHAPTER THREE MEASUREMENT OF SYSTEMIC GALACTOSE
BY ENZYME ASSAY AND FLUORESCENCE 
S PECTROPHOTOMETRY
1. Introduction
2 . Materials and methods
3. Analytical accuracy and
precision
4. Results
5. Discussion
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INTRODUCTION
Until recently, work in numerous areas of 
biological investigation has been restricted by the 
lack of a convenient and reliable technique for 
determining the galactose content of biological 
solutions. Such techniques which have been available 
have been seriously limited in usefulness and 
applicability by complexity, lack of specificity, or by 
a range of sensitivity inadequate to detect the small 
concentrations frequently encountered (Tygstrup et al, 
1954; Date, 1958; Atkinson et al, 1961). This chapter 
describes one of two currently available assays which 
allow adequate detection of galactose in the 
concentration range required in this study. Whole blood 
galactose and urine galactose concentration levels were 
determined in all experiments by application of the 
galactose dehydrogenase enzyme assay (Wallenfels et al, 
1962; Rommel et al, 1968) utilising fluorescence 
spectrophotometry.
The analytical accuracy and precision of the method has 
been assessed from the standard deviation between 
duplicate and/or triplicate precipitations of blood 
from fasted rats after the addition of known quantities 
of galactose, together with the measured recovery of 
galactose from these samples.
The recovery of galactose added to blood from fasted
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human volunteers and the standard deviation between 
triplicate precipitations of this blood was similarly 
assessed.
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MATERIALS AND METHODS
Sampling of Blood
A). In all patient studies, as described in Chapter 4, 
blood was collected in a 1 ml syringe from an 
indwelling venous catheter in the right arm.
All blood samples were deproteinised immediately after 
collection to minimise erythrocyte metabolism. 0 .1ml of 
the venous sample was dispensed into a microcentrifuge 
tube (Sarstedt, West Germany) containing 0.5ml, 
0.3 3mol/L perchloric acid. This was inverted several 
times to ensure complete mixing.
The deproteinized blood sample was then
microcentrifuged (2500rpm, Model 320, Quickfit 
Instrumentation, England) for three minutes and the 
supernatant pipetted into a fresh microcentifuge tube 
and either stored at +4 degrees C for up to three days 
or frozen at -20 + 5 degrees C until analysis.
B). In all animal experiments, male Sprague-Dawley 
rats weighing 250-390 grams were used. 0.2ml blood 
samples were collected at various time intervals, as 
described in Chapter 6, into a 1ml syringe from the 
right cannulated femoral artery after induction of 
anaesthesia with 4% halothane in a 2:1 nitrous 
oxide/oxygen mixture and after a tracheostomy was
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performed. Ventilation of the animal was with a Harvard 
Rat Ventilator (Model 680) as described in chapter 5. 
0.1 ml of the arterial blood was added to 0.5 ml 
perchloric acid, microcentrifuged and stored as 
described above for patient blood prior to analysis. 
Normal saline was flushed into the cannula after each 
blood sample to maintain animal blood volume.
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Enzyme Assay and Fluorescence Spectrophotometry
Blood concentrations of galactose were determined 
by reaction with the specific oxidative enzyme 
galactose dehydrogenase (EC 1.1.1.48) coupled to an 
ultraviolet spectrofluorometric measuring technique. 
The test principle (Figure 4) is based upon the 
interaction of the enzyme with D-galactose and the co­
enzyme nicotinamide-adenine dinucleotide (NAD). The 
resultant enzyme-substrate interaction converts 
galactose into galactono-lactone with formation of the 
fluorescing co-enzyme NADH. The resultant fluorescence 
is proportional to the amount of galactose present in 
the original blood or urine sample and was measured by 
a fluorescence spectrophotometer (Perkin-Elmer MPF-3L), 
using the following settings;
Excitation wavelength-------------- 365nm
Emmission wavelength -------------- 4 60nm
Emmission slit width -------------- 3nm
Excitation slit w i d t h -------------- 20nm
Reference sensitivity -------------- Direct
Response -------------- Fast
Figure 4
Galactose Test Principle
Galactose
Galactose + NAD(+)  > Galactono-lactone
Dehydrogensase + NADH + H( + )
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Galactose Calibration Graph
Before blood samples were measured for galactose 
concentration a standard straight-lined calibration 
graph of relative fluorescence (millivolts) versus 
galactose concentration (mg/1) was constructed.
In rat experiments, two calibration concentration 
ranges of galactose were chosen to allow accurate 
measurement of galactose at low and high 
concentrations in blood. The low concentration range 
consisted of six galactose standards each containing 0, 
2, 4, 6, 8, 10 mg/1 of galactose respectively. These
were prepared from a standard water stock solution of 
10 mg/1 of galactose with the appropriate dilutions 
being made in distilled water. The high concentration 
range of galactose consisted of six galactose standards 
ranging in concentration from 0, 8 , 16, 24, 32, 40
mg/1. These were prepared from a standard water stock 
solution of 40 mg/1 and again the appropriate dilutions 
were made in distilled water.
For the enzyme assay, 0.2ml of each galactose standard 
was added to 3.0ml 0.2mol/l, pH7.5 phosphate buffer and 
0.10ml 13mmol/l NAD. Galactose dehydrogenase, phosphate 
buffer and NAD were commercial preparations from 
Boehringer, Mannheim (F.R.G). This solution was gently 
mixed, transferred into a 3.5ml cuvette and the 
fluorescence A1 measured by the fluorescence
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spectrophotometer. 0.02ml (>2 0U/ml) of the enzyme
galactose dehydrogenase was then added to each sample, 
which was rotamixed and left until completion of the 
reaction, approximately 3 0 to 4 0 minutes, when 
fluorescence A2 was measured. Pilot studies showed that 
no significant change in fluorescence occured later 
than 30 minutes after addition of the enzyme. Final 
fluorescence was calculated as reaction fluorescence 
minus initial fluorescence;
A2 - A1 = A3 .................................3.1
On construction of the graph of relative fluorescence 
(millivolts) versus galactose concentration (mg/1) for 
the assay of blood samples, the galactose concentration 
in each standard was multipied by a factor of six in 
order to correct for the 6 fold dilution which each 
blood sample underwent on deproteinization with 
perchloric acid. The relationship between fluorescence 
and concentration was found to be linear at both the 
low and high concentration ranges (Figures 5 and 6). 
The best fit linear regression of fluorescence on 
galactose concentration was calculated as below,
A3 = a + bCg .................................... 3.2
where Cg = galactose concentration, and the parameters 
of the line (a and b) were used to calculate the 
concentration of galactose in blood samples as
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described below.
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Figure 5
This shows the good correlation between 
Relative Fluorescence (RF) and Galactose 
Concentration (GC) in the low galactose 
concentration range of the calibration graph. 
The relationship is described by the linear 
regression equation RF = 1.107GC + 1.286. A 
correlation coefficient of 0.999 was found 
and the intercept of the linear regression 
line with the Y axis was not significantly 
different from zero.
103
200 - i
>
E 150 -
Ui
ozLUo
(/)
LU
0c o3
100 -
ID
>
I-<
_J
ID
CC
50 -
” 1--------1------- 1------- 1------- 1--------1
50 100 150 200 250 300
GALACTOSE CONCENTRATION (mg/l)
Figure 6
The relationship between Relative Fluorescence 
(RF) and Galactose Concentration (GC) in the high 
galactose concentration range of the calibration 
graph is described by the linear regression 
equation of RF = 0.8160GC + 2.905. The figure 
demonstrates the good correlation between 
relative fluorescence and galactose concentration 
(correlation coefficient = 0.999). The intercept 
of the linear regression line with the Y axis was 
not significantly different from zero.
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Sample analysis
Upon analysis 0.2 ml of the deproteinised 
supernatant from each blood sample was added to 3.0 ml 
phosphate buffer and 0.10 ml NAD as described above for 
the calibration standards. The change in fluorescence 
following addition of 0.02 ml galactose dehydrogenase 
was similarly determined. Galactose concentration (Cg) 
was calculated using the parameters a and b derived 
from equation 3.2 of the calibration curve;
Cg = (A3 - a)/b .................................3.3
In all experiments, between 3 and 6 blood samples were 
taken for measurement of basal galactose concentration, 
which was subtracted from all subsequently measured 
values. Basal galactose concentration was typically in 
the range 0 to 5 mg/1.
Urine samples were similarly analysed (results are 
described in a succeeding chapter), after dilution if 
necessary to bring galactose concentration into the 
calibrated range.
105
ANALYTICAL ACCURACY AND PRECISION
The analytical accuracy and precision of the 
galactose dehydrogenase assay was assessed by analysing 
samples prepared by adding known concentrations of 
galactose to blood collected from fasted rats. Blood
samples were obtained from animals anaesthetised with
ether and subjected to laparotomy in the following 
manner; Upon abdominal incision the intestines were 
expelled from the abdominal cavity and retracted to 
enable clear visualisation of the inferior vena cava. 
Blood was withdrawn from the vena cava into a 
heparinised 10ml syringe. The animal was then
sacrificed by opening the chest.
0.9 ml of the collected blood was added to 0.1 ml of a 
solution of galactose in distilled water at 
concentrations of 100, 200, 400, 800, 1600 mg/1. These
blood standards were treated in the same manner as 
collected blood samples previously described. 
Triplicate precipitations were made at each
concentration. Six precipitations of the collected 
blood without adding galactose were made in order to 
determine basal blood levels of galactose. The average 
basal* galactose concentration measured in each rat was 
subtracted from the galactose concentration measured 
in each sample.
After enzyme analysis and determination of galactose
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concentration in each sample as already described, the 
standard deviation between triplicate precipitations 
was used to assess the precision of the enzyme assay. 
The accuracy of the enzyme assay was assessed from the 
measured recovery of galactose from these blood 
samples.
The same analysis was performed using venous blood 
obtained from human volunteers after an overnight fast. 
Again samples were precipitated in triplicate.
Statistical Analysis
In all experiments, the statistical significance 
between observed differences was tested by the 
Student's t-test.
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RESULTS
The analytical accuracy and precision of the 
method was assessed from the blood of eight rats and 
four human volunteers.
The mean measured concentration of galactose from 
triplicate samples in each rat are tabulated against 
expected values in Table 1. The overall mean, standard 
deviation and standard error of the mean for all rats 
measured for galactose concentration are also shown in 
Table 1. The mean percentage galactose recovery, at 
expected galactose concentrations of 10, 20, 40, 80,
160 mg/1 was 90.6, 100.15, 99.35, 100.01, and 101.18%
respectively (Table 1). No statistically significant 
difference was found between expected and recovered 
galactose concentrations.
Simple linear regression analysis demonstrated a 
correlation coefficient of 0.996 between calculated 
galactose recovery (CG) and expected concentration of 
added galactose (EG), with a linear regression equation 
CG = 1.016EG - 0.847 (Figure 7). The intercept of the 
linear regression line with the Y-axis was not 
significantly different from zero, and the gradient was 
not significantly different from 1.0.
Table 2 demonstrates the standard deviation (SD) and 
coefficient of variation (CV) between replicate samples 
at expected galactose concentrations of 10, 20, 40, 80,
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160 mg/1. At each concentration, the standard
deviation was calculated by pooling the results of 
triplicate precipitations in eight rats, using the 
following formula:
%  (CGij - CGi)
where CGij is the calculated galactose recovery for rat 
i and precipitations j , CGi is the mean of the three 
precipitations for rat i, and the denominator 
represents the number of degrees of freedom within 
groups, i.e. the total number of measurements minus the 
number of groups (or rats). The coefficient of
variation was calculated by expressing SD as a 
percentage of overall mean CG.
As is common in such assays, standard deviations tend 
to increase with increasing concentration, however the 
relationship is not proportional. Depending on 
concentration, the coefficient of variation (CV)
between replicate samples ranged from 4.4% to 17.1% 
(Table 2) . The largest CV's were at the 10 mg/1 
concentration, and the smallest were at the 80 and 160 
mg/1 concentration.
The mean measured concentration of galactose from
triplicate samples in each human volunteer are
tabulated against expected values in Table 3. The
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overall mean, standard deviation and standard error of 
the mean for all volunteers measured for galactose 
concentration are also shown in Table 3. The mean 
percentage recovery of galactose, at expected galactose 
concentration of 10, 20, 40, 80 mg/1 was 98.0, 110.0,
105.25, and 106.5% respectively (Table 3). No 
statistically significant difference was found between 
expected and recovered galactose concentrations.
Simple linear regression analysis demonstrated a 
correlation coefficient of 0.992 between calculated 
galactose recovery (CG) and expected concentration of 
galactose (EG), with a linear regression equation CG = 
1.069EG - 0.284 (Figure 8). The intercept of the linear 
regression line with the Y-axis was not significantly 
different from zero, and the gradient was not 
statistically different from 1.0.
Table 4 shows the standard deviation (SD) and 
coefficient of variation (CV) between replicate samples 
at expected galactose concentrations of 10, 20, 40, 80
mg/1. Depending on concentration, the coefficient of 
variation (CV) between replicate samples ranged from 
10.1% to 15.6%. The largest CV's were at the 10 mg/1 
concentration. Standard deviation values tended to 
increase with increasing concentration. Values ranging 
from 1.53 to 8.64 mg/1 were found.
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TABLE 1
Expected concentration of
galactose (mg/1)
10 20 40 80 160
it (n = 8) Mean galactose recovery
1 6.5 20.1 41.2 82 .7 165.7
2 9.6 21.0 41.6 91.1 182 . 6
3 13.5 22.6 40.9 83 . 2 162 .1
4 9.6 19.9 35.9 80. 5 157.0
5 6. 6 18. 1 37.5 72.9 152 .9
6 7.4 23 . 3 42 . 6 74 . 3 149.2
7 7.5 17.7 39.2 80.1 160. 6
8 11.8 17.5 39.0 75. 3 164 . 9
MEAN 9. 06 20. 03 39.74 80.01 161.88
SD 2 . 55 2.20 2 . 26 5. 93 10. 14
SE 0.90 0.78 0.80 2 . 10 3 . 59
Mean percent 
galactose 90. 60 100.15 99. 35 100.01 101. 1!
recovery
The precision and accuracy of the galactose 
dehydrogenase enzyme assay has been assessed from 
triplicate precipitations of blood from eight rats. The 
individual and overall mean galactose recovery, the 
standard deviation between animals and the standard 
error of the overall mean at each expected 
concentration are tabulated above.
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EXPECTED GALACTOSE CONCENTRATION (mg/l)
Figure 7
The relationship between Mean Calculated 
Galactose Recovery (CG) and Expected Galactose 
Concentration (EG) from eight rats is described 
by the linear regression equation CG = 1.016EG -
0.847. The correlation coefficient was 0.996.
The intercept of the linear regression line with the 
Y axis was not significantly different from zero, 
and the gradient was not signficantly different from 
1.0 .
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TABLE 2
SD
between
replicates
(mg/l)
CV
between
replicates
(%)
Expected concentration 
galactose (mg/l)
10 20 40 80
1.55 1.63 2.22 3.96
17.1 8.1 5.6 4.9
of
160
7 .16 
4.4
Standard deviations and coefficients of variation 
have been determined between replicate samples measured 
for galactose concentrations in rats.
TABLE 3
Expected concentration of
galactose (mg/l)
10 20 40 80
Human
Volunteer
Overall mean of 
galactose
recovered
(mg/l)
SS 10.4 21.8 40.1 83 . 4
GF 9.1 18.6 39.4 79 . 7
HB 8.6 23 . 3 42.2 95. 5
DM 11.2 24.3 46.7 82 . 3
MEAN 9.8 22 . 0 42 . 1 85.2
SD 1. 19 2.49 3 .29 7 . 02
SE 0.59 1.24 1. 64 3 . 51
Mean percent 
galactose 98.0 110.0 105.25 106.50
recovery
The individual and overall mean galactose 
recovery, the standard deviation between individuals 
and the standard error of the mean at each expected 
concentration are tabulated above.
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Figure 8
The relationship between Mean Calculated 
Galactose Recovery (CG) and Expected Concentration 
of Galactose (EG) from four control volunteers is 
described by the linear regression equation CG = 
1.069EG - 0.284. The correlation coefficient was
0.992. The intercept of the linear regression 
line with the Y axis was not significantly 
different from zero, and the gradient was not 
significantly different from 1.0.
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TABLE 4
Expected concentration of
galactose (mg/l)
10 20 40 80
SD 1.53 2.84 5.15 8.64
between
replicates
(mg/l)
CV 15.6 12.9 12.2 10.1
between 
replicates 
(%)
Standard deviations and coefficients of variation 
have been determined between replicate samples measured 
for galactose concentrations in human volunteers.
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DISCUSSION
The ability to accurately measure galactose 
concentrations in the blood depends upon the 
sensitivity and the specificity of the method so 
applied. Early problems encountered in the analysis of 
biological solutions have been the presence of other 
sugars particularly glucose, which react along with 
galactose, and the inability to measure galactose in 
physiological concentrations (Raymond et al, 1928; 
Atkinson et al, 1961). The development of two standard 
enzyme assays, which are galactose specific, eliminated 
many of the earlier problems (Henderson and Fales, 
1980; Rommel et al, 1968).
The galactose dehydrogenase enzyme assay used in this 
study was first described by Rommel et al (1968). The 
specificity of the oxidative enzyme galactose 
dehydrogenase (EC.1.1.1.48) for galactose was first 
demonstrated by Wallenfels et al (1962), and early 
assays were initially coupled to colourimetric 
reactions (Roth et al, 1965). Sensitivity was enhanced, 
however, when fluorometry was exploited (Grenier et al, 
1973) , which proved to be approximately 25-fold more 
sensitive than the colourimetric galactose oxidase 
assay as reported by Tengstrom (1969). However, such 
concentrations which were being measured were still in 
the concentration range 200 to 600 mg/l.
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This study has applied the galactose dehydrogenase 
enzyme assay with fluorescence spectrophotometry to 
measure whole blood galactose concentrations at less 
than 100 mg/l. The assay has been successfully applied 
to measure galactose concentrations in pigs and humans 
in excess of 100 mg/l (Keiding et al, 1976; Zaramella 
et al, 1985) . However, few investigators have measured 
galactose concentrations in the range below 100 mg/l. 
End point assays, such as this one, should yield the 
most precise results, being unaffected by small changes 
in temperature, enzyme activity and time of 
measurement, since measurement is made after reaction 
is complete. As is common with such assays, and 
demonstrated in this study, standard deviations tend to 
increase with increasing concentration as errors that 
are constant in percentage terms become more pronounced 
in absolute terms at higher concentrations. Such 
concentration-dependent variability is due to random 
errors in pipetting, sample mixing, concentration 
preparation and general laboratory techniques. 
Conversely, coefficients of variation (CV) tend to be 
increased at low concentrations since measurements at 
these concentrations are very close to the sensitivity 
limit of the assay and measurements are often overlaid 
with instrumental noise. This study demonstrated a CV 
of 17.1% at an expected concentration of 10 mg/l. A 
7.7% CV was reported by Henderson and Fales (1980) at
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the same galactose concentration, however, these 
authors used the alternative assay of galactose oxidase 
utilising continuous flow fluorometry. This more 
automated assay would tend to reduce random errors and 
enhance assay precision. The galactose dehydrogenase 
enzyme assay has been applied by Keiding (1988) to 
measure low blood galactose concentrations from human 
volunteers in hepatic blood flow studies. Arterial 
galactose concentrations below 18 mg/l and hepatic 
venous concentrations of almost 0 mg/l have been 
measured during continuous galactose infusion.
Venous blood from human volunteers in this study 
demonstrated standard deviations of less than 1.4 mg/l 
at an expected concentration of 10 mg/l. The standard 
deviations and coefficients of variation shown in this 
study are slightly greater than those reported by 
Henderson and Fales (1980), however they are not 
unrealistic for this type of assay. At expected 
concentrations greater than 20 mg/l the scatter of 
results is small (CV of less than 6%), and the method 
is reproducible with good resolution. At
concentrations of 10 mg/l and below resolution is 
reduced as one reaches the limits of assay sensitivity. 
The accuracy of an assay is reflected in the percent 
recovery of galactose added to blood samples. Henderson 
and Fales (1980) recovered 97.0%, 99.3%, 101.0%, 98.5%
of galactose from blood with expected
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galactose concentrations of 10, 40, 70, 100 mg/l. A
similar percentage recovery of galactose was achieved 
from this study at expected galactose concentrations of 
10, 20, 40, 80, 160 mg/l. Keiding (1988), however
reported lower percent recoveries ranging from 77% to 
89% in six human volunteers at a concentration of 
approximately 20 mg/l.
The accuracy of an assay will owe much to errors which 
are independent of concentration. Errors which would be 
a major contributory factor would be those which in 
some way affected basal galactose measurements. Since 
the average basal galactose concentration is subtracted 
from the galactose concentration measured in samples an 
error producing basal galactose inaccuracies would thus 
alter final galactose concentration. Fluorescence 
spectrophotometry is particularly sensitive to 
contaminating substances and part of the signal 
detected may in fact not be fluorescence. Raman 
scattering and Rayleigh scattering, both provide 
signals to the detector which can be mistaken for 
fluorescence. Further the cuvette may be contaminated 
by fluorescent material such as fingerprints. 
Systematic errors are minimised and accuracy maximised 
by using linear relations for calibration and by 
measuring at or near the wavelength of maximal 
fluorescence, so that a small error in applied 
wavelength has a minimal effect on the value measured.
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The accuracy of the method in this study has proven to 
be very high and values of recovered galactose are not 
statistically different from expected galactose 
concentrations.
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INTRODUCTION
Portasystemic shunting is an important consequence 
of all diseases that lead to portal hypertension. In 
view of the many abnormalities possibly related to 
portasystemic shunting it is surprising that so far no 
non-invasive method has been developed to measure this 
abnormality in patients and to define its clinical 
significance.
According to pharmacokinetic principles, as already 
described in Chapter 2, a procedure for assessing 
portacaval shunting might be designed by combining oral 
and intravenous clearances of a substance (Porchet and 
Bircher, 1982). The naturally occuring monosaccharide 
D-galactose was found to possess very promising 
features as a test substance. These features being that 
galactose is non-toxic, is rapidly and completely 
absorbed from the gastrointestinal tract, does not 
undergo intestinal first-pass elimination and is 
eliminated almost exclusively by the liver by an active 
metabolic process which has a maximum limiting rate 
(Vmax). In this chapter galactose was used to evaluate 
the hypothesis that the systemic availability of oral 
galactose should indicate the fraction of portal blood 
by-passing functioning liver hepatocytes, assuming that 
the systemic spillover mainly depends on intra or extra 
hepatic shunting.
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An initial pilot study was carried out in order to 
establish a suitable oral dose of galactose, that 
following absorption from the small intestine was 
completely cleared from portal blood on its first pass 
through the liver in normal volunteers who had no 
history of liver disease. Once established, this dose 
was given to control patients with no history of liver 
disease and to patients with liver disease, and a 
comparison of the systemic availability of the oral 
galactose dose made. In all patients systemic 
clearance of galactose was determined following an 
intravenous infusion of galactose below the maximum 
elimination rate of the liver (Vmax). The methods used 
and results are described in this chapter.
Adherance of galactose elimination to first-order 
kinetics within the concentration range of this study 
were also examined. If elimination of galactose is a 
first order process i.e. systemic clearance is 
independent of concentration, then a doubling of the 
galactose infusion rate should result in a two fold 
increase in the equilibrium concentration of galactose. 
This ideal was examined in control volunteers by 
calculating galactose clearances from mean systemic 
eguilibrium galactose concentrations at intravenous 
infusion rates of 40 and 80 mg galactose/min. The 
ratio of the clearance values from the two infusion 
rates were then statistically compared to the ideal of
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one.
Further, as a test of the method, control volunteers 
were also given a short intravenous infusion of
galactose, and the systemic appearance/clearance curve 
was analysed as if it had been produced by the same 
quantity of galactose administered orally. The short 
intravenous dose thus simulated an oral dose of 
galactose which was completely absorbed from the small 
intestine and completely diverted into the systemic 
circulation. The calculated systemic availability of 
galactose should thus ideally be 100 percent. The
systemic availability was calculated in all subjects 
utilising both galactose clearance values at
intravenous infusion rates of 40 and 80 mg galactose 
/min. The results obtained were statistically compared 
to the ideal of 100.
125
SECTION A. ORAL GALACTOSE PILOT STUDY
MATERIALS AND METHOD
The subjects were all male volunteers with a mean 
+ SD age of 21.7 + 1.03 years and a mean + SD weight of 
68.5 + 5.05 kg. All subjects had fasted for at least
nine hours prior to the beginning of the study. All 
studies were carried out in a quiet room with the 
subjects supine and their heads elevated to a 
comfortable angle. The oral dose of galactose ranged 
from 1.5 to 7 grams, and was dissolved in 50 ml of 
distilled water. A catheter (Venisystems, Butterfly- 
23, Abbott Ireland Ltd, Rep.Ireland) was placed in 
the right forearm vein and maintained by flushing with 
a dilute heparin solution (Hepsal, CP Pharmaceuticals 
Ltd, Wrexham). Approximately 0.5 ml blood samples were 
collected at 2 to 4 minute intervals for a total of 40 
minutes following administration of the oral dose. 
Prior to all sample collections a 1 ml blood sample was 
collected and discarded. This sample contained largely 
heparinised saline which maintained the venous line. 
0.1 ml of the collected blood was added to 0.5 ml 
perchloric acid, centrifuged and the supernatant 
measured for galactose concentration as described in 
Chapter 3. Prior to administering the oral dose a 
venous blood sample was collected to allow
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determination of basal galactose concentrations.
In only two subjects were systemic clearance 
measurements made. In these volunteers galactose 
dissolved in distilled water was infused into an 
indwelling catheter (Venisystems, Butterfly-23, 
Abbott Ireland Ltd, Rep.Ireland) in a left forearm vein 
by a Treonic IP3 infusion pump (Vickers Medical, 
Basingstoke, England) at a rate of 3 0 ml/hr (40 mg 
galactose/min). Blood samples were collected at 10 
minute intervals from 50 to 90 minutes after the start 
of the infusion. The oral and clearance studies were 
performed on different dates, and the systemic 
availability calculation in these two subjects was 
based on the assumption that clearance had a similar 
value on both occasions. Systemic availability of the 
oral dose in the two subjects was calculated as 
described below.
127
AUC, clearance and systemic availability calculations
In all subjects, areas under the galactose 
appearance curve (AUC) from concentration time graphs 
were determined by a specially written computer 
program, using linear interpolation between points.
In two subjects systemic galactose clearance (K) was 
calculated using equation 2.14 in chapter 2,
I/Calv = K .................................. (2.14)
where,.I = rate of galactose infusion
Calv = mean equilibrium blood galactose
concentration following an intravenous 
infusion
The mean equilibrium venous concentration of galactose 
(Calv) was determined by subtracting the basal 
concentration of galactose at time zero (Co) from the 
mean equilibrium galactose concentration (Css) i.e. 
Calv = Css - Co.
The systemic availability of galactose was calculated 
using equation 2.15 in chapter 2, where
SA = I.AUC/Q.Caiv ............................ (2.15)
Where, SA = Systemic availability of galactose
AUC = area under the galactose appearance curve 
I = rate of galactose infusion 
.0 = oral galactose dose 
Ca1 = mean equilibrium venous blood galactose 
concentration
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RESULTS
A clearly defined blood galactose appearance peak 
was only seen in subjects who received at least 5 grams 
of galactose orally (Table 5). Blood galactose
reached a maximum level 14 to 18 minutes after 
administration of the oral dose, and had declined to 
basal level by 40 minutes in all but one subject, who 
received 7 grams of galactose and showed peak and 4 0 
minute concentrations of 46 mg/1 and 6 mg/1 
respectively. In subjects who received 3 grams 
of galactose or less, and in one out of two who 
received 5 grams, there was no well-defined appearance 
peak, and the maximum concentration recorded in blood 
did not exceed 4 mg/1 above baseline.
In the two subjects in whom clearance measurements were 
performed, blood galactose concentration was constant 
over the 40 minute sampling period to within 2 mg/1,
and the average concentration was used for calculation. 
Clearance values of 2.58 1/min and 1.78 1/min were 
obtained, giving estimates of 4.3% and 17.4% for the 
systemic availability of oral doses of 3 grams and 7 
grams of galactose respectively (Table 5).
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TABLE 5
Subject Dose CGmax Tpk AUC Clearance SA
(g) (mg/1) (min) (mg.min/1) (1/min) (%)
1 1.5 3 a 30 ----
2 3.0 1 a 16 ----
3 3 . 0 4 a 47 ----
4 5.0 4 a 50 2 . 58
5 5.0 16 18 115 ----
6 7 . 0 18 14 186 ----
7 7.0 46 18 687 1.78
4.3
17 .4
CGmax = maximum blood galactose concentration 
after oral dose 
Tpk = time of blood galactose appearance peak
a = no clearly defined peak observed
AUC = area under appearance curve from 0 to 4 0
minutes 
Clearance = I/Calv
SA = Systemic availability of oral dose
(eg.I.AUC/oral dose.Calv)
This shows the area under the galactose appearance 
curve and other calculated expressions at various oral 
doses of galactose in control volunteers.
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DISCUSSION
The aim of this pilot study was to determine an 
oral dose of galactose that after absorption from the 
small intestine would be completely cleared by the 
liver in control volunteers. The results show that 
oral doses of 5 grams of galactose and above are not 
completely extracted on first pass through the normal 
liver, although the calculated systemic availability of 
a 7 gram dose in the subject showing the highest level 
of breakthrough was still less then 20%. The ability 
to detect an apperance peak at lower doses is limited 
by measurement accuracy, and determination of the area 
under the appearance curve is subject to errors of 
measurement, particularly in the basal level of blood 
galactose which is the reference point for all 
subsequent measurements. An error of 1 mg/1 in this 
basal level would lead to an error of 40 mg.min/1 in 
the area under the appearance curve. However, in 
absolute terms this would translate into only a small 
error in systemic availability. Such errors would be 
minimised by choosing as large a dose as is consistent 
with high extraction efficiency by the normal liver, 
and on the basis of this pilot study it was decided to 
use a dose of 4 grams for further investigations. It 
was also decided that blood sampling following the oral 
dose shuld be extended to 60 minutes, and should be
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most frequent during the first twenty minutes to cover 
the relatively steep rise to the concentration peak.
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SECTION B. PATIENT STUDY
MATERIALS AND METHODS 
SUBJECTS
A ) . Control volunteers
Six control volunteers from our Department of 
Surgery, Glasgow Royal Infirmary, were studied for the 
purpose of assessing the adherance of galactose 
elimination to first-order kinetics. The same 
volunteers were also studied for the purpose of 
assessing whether or not a short intravenous infusion 
of galactose, treated as a dummy oral dose, which 
ideally should produce a systemic availability of 100 
percent, did indeed produce this ideal. The 5 men and 
1 woman studied had a mean age of 31.6 + 7.02 (SD)
years and had a weight range of 55.0 to 85.7 kg. All 
were healthy and had normal biochemical data (Table 6).
B). Patients with and without liver disease/portal 
hypertension
Six control subjects without, and seven subjects 
with liver disease and one patient with portal vein 
thrombosis were studied over a 2 hour time period in 
order to examine the systemic availability of galactose
133
following a low oral dose of galactose. All six 
subjects without liver disease were studied exclusively 
for the purpose of establishing normal data. The 5 men 
and 1 woman had a mean age of 65.8 + 8.5 (SD) years, 
and ranged in weight from 58.8 to 92.0 kg. All were 
healthy and had normal values of total bilirubin, 
aspartate transaminase and alanine transaminase, gamma- 
glutamyl transpeptidase, alkaline phosphatase (Table 
7). In all cases the contol patients were in a pre­
operative state and had been admitted to the Glasgow 
Royal Infirmary for minor operations, for example, 
surgery for a lipoma on the arm and removal of 
gallstones.
The seven patients with liver disease and one patient 
with portal vein thrombosis had a mean age of 51.2 ±
11.96 (SD) years and had been referred to our 
department by practicing physicians. The weights of 
the patients ranged from 52.0 to 90.0 kg. All patients 
had evidence of portal hypertension with portasystemic 
shunting in that they had endoscopically-diagnosed 
oesophageal varices. All but two patients had elevated 
fasting bile acid concentrations. The patients are 
defined in Table 7 by conventional biochemical data.
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TABLE 6
Volunteers Albumin Bilirubin AlkPhos AST ALT Gamma GT Glucose
(fasting)
(g/1) (umol/l) (U/l) (U/l) (U/l) (mmol/1)
JA 47 13 205 17 9 47 5.1
GF 45 7 115 11 8 82 4 . 9
DMcM 44 17 140 20 11 15 5.3
WA 45 11 120 10 <5 13 5.7
HB 46 5 100 15 <5 6 4 . 9
HT 41 7 75 10 12 9 5. 1
Normal
Range
35-55 3-22 80-280 12-48 3-55 <36 4-5.
Aik Phos = Alkaline Phosphatase
AST = Aspartate Transaminase 
ALT = Alanine Transaminase 
Gamma GT = Gamma-glutamyl Transpeptidase
This shows the biochemical data for six control 
volunteers. Normal ranges are given as defined by the 
Biochemistry Department, Glasgow Royal Infirmary. All 
had normal biochemical data, except volunteers JA and 
GF who had slightly elevated Gamma GT 
levels above normal.
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TABLE 7
Patients Albumin Bilirubin AlkPhos AsT ALT Gamma GT Glucose
(fasting)
(g/1) (umol/1) (U/l) (U/l) (U/l) (mmol/1)
Without liver disease/portal hypertension
JC 45 9 135 20 13 38 5.1
FMcC 47 10 16 <5 25 6.0
RS 46 23 155 23 8 41 7 . 3
JA 48 10 160 23 7 19 5.4
CMcN 32 10 140 <5 <5 9 6.0
RH — 4 210 20 23 35 ---
7ith liver disease/portal hypertension
TM 41 25 275 22 6 206 8.6
GL 26 120 --- 71 21 191 5.1
AMcM 34 32 320 42 <5 287 6.1
WMcC 29 19 160 24 <5 93 5.9
JN 30 44 430 40 8 76 5.8
*AMcA 40 26 250 30 9 32 5.6
JE 34 11 980 25 33 340 ---
MK 30 34 1320 82 27 147 ---
Normal 35-55 3-22 80-280 12-48 3-!55 <36 4-5.
Range
* = patient with portal vein thrombosis 
This shows the biochemical data, for patients 
with and without liver disease/portal hypertension. 
Normal ranges are given as defined by the Biochemistry 
Department, Glasgow Royal Infirmary.
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The definitions of the enzymes in Table 7 are shown 
below;
Aik Phos = Alkaline Phosphatase
AST = Aspartate Transaminase 
ALT = Alanine Transaminase 
Gamma GT = Gamma-glutamyl Transpeptidase
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METHOD
A) Control volunteers
All control volunteers were asked to fast 
overnight and throughout the study. All studies were 
carried out in a quiet room. Studies were carried out 
with the subjects supine and their heads elevated to a 
comfortable angle. A solution of eight percent D-
galactose (BDH Chemicals Ltd, Poole) was prepared by 
the Pharmacy Department, Glasgow Royal Infirmary, and 
was given by intravenous infusion into the left 
forearm vein catheter (Venisystems, Butterfly-23, 
Abbott Ireland Ltd, Rep.Ireland) at a constant rate of 
90 ml/hr by Treonic IP3 infusion pump (Vickers Medical, 
Basingstoke, England) for 30 minutes. 1 ml blood
samples were collected, from an indwelling catheter 
(Venisystems, Butterfly-23 Abbott Ireland Ltd, 
Rep.Ireland) in the right forearm vein, throughout this 
time period approximately every 4 minutes, and sampling 
was then continued after the end of the infusion until 
60 minutes had elapsed. The venous catheter was 
maintained by flushing with a dilute heparin solution 
(Hepsal, CP Pharmaceuticals Ltd, Wrexham). Data from 
this part of the experiment were subsequently analysed 
as if the 3.6 grams of galactose infused over 30
minutes had in fact been given orally. Prior to
beginning the 90 ml/hr infusion a blood sample was
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collected to allow determination of basal galactose 
concentrations.
A second intravenous infusion at a rate of 3 0 ml/hr 
(40 mg galactose/min) was performed thereafter for an 
hour followed by a third infusion at 60 ml/hr (80 mg 
galactose/min) for a further hour (Treonic IP3 infusion 
pump) . No priming doses were used in any of the 
infusions. In both the latter infusions 1 ml blood 
samples were collected every five minutes after 
equilibrium had been reached, approximately 30 minutes 
after beginning the infusion, and continued thereafter 
until 60 minutes.
In all cases 0.1 ml of the collected blood sample was 
immediately added to 0.5 ml, 0.33 mol/1 perchloric acid 
and microcentrifuged for three minutes, as described in 
Chapter 3. Double precipitations of each sample were 
made, and samples analysed as described in Chapter 3. 
Prior to all sample collections an initial 1 ml blood 
sample was drawn and discarded. This sample contained 
largely heparinised saline which maintained the venous 
line.
Area under the galactose appearance curve from the 
first infusion, galactose clearance at the subsequent 
two infusion rates, and systemic availability were 
calculated as described in Section A.
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B) Patients with and without liver disease
Patients were similarly prepared as described 
above. All patients were fasted overnight and 
throughout the study. 50 ml of a solution of eight 
percent D-galactose, prepared by the Pharmacy 
Department, Glasgow Royal Infirmary, was given orally 
to the patients. 1 ml blood samples were collected from 
an indwelling catheter in the right forearm vein 
(Venisystems, Butterfly-23, Abbott Ireland Ltd, Rep. 
Ireland), every 2 minutes for the first 20 minutes and 
thereafter every four minutes until 60 minutes. Prior 
to administering the oral dose a blood sample was 
collected to allow determination of basal galactose 
concentrations. Upon completion of oral blood sampling 
an intravenous infusion of galactose was given in order 
to determine systemic clearance of galactose. A 
constant intravenous infusion rate of 30 ml/hr (40 mg 
galactose/min) was given by Treonic IP3 infusion pump 
(Vickers Medical, Basingstoke, England) into the left 
forearm vein catheter (Venisystems, Butterfly-23, 
Abbott Ireland Ltd, Rep.Ireland). 1 ml blood samples
were collected every five minutes, after equilibrium 
had been reached, approximately 30 minutes after 
beginning the infusion, and continued thereafter until 
60 minutes. 0.1 ml of each collected blood sample was 
deproteinised and analysed as described in Chapter 3.
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Again double precipitations of each sample were made. 
Prior to all sample collections an initial 1 ml blood 
sample was drawn and discarded. This sample contained 
largely heparinised saline which maintained the venous 
line.
The area under the galactose appearance curve, 
galactose clearance at an infusion rate of 40 mg 
galactose/min and systemic availability were calculated 
as described in Section A.
Statistical analysis
In control volunteers the mean ratio of the 
calculated galactose clearance values at intravenous 
infusion rates of 40 and 80 mg galactose/min, which 
ideally should equal one if elimination of galactose in 
the concentration range chosen in this study is first- 
order, was tested equal to one by the Student's t-test. 
Similarly, in the same control volunteers, the systemic 
availability of a short intravenous infusion, at a rate 
of 90 ml/hr, which ideally should result in a 
bioavailability of galactose of 100 percent, was tested 
equal to 100 by the Student's t-test.
In control and liver diseased patients the statistical 
significance between observed differences in 
was tested by using the Student's t-test.
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RESULTS
CONTROL VOLUNTEERS
All subjects achieved equilibrium whole blood 
galactose concentrations at intravenous galactose 
infusion rates of 40 and 80 mg galactose/min between 30 
and 60 minutes after beginning the infusion. Figure 9 
shows systemic whole blood equilibrium galactose 
concentrations in a control volunteer at infusion rates 
of 40 and 80 mg galactose/min. Systemic galactose 
concentrations were constant to within 2 mg/1, and the 
average concentration was used for calculation of 
systemic galactose clearance.
Individual clearance values in six control volunteers 
at an intravenous galactose infusion rate of 40 and 80 
mg galactose/min ranged from 1320 to 2303 ml/min and 
1670 to 1970 ml/min respectively (Table 8). The mean 
galactose clearance + SD was 1851 + 330.6 ml/min and
1812.5 + 126.1 ml/min at intravenous infusion rates of 
40 and 80 mg galactose/min respectively (Table 8). 
Galactose clearance adhered to first-order kinetics 
within the concentration range of this study. The 
ideal, a doubling of the systemic whole blood galactose 
concentration with a doubling of the infusion rate, was 
approached in all volunteers. In only four out of the 
six control volunteers originally studied was galactose 
clearance actually measured at the higher intravenous
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infusion rate of 80 mg galactose/min. The was due to a 
pump failure in one study and a power cut in the other. 
The individual ratio of clearance at a galactose 
infusion rate of 80 mg galactose/min divided by 
clearance at a galactose infusion rate of 40 mg 
galactose/min in four control volunteers ranged from 
0.903 to 1.027, with a mean + SD of 0.970 ± 0.053.
This mean ratio was not significantly different from 
the ideal of 1.00 (p = 0.172) (Table 9).
Table 8 also shows individual areas under the 
galactose appearance curve after a 90 ml/hr short 
intravenous infusion of galactose, and the 
corresponding systemic availability of galactose 
expressed as a percentage and calculated using 
clearance values at infusion rates of 40 and 80 mg 
galactose/min in control volunteers. A mean + SD area 
under the galactose appearance curve (AUC) of 2291.3 +
389.7 mg.min/1 was found after a 30 minute intravenous
infusion at a rate of 90 ml/hr in control volunteers.
Individual values for AUC ranged from 1916 to 2963 
mg.min/1 (Table 8). Figure 10 shows the typical form of 
the galactose concentration time curve following the 
short intravenous infusion of galactose at 90 ml/hr in 
a control volunteer.
The ideal of simulating the complete absorption of an 
oral dose of galactose which resulted in a systemic
availability of galactose of 100 percent by infusing
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intravenously galactose at a rate of 90 ml/hr, was
approached in all control volunteers. Individual
systemic availability values calculated using galactose 
clearance values at intravenous infusion rates of 4 0 
and 80 mg galactose/min, ranged from 99.0 to 122.6 
percent and 99.5 to 105.7 percent respectively (Table 
8). The mean + SD systemic availability of galactose
was 108.7 + 9.2 percent and 102.5 + 2.6 percent at
clearance values determined at intravenous infusion 
rates of 40 and 80 mg galactose/min respectively (Table 
8). Neither of these mean shunting values were 
significantly different from the ideal of 100 (p > 
0.01).
PATIENTS WITH AND WITHOUT LIVER DISEASE
All patients achieved eguilibrium whole blood 
galactose concentrations at a galactose intravenous 
infusion rate of 40 mg galactose/min between 30 and 60 
minutes after beginning the infusion, as already shown 
in Figure 9 for control volunteers.
Individual systemic galactose clearance values, areas 
under the galactose appearance curve and percent 
systemic availability for control patients without 
liver disease and patients with liver disease are 
tabulated in Table 10.
Systemic galactose clearance ranged from 1064 to 1835
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ml/min and 892 to 2060 ml/min in control patients and 
patients with liver disease at a intravenous infusion 
rate of 40 mg galactose/min respectively (Table 10). 
The mean systemic galactose clearance + SD for control 
patients without liver disease was 1455.7 ± 288.49
ml/min which was not significantly different from 
patients with liver disease, who showed a mean + SD of
1482.6 + 375.46 ml/min at a galactose infusion rate of
40 mg galactose/min (Table 10). Neither the mean 
galactose clearance in control patients and patients 
with liver disease was significantly different from 
the mean galactose clearance found in control 
volunteers, 1851 + 330.6 ml/min, at an intravenous
infusion rate of 40 mg galactose/min.
The area under the galactose appearace curve (AUC) 
following oral ingestion of 4g of galactose in control 
patients without liver disease ranged from 177 to 519 
mg.min/1, with a mean ± SD of 351.8 + 130.5 mg.min/1. 
The AUC in control patients was significantly lower 
than the area under the galactose appearance curve in 
patients with liver disease, who showed AUC to range 
from 799 to 3185 mg.min/1, with a mean ± SD of 1940.1 ± 
863.35 mg.min/1 (Table 10). Figures 11 and 12 show the 
the differing areas under the galactose appearance 
curve after a 50 ml (4 gram) oral dose of galactose in 
a control patient and a patient with liver disease. 
Individual systemic availability of galactose in
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control patients and patients with liver disease ranged 
from 7.1 to 23.8 percent and 26.4 to 108.0 percent 
respectively (Table 10) . The mean ± SD systemic 
availability in patients with liver disease was 72.19 ± 
33.38 percent which was significantly different (p < 
0.005) from the systemic availability found in control 
patients without liver disease who showed a mean ± SD 
of 13.65 + 6.31 percent (Table 10).
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Figure 9
This shows whole blood equilibrium galactose 
concentrations in a control volunteer at intravenous 
infusion rates of 40 and 80mg galactose/min. If 
elimination of galactose by the liver follows first 
order kinetics then a doubling of the intravenous 
infusion rate will result in a doubling of systemic 
galactose concentration.
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TABLE 8
Control
Volunteers
Clearance
(ml/min)
40 80
(mg/min)
AUC
(mg.min/1)
Systemic
availability
(%)
40 80
(mg/min)
WA 1850 1670
GF 2060 1970
HT 1320 ----
JA 1850 1840
HB 1723 1770
DM 2303 ----
Mean 1851 1812.5
SD 330.6 126.1
2283 117.4 105.7
2020 104.1 99.5
2963 105.1 ---
2499 104.2 103.3
2067 99.0 101.6
1916 122.6 ---
2291.3 108.7 102.5
389.7 9.2 2.6
Clearance = Volume of blood completely cleared of 
galactose by the liver per minute 
AUC = Area under the galactose appearance 
curve following a short intravenous 
infusion
This shows whole blood galactose clearance at 
intravenous infusion rates of 4 0 and 8 0 mg 
galactose/min, the area under the galactose appearance 
curve calculated from a 30 minute intravenous infusion 
at a rate of 90 ml/hr, and the systemic availability of 
galactose at both clearance values in control 
volunteers.
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TABLE 9
CONTROL VOLUNTEERS
WA GF JA
Infusion rate 1 
(mg galactose/min)
Infusion rate 2 
(mg galactose/min)
Clearance 1 
(ml/min)
Clearance 2 
(ml/min)
Clearance 2
Clearance 1
40 40
80 80
40
80
HB
40
80
1850 2060 1850 1723
1670 1970 1840 1770
0.903 0.956 0.995 1.027
This table demonstrates galactose clearance 
measured at two infusion rates (Infusion 2 = Infusion 1 
x 2) in each control volunteer on the same day. The 
mean + SD ratio clearance 2/ clearance 1 was 0.970 +
0.053. This ratio was not significantly different from 
the ideal of 1.00.
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Figure 10
This shows the galactose concentration time curve 
following a 30 minute intravenous infusion of 
galactose at a rate of 90 ml/hr in a control 
volunteer. The area under the galactose appearance 
curve was 2020 mg. min/1.
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TABLE 10
Subject
CONTROLS
Clearance 
4 0 mg/min 
(ml/min)
AUC
(mg.min/1)
Systemic
availability
(%)
RS 1780 375 16.8
AMcC 1064 458 12 . 2
JA 1230 230 7 . 1
CMcN 1403 352 14 . 7
JC 1835 519 23 . 8
RH 1494 177 7.3
Mean 1455.70 351.80 13 . 65
SD 288.49 130.50 6.31
PATIENTS
WMcC 2060 1866 96.2
*AMcA 1754 983 43 . 1
TM 892 1727 38 . 5
GMcM 1794 2265 101. 6
JN 1490 1655 61.7
GL 1276 3185 102 . 0
JE 1191 799 26.4
MK 1404 3041 108 . 0
Mean 1482.60 1940.10 72 . 19
SD 375.46 863.35 33.38
* = Patient with portal vein thrombosis
Whole blood galactose clearance at an intravenous 
infusion rate of 40 mg galactose/min, the areas under 
the galactose appearance curve calculated after a 50
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ml (4 gram) oral dose of galactose, and the systemic 
availability of galactose are shown in control patients 
and patients liver disease/portal hypertension.
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Figure 11
This shows the galactose concentration time curve 
after oral administration of 4 grams of galactose 
to a control patient. The area under the galactose 
appearance curve was 230mg min/1 and percent 
systemic availability was 7.1.
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Figure 12
This shows the galactose concentration time curve 
after oral administration of 4 grams of galactose 
to a patient with liver disease and portal 
hypertension. The area under the galactose 
appearance curve was 1866mg min/1 and percent 
systemic availability was 96.2.
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DISCUSSION
The majority of methods employed to quantitate 
portasystemic shunting are invasive in nature, 
requiring intrasplenic injection of radioactive 
indicator substance and hepatic venous sampling (Caesar 
et al, 1962; Groszmann et al, 1972). Only within the 
last ten years have realistic non-invasive attempts 
been made to quantitate the magnitude of portasystemic 
shunting. The basis of work carried out in this thesis 
arises from research by Porchet and Bircher (1982) in 
which a procedure for assessing portasystemic shunting 
was designed which combined oral and intravenous 
clearances of a susbstance. The aim of their study and 
indeed this study was to administer sufficiently low 
oral doses of a substance which on first pass through 
the normal liver would be completely extracted. The 
same oral dose when administered to a subject with 
liver disease/portal hypertension would by-pass the
liver in proportion to the degree of portasystemic
shunting, and the systemic availability of the oral 
dose would thus be a measure of the magnitude of
portasystemic shunting.
The data of this study suggest that, in patients with 
portal hypertension and/or liver disease galactose may 
be a valuable test compound for the non-invasive
assessment of portasystemic shunting. The procedure is
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safe, simple, well accepted by patients and the 
inconvenience appeared to be minimal. Furthermore, the 
subjects investigated had to remain within the 
investigation laboratory for only two hours. These 
conclusions, however, have to be carefully reviewed 
within the light of the limitations imposed by the 
chosen methodology.
On theoretical grounds, a clearance test which is 
designed for the investigation of portasystemic 
shunting should fulfill the following requirements: the 
test compound should be non-toxic and easy to measure; 
it should be absorbed completely and rapidly from the 
gastrointestinal tract; intestinal first-pass
elimination should be negligible; once in the portal 
vein, it should be removed virtually completely in a 
single passage through the normal liver, i.e., through 
a normal sinusoidal pathway from the portal triad to 
the central vein; the fraction of the test compound 
reaching the systemic circulation should be cleared by 
reproducible first-order mechanisms rendering an 
intravenous and oral comparison valid.
Galactose fulfills the above postulates to a high 
degree. Galactose is a naturally occuring 
monosaccharide and is non-toxic, thus oral and 
intravenous doses of galactose are safe. Whole blood 
concentrations of galactose between 0 and 100 mg/1 can 
be measured specifically and easily by the galactose
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dehydrogenase enzyme assay, as described in chapter 3,
(Wallenfels et al, 1962). The accuracy of measuring
galactose concentrations below 10 mg/1 tends to
decrease as we approach the limits of assay 
sensitivity.
Absorption of 4 grams of galactose from the
gastrointestinal tract is rapid as evidenced by raised 
blood concentrations of galactose within 10 minutes 
after an oral dose and a concentration peak at about 
twenty minutes.
To our knowledge galactose does not undergo metabolised 
in the duodenal mucosa while being absorbed from the 
gastrointestinal tract.
The liver is the major organ for galactose elimination, 
wherein several known enzymatic processes convert it to 
glucose through the sugar nucleotide pathway (Kalckar, 
1957). Extraction of galactose by the liver is also 
very high in normal subjects, between 93 and 95 percent 
(Henderson et al, 1982). The short half life of 
galactose of approximately 10 to 30 minutes (Henderson 
et al, 1982), is an important advantage, because it 
allows establishment of a steady-state within a few 
minutes, thus ensuring in this study that hepatic 
clearance of galactose is flow dependent , and that 
bioavailability of orally administered doses reflects 
portacaval shunting only. Extrahepatic elimination of 
galactose, for example urinary excretion, renal
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metabolism and erythrocyte metabolism does not appear 
to be quantitatively significant. In a study by 
Henderson et al (1982) urinary excretion and 
erythrocyte metabolism accounted for only 4 percent of 
the galactose eliminated.
The technique for assessing galactose systemic 
availability requires the assumption of first-order 
kinetics. Saturation of first-pass elimination of 
galactose is well recognised, (Colcher et al 1946; 
Tygstrup, 1964). Therefore, in a study such as this it 
was necessary to apply small oral doses of 4 grams of 
galactose which were almost completely eliminated in 
control volunteers, as shown in section A of this 
chapter. Such small oral doses avoided any evidence of 
hepatic saturation. Evaluation of the non-steady state 
kinetics after the oral dose with steady-state 
(equilibrium) kinetics after the intravenous infusion 
appears, therefore, to be justifiable. Empirically this 
approach has been verified by the rapidly increasing 
and decreasing systemic galactose concentrations at an 
intravenous infusion rate of 90 ml/hr in control 
volunteers which simulated the non-steady state of an 
oral dose but assured a 100 percent systemic 
availability. The result of 108.7 and 102.5 percent 
systemic availability of galactose calculated by using 
systemic clearance values at steady-state intravenous 
infusion rates of 40 and 80 mg galactose/hr, confirms
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this general procedure.
In all subjects in this study systemic galactose 
clearance was calculated from mean equilibrium 
galactose concentrations, during a continuous 
intravenous infusion at a rate well below the intrinsic 
elimination capacity of the liver in a deliberate 
attempt to study flow-dependent clearance. Tygstrup 
(1964) found the galactose elimination capacity in 
control subjects to be 440 mg galactose/min and in 
patients with alcoholic cirrhosis to be 263 mg 
galactose/min. In this study the intravenous infusions 
of galactose were performed at infusion rates of 40 and 
80 mg galactose/min. Reproducible first-order kinetics 
have been well documented for galactose (Tygstrup and 
Winkler, 1958; Henderson et al, 1982). In this study 
the ratio of clearance at an intravenous infusion rate 
of 40 mg galactose/min to clearance at an intravenous 
infusion rate of 80 mg galactose/min in control 
volunteers did not vary significantly from the ideal of 
one. This data shows galactose elimination to be 
first-order within the defined ranges in this study, 
and the high extraction of galactose by the liver is 
maintained when the infusion rate is doubled. A 
similar study carried out by Henderson et al (1982) 
found that a doubling of the infusion rate from 50 to 
100 mg galactose/min reduced systemic galactose 
clearance by 8.1 percent. This fall was attributed to a
combination of a reduction in hepatic extraction, the 
effect of extrahepatic elimination, and the possible 
influence of non-free galactose derivatives such as 
amino sugars and galactosides on the clearance 
calculation. It is possible that the absence of any 
such effect in the present study is due to the lower 
rates of galactose infusion, which would be less likely 
to give rise to a departure from first-order kinetics. 
In agreement with the earlier postulates, the 
bioavailability of a 4 gram oral dose of galactose was 
acceptably low in control patients with no history of 
liver disease, but was nonetheless higher than expected 
on the basis of the pilot study in young healthy 
volunteers. This may have occured due to the age 
difference and general health difference between the 
two groups. However, in patients with documented 
portasystemic shunting, as assessed by independent 
methods, the same oral dose produced much greater areas 
under the curve and systemic availabilities ranged from 
26.4 to 108.0 percent. To our knowledge no 
investigators have previously used galactose as a test 
compound to assess the magnitude of portasystemic 
shunting in patients with liver disease. In a recent 
study carried out by Cavanna et al (1987) the 
bioavailability of the naturally occuring polyol D- 
sorbitol was used to assess the magnitude of 
portasystemic shunting in a group of control and liver
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diseased patients. In normal patients the 
bioavailability of sorbitol was found to be zero and 29 
percent in cirrhotic patients. However, in patients 
with portacaval shunts an expected bioavailability of 
100 percent was reduced to 38 percent, due to 
intestinal first-pass elimination of at least 50 
percent of the oral sorbitol dose. Another method using 
glyceryl trinitrate, and based on the same principle as 
this study, did almost give 100 percent bioavailability 
in patients with portacaval shunts (Porchet and 
Bircher, 1982). Porchet and Bircher's technique was, 
however, assessed in the University Department of 
Surgery at Glasgow Royal Infirmary (Garden and 
Angerson, unpublished observations) and it was found 
that the indirect plethsmographic technique used to 
measure circulating nitroglycerine was subject to large 
errors. It would thus appear to be very difficult to 
find test substances which are not subject to some form 
of measurement difficulity and/or suffer from 
intestinal first-pass elimination.
From the results of this study, it would appear, that 
galactose is by far a better test compound when applied 
orally to assess portasystemic shunting in liver 
diseased patients. Although in the present study there 
was no patient who was independently known to have 100 
percent shunting, the fact that values close to 100
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percent were found in four cirrhotic patients suggests 
that there is unlikely to be significant 
underestimation of portasystemic shunting because of 
underestimated elimination of galactose.
The slight systemic availability of galactose seen in 
the six control patients may be due to galactose 
absorption through oral or oesophageal mucosa which may 
bypass the liver and simulate portasystemic shunting. 
It was assumed that out of the total volume of 50 ml 
of galactose only a few milliliters might be retained 
above the diaphragm for galactose absorption. 
Correspondingly, the error should be small. Another 
possible source of error, which would underestimate the 
availability of an oral dose of galactose, arises if 
galactose is infused intravenously. Here some of the 
sugar may be lost in the tubing of the infusion set, 
thereby leading to a systematic error in the 
calculation of infusion rates and systemic 
availabilities.
The galactose test, however, seems to provide 
information that hitherto has been available only 
through highly invasive (Shand, 1979; Okuda et al, 
1977) or time consuming (McLean et al, 1979) 
investigations. Inasmuch as incomplete clearance of a 
high extraction substance from portal blood represents 
portasystemic shunting, the galactose test described in 
this study may be regarded as a tool to assess this
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abnormality.
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INTRODUCTION
This chapter is divided into three sections. The 
first section describes both the animals used during 
the study period and the environment in which they were 
housed. A basic outline of the relevant rat anatomy is 
given and emphasis is placed on the anatomy of the 
splanchnic circulation.
The second section describes an experimental rat model 
of prehepatic portal hypertension which is produced by 
creating a calibrated resistance to portal venous flow 
(Myking and Halvorsen, 1973). Various animals and 
techniques have been used over the years in an attempt 
to reproduce in an experimental model the clinical 
syndrome of portal hypertension (Childs et al, 1950; 
Rozga et al, 1985). The rat and the technique of 
partial portal vein ligation have emerged as the most 
favourable in establishing a prehepatic model of 
portal hypertension. Although rat models of hepatic 
cirrhosis are available (McLean et al, 1969; Proctor 
and Chatamra, 1982) and would more closely reproduce 
the clinical syndrome in its most commonly encountered 
form, agents such as galactose which are normally 
extracted by the liver with high efficiency may pass 
through sinusoids in the cirrhotic liver with 
relatively little extraction. This "functional 
shunting" is difficult to quantify with an independent
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measurement technique. In prehepatic portal
hypertension, liver function is normal and shunting 
occurs through relatively large calibre extrahepatic 
collateral vessels. This "anatomical shunting" can be 
independently measured, and a prehepatic model 
therefore provides a better basis for validating the 
oral galactose technique as a measure of shunting.
The choice of model was based upon work carried out by 
Geraghty et al (1989) in which the relationship between 
portal venous pressure and shunting of mesenteric 
venous blood was examined in the rat prehepatic model 
of portal hypertension as described by Myking and 
Halvorsen (1973). Ideally for this study the choice of 
model should be one that demonstates a variable degree 
of shunting. Geraghty and colleagues have demonstrated 
that the Myking and Halvorsen (1973) prehepatic model 
of portal hypertension is associated with highly 
variable degrees of shunting from the mesenteric 
vascular bed, with no clear relationship between 
individual values of portal venous pressure and 
shunting during the three to seven day period following 
portal vein ligation. Such observations have led to 
experiments in this study being conducted 6 to 8 days 
following portal vein ligation, a point in time where 
gross haemodynamic changes in splanchnic blood flow are 
minimised and portasystemic shunting has largely become 
evolved.
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The third section in this chapter describes the 
anaesthetic agents used throughout the experimental 
period, and the technique used to measure mean arterial 
pressure and portal venous pressure, both of which are 
recorded in most haemodynamic studies, is also outined 
in this section. Further, the use of gamma-labelled 
microspheres in quantitating the magnitude of 
portasystemic shunting as described by Chojkier and 
Groszmann (1981) is also detailed in this section.
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SECTION A. BASIC MODEL
ANIMALS AND HOUSING
In all experiments male Sprague-Dawley rats 
(Banton and Kingman limited, Hull) were used. All were 
housed in stainless steel cages, with a maximum of four 
rats per cage. The animals were fed on a standard rat 
diet (RNM, Type 1) with water ad libitum, and exposed 
to a 12 hour light/dark cycle, a relative humidity of 
5 0 + 5  percent and a temperature range of 21 + 1
degrees C as implemented in the animal facility. 
Twenty-four hour fasting prior to experimentation was 
carried out by housing an individual rat in a wire 
bottom stainless steel cage during which time water was 
freely available.
RELEVANT RAT ANATOMY 
Liver
The gross anatomy of the rat liver is comparable 
to that in man. The rat liver is situated below the 
right hemidiaphragm in the peritoneal cavity, and 
consists of the left lateral, right lateral, median 
and caudate lobes. Its blood supply is via the portal 
vein and the hepatic artery, and it is drained by two 
or three hepatic veins into the inferior vena cava. As
in man the liver is divided into hepatic lobules which 
contain central venules, hepatic sinusoids, hepatocytes 
and portal vessels.
Portal Circulation
The portal vein drains the intestinal tract from 
the stomach to the upper rectum and is formed by the 
union of the superior mesenteric, splenic and pyloric 
veins. The superior mesenteric vein is formed by the 
union of approximately fifteen intestinal branches, the 
ileo-colic, right colic and middle colic veins (Figure 
13) .
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A N A T O M Y  O F  P O R T A L  V L N O U S  S Y S T E M  O F  T H E  R A T
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Figure 13
The ileocolic branch of the portal vein was 
cannulated for measurement of portal venous 
pressure, infusions of galactose into the portal vein, 
and quantitation of the magnitude of portasystemic 
shunting by injecting radioactive microspheres into 
the portal venous system via the ileocolic cannula.
SECTION B. A PREHEPATIC MODEL OF PORTAL
HYPERTENSION
With reference to the introduction, the following 
text describes the experimental rat model of prehepatic 
portal hypertension.
MATERIALS AND METHODS 
Animals
In all experiments male Sprague-Dawley rats 
weighing between 250 and 390 grams were used. A 
maximum of four animals were housed in each cage, which 
contained on average an equal number of sham operated 
and portal vein ligated animals.
Technique of portal vein ligation
A rat model of prehepatic portal hypertension was 
established by creating a calibrated resistance to 
portal venous flow using the portal vein ligation 
technique (Myking and Halvorsen, 1973). Under light 
ether anaesthesia animals were subjected to laparotomy. 
The liver and intestines were then expelled from the 
abdominal cavity and retracted to enable clear 
visualisation of the portal vein. The portal vein was 
mobilised over a length of 1cm just distal to its 
bifurcation into the right and left hepatic branches.
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In all cases it was important to ensure that the 
hepatic artery which lies adjacent, was separated from 
the portal vein. A 21 gauge needle (OD = 0.86mm) with a 
blunt tip was placed alongside the mobilised portion of 
the portal vein and a 3/0 silk tie placed around both 
the portal vein and the needle and secured. A 
calibrated resistance to portal venous flow was created 
on removal of the needle (Figure 14). The liver and 
intestines were then returned to the abdominal cavity 
and the incision closed in two layers. In sham operated 
controls the portal vein was mobilised but not 
stenosed.
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/TECHNIQUE OF PORTAL VEIN LIGATION
Liver
Portal VeinPyloric Vein
Figure 14
A 21 gauge needle was placed alongside the mobilised portal 
vein and a 3/0 silk tie placed around both vein and needle. 
Removal of the needle resulted in a calibrated resistance 
to portal venous flow.
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SECTION C. BASIC METHODS
The following text describes the anaesthetic 
agents used throughout experimental procedures, and the 
technique used to measure mean arterial pressure and 
portal venous pressure. Further, this section 
describes microspheres and the injection of radioactive 
microspheres in the quantitation of portasystemic 
shunting (Chojkier and Groszmann, 1981).
ANAESTHESIA 
A. ETHER
Animals while undergoing the recovery procedure of 
partial portal vein ligation, were subjected to ether 
anaesthesia maintained throughout surgery by means of a 
50ml flask containing etherised cotton wool.
B_j_ NITROUS OXIDE : OXYGEN : HALOTHANE
All haemodynamics studies were conducted using a 
nitrous oxide, oxygen, halothane mixture. Induction was 
carried out by delivering to a perspex box 4% halothane 
in a 2:1 nitrous oxide : oxygen mixture at a 0.6 litres 
per minute flow rate. Following induction a
tracheostomy was performed (5 French Gauge Portex
tubing) and the animal ventilated using a Harvard rat 
ventilator (Model 680) which maintained a respiratory 
rate of 35-45 strokes per minute, and a tidal volume of 
3.0-4.0ml. Ventilation was maintained with 0.5%-1.0% 
halothane in the same nitrous oxide : oxygen mixture.
The adequacy of the depth of anaesthesia was guaged by 
the absence of response to painful stimuli, and 
occassionally it was necessary to increase halothane 
concentration by up to 1% to achieve this. Blood gas 
analysis was performed with a regularly-calibrated 
automatic analyser (ABL 2, Radiometer) on a volume of 
0.3ml arterial blood drawn from the right femoral 
artery cannula and experiments were only performed when 
a p02 over 90mmHg, pC02 between 3 5-45mmHg and a pH over 
7.30 could be maintained throughout the experimental 
period. Occasionally minor adjustments in respiratory 
rate were necessary to maintain pC02 within the above 
range. A rectal thermometer monitered core
temperature, which was maintained at 3 7 + 0.5 degrees C 
by means of heating lamp.
C. PENTOBARBITOL
Intraperitoneal pentobarbitol was used in some 
initial oral galactose experiments. 60mg/kg body weight 
of pentobarbitol was injected into the peritoneal 
cavity with a 25 gauge needle. Adequate anaethesia was
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provided with this dose for approximately 90 minutes 
and if neccesary it was supplemented with 0.2mg/kg of 
pentobarbitol.
MEASUREMENT OF MEAN ARTERIAL PRESSURE
On commencing artificial ventilation, the animal 
was placed supine on the operating table and a 
transverse groin incision made, followed by isolation 
of the femoral artery. Cannulation was performed with 
a polyethelene catheter (outside diameter = 0.96 mm,
inside diameter= 0.51mm) which was then connected to a 
(Statham) strain gauge transducer and a Gould series 
800 recorder which recorded arterial pressure. The 
recorder noted systolic, diastolic and mean arterial 
pressure readings, and only animals with a mean 
arterial pressure of at least 90mmHg were included in 
all haemodynamic studies. Each animal was heparinised 
(130 units/kg body weight) on placement of the femoral 
artery cannula as clotting of the cannulae was found to 
impede pressure tracings.
Some experiments necessitated the cannulation of both 
femoral arteries, a femoral vein and the portal vein. 
In all cases the same type of cannula was used.
MEASUREMENT OF PORTAL VENOUS PRESSURE
Portal venous pressure was measured directly in 
all haemodynamic studies by cannulation of the portal 
vein. A lower mid-line abdominal incision was made 
following anaesthesia, and the caecum and the distal
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small bowel delivered to the surface of the abdomen. 
The intestines were wrapped in a saline soaked swab and 
the ileo-colic branch of the portal vein isolated and 
cannulated (Polyethelene cannula, OD = 0.96mm). The 
cannula was positioned approximately 3cm into the 
superior mesenteric vein and secured in place with a 3- 
0 silk tie. The abdomen was closed and the cannula was 
connected to a strain gauge transducer to record portal 
venous pressure as previously described for arterial 
pressure.
CALIBRATION OF TRANSDUCERS
Calibration of both arterial and venous 
transducers were performed before each experiment. The 
zero balance and calibration was re-checked again 
before formal pressure readings were recorded. A 
mercury manometer using a lOOmmHg column was used to 
calibrate the strain guage transducer measuring mean 
arterial pressure.
Calibration of portal venous pressure was performed by 
use of a specially constructed manometer with a column 
of water equivalent to 25mmHg, this allowed precise 
calibration of the portal venous strain guage. 
Measurement by use of the mercury column proved to be 
inaccurate in the calibration of the portal venous
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pressure due to the different range settings. Portal
venous pressures were recorded approximately 2 0 minutes 
after abdominal closure and when a respiratory pattern 
was present on the portal venous tracing. A final
portal venous pressure measurement, therefore required
accurate calibration of the strain guage transducer, 
correct zero balance readings before and after pressure 
measurements, normal blood gases and a respiratory 
pattern on the portal venous tracing.
THE USE OF GAMMA-LABELLED MICROSPHERES TO QUANTITATE
THE MAGNITUDE OF PORTASYSTEMIC SHUNTING
Before describing the measurement of radioactive
microspheres in quantitating portasystemic shunting a 
resume of the nature of microspheres themselves and 
potential problems in their use in quantitating 
portasystemic shunting is given.
A. Physical Properties of Radioactive Microsoheres
Microspheres are resin-coated spherical beads
which are manufactured in various sizes and can be 
labelled with a wide range of radioisotopes. The 
radioisotopes contain unstable nuclei and emit
differing forms of radiation, including gamma rays, 
during the process of radioactive decay. The magnitude 
of portasystemic shunting was quantitated by use of 
microspheres labelled with Cobalt-57.
The microspheres used in the study had a diameter of 
1 5 + 1  microns (mean + SD) whereas rat capillaries have 
a mean diameter of approximately 8 microns (Gannon and 
O'Brien, 1982). Therefore the microspheres will be 
trapped in rat capillaries following intraportal 
injection. Further, if the microsperes mix uniformly 
with blood, then their distribution to target organs 
following injection will give an index of the
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distribution of blood flow from the injection site to 
that organ. All microspheres injected into the portal 
vein in normal rats without portasystemic shunting will 
be trapped in the hepatic sinusoids. If portasystemic 
shunting is present, however, microspheres will bypass 
the liver in proportion to the degree of diversion of 
portal venous blood into the systemic circulation and 
become trapped in lung capillaries. An index of the 
magnitude of portasystemic shunting is thus given by 
the ratio of microspheres in lungs to that in liver and 
lungs.
B. Sources of error when using radioactive 
microsoheres to quantitate the magnitude 
of portasystemic shunting
A number of physical properties of a radioactive 
microsphere exist which may lead to inaccuracies in 
quantitating the magnitude of portasystemic shunting.
ij_ Aggregation of microspheres
Microspheres readily adhere and clump together 
despite the presence of a polymeric coat. This physical 
property can therefore give rise to large sources of 
error when measuring the degree of portasystemic
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shunting. Clumping of microspheres can be easily 
checked by placing a drop of microsphere suspension on 
a slide and inspecting it for clumping under light 
microscopy.
Microspheres are prepared by suspension in a high 
molecular weight solution (10% dextran) to which 0.01% 
of the surfactant "Tweenu-80 (BDH) is added to minimise 
clumping. However despite this, microsphere
suspensions aggregate when left standing for prolonged 
periods of time. Therefore in order to minimise 
clumping of microspheres both the container, and 
subsequently the syringe containing the microspheres
are vortexed immediately prior to injection.
ii) Leaching
The separation of radio-isotope from the 
microsphere is known as leaching. If leaching occurs
the radio-isotope will circulate freely in the systemic
circulation while microspheres will continue to be 
trapped by target organs such as the liver. Elevated 
levels of radioactivity in the lungs and kidneys 
following intraportal injection of radioactive 
microspheres in control animals is indicative of
leaching. Regular checks on the microsphere suspension 
were performed by centrifugation of the microsphere 
suspension and measuring radioactivity in the
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supernatant fluid relative to that in the sedimented 
microspheres. Microspheres were resuspended in fresh 
dextran if greater than 1% of total radioactivity had 
leached. As a quality control procedure in each 
experiment the kidneys were removed and counted to 
ensure that radioactivity was not greater than that of 
background levels.
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MEASUREMENT OF RADIOACTIVE MICROSPHERES IN QUANTITATING
PORTASYSTEMIC SHUNTING
On completion of each experiment, when formal 
recordings for mean arterial pressure, arterial blood 
gases, portal venous pressure and rectal temperature
had been performed as previously described, a vial 
containing radioactive microspheres (New England, 
Nuclear) was vortexed for 3 0 seconds and a 0.3ml 
suspension containing in excess 500,000 gamma-labelled 
microspheres was drawn into a 1ml syringe. The 
syringe, needle and cap were vortexed for a further 20 
seconds immediately prior to injection into the portal 
vein via the ileo-colic cannula. The cannula was then 
flushed with 0.5ml of normal saline. Approximately 
three minutes following intraportal injection of
radioactive microspheres, the animal was sacrified by 
opening the chest, and liver, lungs and kidneys were 
removed. The liver, lungs and kidneys were each sliced 
individually into approximately 1 cm long segments and 
then placed in counting vials for radioactivity 
maesurements. This was performed by use of a Gamma 
Scintillation counter (Packard Instruments, Auto-gamma 
5000) which contained a sodium iodide crystal.
Measurements were made using an open energy window (15- 
2000KeV). The magnitude of portasystemic shunting was 
calculated by use of the following formula;
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Lung Radioactivity (dpm)
Portasystemic shunting = -----------------------------
Liver + Lung Radioactivity
(dpm)
5.1
(Chojkier and Groszmann, 1981)
Each animal was checked to ensure absence of 
significant leaching or lung shunting by assuring that 
kidney counts were no higher than background levels.
DISCUSSION
ANIMAL MODEL
Many attempts have been made to reproduce in 
experimental animals, the clinical syndrome of portal 
hypertension as seen in man. Results have been 
disappointing in both the dog (Seiro et al, 1963) and 
monkey (Childs et al, 1950) as collateral vessels 
sufficient to decompress the portal vein readily 
develop. The rat, however, has proved to be a better 
model of portal hypertension, in so much that portal 
venous pressure has been demonstrated to remain 
elevated for at least eight weeks following portal 
venous stenosis despite the presence of portasystemic 
collateral vessels (Halvorsen and Myking, 1979) .
A variety of techniques have been used in the rat to 
produce prehepatic portal hypertension. Such
techniques include ameroid constriction of the portal 
vein (Saku et al, 1976), placement of a silastic button 
around the portal vein (Rozga et al, 1985) and simple 
partial ligation of the portal vein (Myking and 
Halvorsen, 1973). Although the technique of portal 
vein ligation is in practise relatively easy, a fine 
balance does exist between the degree of stenosis of 
the portal vein and subsequent mortality. In 1973 
Myking and Halvorsen examined the relationship between 
animal survival and the degree of stenosis and
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demonstrated that 1.0mm stenosis of the portal vein 
resulted in almost 100% mortality due to mesenteric 
vein thrombosis. In contrast at 1.2mm stenosis reduced 
mortality to 25%. Since the degree of stenosis and so 
mortality will vary with the diameter of the portal 
vein and thereby with the weight of the animal, it was 
necessary in this study to use animals within a narrow 
weight range (250 to 390 grams). This range negated the 
need for different gauge needles with varying animal 
weights and avoided any influence that animal age may 
have on the development and course of portasystemic 
shunting.
The need for a prehepatic model of portal hypertension 
which is associated with a wide range of portasystemic 
shunting is fundamental to this study. Only with a 
wide range of portasystemic shunting can the ability of 
galactose to accurately measure all magnitudes of 
portasystemic shunting be addressed. The prehepatic 
model of portal hypertension has been shown to be 
associated with a wide spectrum of portasystemic 
shunting, with values ranging from zero to 85% as early 
as one day after portal vein ligation (Geraghty et al, 
1989). This variation continued and at 7 days after 
portal vein ligation, a time period which was 
comparable with that of this study, mean portasystemic 
shunting was 60.4 ± 8.8 percent (Geraghty et al, 1989). 
The technique used to quantify the magnitude of
portasystemic shunting in experimental models of portal 
hypertension was first described by Chojkier and 
Groszmann (1981). The model so described by Chojkier 
and Groszmann (1981) involved intrasplenic injection of 
radioactive microspheres and was associated with a 
narrow range, 89 percent to 99 percent of portasystemic 
shunting ten days following portal vein ligation. 
Indeed by means of this technique, blood from the 
splenic vascular bed has consistently been found to be 
almost totally shunted in rats with established 
prehepatic portal hypertension (Benoit et al, 1985; 
Groszmann et al, 1982). In contrast, the model 
described by Geraghty et al (1989) involved injection 
of radioactive microspheres into the portal vein. From 
this the mesenteric contribution to portal venous 
inflow was found to be subject to lower and more 
variable degrees of shunting. The model so described by 
Geraghty et al (1989) would thus appear to be more 
suitable for the needs of this study. However, it must 
be stressed that shunting of microspheres injected at 
any given point will not mirror exactly the shunting of 
blood from all tributaries of the portal vein, but 
administration via the superior mesenteric vein ensures 
that they are mixed with the dominant contribution of 
portal venous inflow.
By virtue of this type of rat model of portal 
hypertension, which was associated with a wide range of
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portasystemic shunting, Geraghty et al (1989) were able 
to carry out a comparative study between the magnitude 
of portasystemic shunting and corresponding level of 
portal venous pressure at various time intervals 
following portal vein ligation. Since it is generally 
accepted that shunts develop as a response to increased 
portal venous pressure, it might be expected that there 
would be a direct relationship between the level of 
pressure and the degree of shunting to which it gives 
rise. However, as the effect of shunting is to 
decompress the portal vein, equally plausable is the 
idea of an inverse relationship in which high degrees 
of shunting are associated with low pressure. An 
inverse relationship between pressure and shunting 
could occur if factors other than pressure, such as 
anatomical variation, control the development of 
shunts. In the study carried out by Geraghty et al 
(1989) an initial increase in shunting and a 
progressive fall in portal venous pressure with time 
was demonstrated, however no clear relationship between 
individual values of pressure and shunting during a 3 
to 7 day period could be established. Further, at later 
time intervals a direct relationship between portal 
venous pressure and portasystemic shunting was 
established wherein increasing degrees of shunting were 
associated with increasing levels of portal venous 
pressure. The relationship between portal venous
pressure and portasystemic shunting is in itself
poorly understood. The variation in the magnitude of 
portasystemic shunting and thus the differing
relationships between pressure and shunting as seen in 
the study by Geraghty et al (1989) could be attributed 
to the ability to open portasystemic shunts in response 
to an initial elevated portal venous pressure, the
anatomical variation in the site of these shunts and 
the inter-operator variability while performing the 
technique of partial portal vein ligation. However, the 
direct relationship between portal venous pressure and 
portasystemic shunting is consistent with the idea that 
pressure is the driving force for the evolution of 
shunts. Alternative interpretations of this direct 
relationship between portal venous pressure and 
portasystemic shunting have also been proposed (Benoit 
et al, 1985; Vorobioff et al, 1983; Blanchet and
Lebrec, 1982).
The idea that anatomical variations in the site of 
portasystemic shunts may be a factor in controlling the 
development of collaterals, would appear to be 
doubtful. Investigators have repeatedly found that on 
stenosis of the portal vein the development of 
portasystemic collaterals show little variability in 
the their site and quantity (Bengmark et al, 1976; 
Halvorsen and Myking, 1974).
In patients with portal hypertension relatively little
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is known about the relationship between magnitude of 
portasystemic shunting and level of portal venous 
primarily because of the difficulty of measuring these 
parameters non-invasively. Most of the few studies in 
which shunting has been quantified in humans have 
failed to demonstrate any definate correlation with 
portal pressure (Caesar et al, 1962; Groszmann et al, 
1972) .
ANAESTHESIA
The use of anaesthetic agents in any experimental 
animal work must achieve two objectives. The first, and 
most obvious is in providing an adequate level of 
anaesthesia and the second is in maintaining normal 
cardio-respiratory function throughout the anaesthetic 
period. Many anaesthetic agents have been described 
which provide small animals with an adequate level of 
anaesthesia, however in parallel these agents have been 
associated with inducing abnormal cardiac or 
respiratory function. For example, the irritant 
properties of ether, which can result in respiratory 
difficulties sufficiently pronounced to induce 
respiratory arrest has limited its experimental use to 
short spanned recovery procedures in which measurements 
of systemic haemodynamics were not necessary. 
Fluctuating levels of anaesthesia were also experienced
in pilot studies using intraperitoneal pentobarbitol.
To a large extent the experimental animal work carried 
out in this thesis was haemodynamic in nature, 
therefore necessitating a choice of anaesthetic which 
would produce a minimun derangement in cardio­
respiratory function. This was particularly relevent 
in the measurement of portal venous pressure and the 
measurement of the magnitude of portaystemic shunting 
where alterations in splanchnic inflow would affect 
both parameters. Cooperman (1972) demonstrated that 
splanchnic inflow was affected by the partial pressure 
of carbon dioxide, with hypercapnia producing 
splanchnic vasoconstriction and diminished splanchnic 
blood flow while hypocapnia produced the opposite 
effect. Particular emphasis was therefore placed on 
early pilot work in which tidal volume and respiratory 
rates associated with normal arterial blood gases were 
determined.
Depression of the vasomotor centre frequently occurs on 
usage of most anaesthetic agents, therefore the effect 
of halothane on systemic and regional haemodynamics is 
of particular interest. Examination of the effects of a 
1 and 2% halothane mixture with oxygen on left 
ventricular function in dogs and primates was carried 
out by Vatner and Smith (1974). A concentration 
dependent depression of myocardial contractility with a 
fall in mean arterial pressure from 100 to 86mm Hg was
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observed in dogs anaesthetised with 1% halothane, the 
effect being further accentuated in dogs receiving 2% 
halothane. In parallel studies carried out by Hughes 
et al (1980) halothane reduced to 0.5% did not result 
in a significant reduction in cardiac output, however 
on increasing inspired halothane to 1.5% a significant 
depression in cardiac output was observed. A dose 
dependent decrease in portal venous blood flow was also 
observed, whereas no significant fall in total 
peripheral resistance with 0.5% halothane occured. 
Futher, increases in halothane concentration from 0.5 
to 2% did not significantly alter portal venous 
pressure. It would thus appear from the collated 
evidence that high levels of inspired halothane depress 
myocardial function, whereas in contrast, a 
concentration of 0.5% halothane produced minor effects 
on systemic and splanchnic haemodynamics. Subsequently 
the level of inspired halothane used in all animal 
experiments rarely exceeded 0.5%.
Splanchnic haemodynamics are also affected by animal 
core temperature, and heat loss invariably occurred 
during cannulation of the portal vein. A minimum 
period of 30 minutes therefore elapsed between 
abdominal closure and measurement of portal venous 
pressure. Further, experiments were initiated only 
when a core temperature of 37 + 0.5 degrees C was 
recorded. Therefore by minimising factors known to
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affect systemic and splanchnic haemodynamics a 
experimental animal preparation was achieved.
stable
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SECTION A. OROGASTRIC ADMINISTRATION OF GALACTOSE
INTRODUCTION
The aim of the following experiments were to 
establish an oral dose of galactose, that following 
absorption from the small intestine was comlpletely 
cleared from portal blood on its first pass through the 
liver in control animals.
In order to establish a liver threshold dose for first 
pass clearance of galactose, descending oral doses of 
galactose were administered to sham operated rats and 
systemic blood galactose concentrations measured by 
galactose dehydrogenase enzyme assay, as described in 
Chapter 3. Once established, this liver threshold dose 
was orally administered to portal vein ligated animals, 
and blood galactose concentrations measured as already 
described.
The areas under the galactose appearance curve, and so 
systemic availability from these blood galactose time 
graphs were calculated in both control and portal 
hypertensive rats. The technique used and the results 
are described in this section.
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MATERIALS AND METHODS
Male Sprague-Dawley rats weighing 310 + 79.1 grains 
(mean + SD) were used. Sham operation and portal vein 
ligation was performed as described in Chapter 5. All 
animals were fasted for 24 hours but allowed free
access to water. Anaesthesia was induced and the animal 
ventilated as previously described in Chapter 5. Both 
femoral arteries were cannulated and arterial blood 
samples were taken for blood gas analysis. Arterial 
pressure was monitored continuously via the left 
femoral artery cannula and core temperature was 
maintained at 3 7 + 0 . 5  degrees C by means of a heat 
lamp. Before gavage an arterial blood sample was
collected to determine basal galactose concentration. 
All blood samples were analysed as described in 
Chapter 3.
Galactose was administered via a 6 French guage portex 
infants feeding tube which was advanced from the mouth 
into the stomach. A water gavage of 2mls was
administered approximately twenty minutes before the 
galactose in order to empty any residual stomach
contents. D-galactose dissolved in distilled water to a 
concentration of 4 0 mg/ml was used to prepare doses in 
the range 2 5 to 13 0 mg/kg body weight, which were 
flushed into the stomach of the animal. The gavage tube 
was removed and timed arterial blood samples collected
every 10 minutes, from the right femoral artery cannula 
(Figure 15). An increase in blood pressure occurred on 
gavage which almost immediately returned to normal on 
withdrawal of the tube. All experiments were 
terminated if blood pressure fell below SOmmHg. 
However, no experiments were discarded as it was found 
on enzyme analysis, that in all cases, systemic 
galactose concentrations had reached a maximum and were 
returning towards basal levels as arterial pressure 
fell below 80 mmHg. If arterial pressure remained above 
80 mmHg, blood samples were collected until systemic 
galactose concentrations had returned to basal levels. 
Early experiments showed this to occur between two and 
two and a half hours after the initial gavage.
At the end of the experiment the animal was killed by 
opening of the chest. In all cases the stomach of the 
animal was removed and examined for the 
presence of food.
The aim and expectation of these experiments was to 
demonstrate a significant difference in systemic 
availability of oral galactose between portal 
hypertensive and control rats, as had been found 
readily in patients (Chapter 4). The extensive blood 
sampling procedure placed a heavy load on the 
circulation, and it was found in pilot experiments that 
the additional stress produced by the procedure of 
portal vein cannulation made it difficult to maintain
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an adequate level of arterial pressure. As previously 
discussed in chapter 5 the technique of portal vein 
ligation applied in this study produced portasystemic 
shunting in excess of 50% with high reliability 
(Geraghty et al, 1989), therefore portal vein 
cannulation and measurement of portasystemic shunting 
was dispensed with in all of these experiments.
GALACTOSE GAVAGE AND SAMPLING TECHNIQUE
Syringe wilh galaclosc Tracheostomy
U  Femoral artery
Femoral artery 
(arterial sampling)
Rectal probe
Figure 15
Oral administration of galactose in rats was 
performed by flushing concentrations of galactose 
into a 6 French gauge portex infants feeding tube 
which had been advanced from the mouth into the 
stomach. Timed artejrial samples were collected 
from the right femoral artery and analysed as 
described in Chapter 3.
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Design of study
In an attempt to discover the liver threshold 
dose of galactose, descending doses of galactose, 130 
mg/kg to 2 5 mg/kg were orogastrically administered to 
sham operated rats. Six rats received 13 0 mg/kg of 
galactose. The dose was then reduced to 100 mg/kg, 50 
mg/kg and finally 25 mg/kg, with two, two and nine sham 
operated rats receiving the dose respectively.
After provisionally accepting a liver threshold dose 
for first pass clearance of galactose in sham operated 
rats, seven portal vein ligated rats were
orogastrically administered doses of 25 mg/kg.
AUC calculation and Statistical analysis
In all experiments, areas under the galactose 
appearance curve (AUC) from concentration time graphs 
were determined by a specially written computer 
program, using linear interpolation between points, and 
the statistical significance of observed differences 
between sham operated and portal vein ligated animals 
was tested by the Student's t-test. In calculating AUC 
a standardised total time of sampling of 70 minutes was 
imposed in all experiments. The total AUC, however, 
was also calculated in experiments which exceeded 70 
minutes. The area under the curve divided by its
corresponding dose (AUC/dose) at both 7 0 minutes and in 
total was also calculated.
The expectation of increasing AUC/dose with an 
increasing dose is shown by the following 
equations:
With reference to Chapter 2 and by rearranging equation 
2.13,
AUC/Q = SA/K = S + (1-S) ( 1 - E ) / K.............. 6.1
Where,
Q = Oral dose of galactose
SA = Systemic availability of galactose
K = Systemic galactose clearance
E = Hepatic extraction efficiency of galactose
If absorption of galactose from the gut is not complete 
then,
AUC/Q = A.{S + (1-S) (1-E) }/K ................... 6.2
in which the term A represents that fraction of 
galactose which has been absorbed from the gut.
From equations 2.10 and 2.11, (Chapter 2),
K = E.F ........................................... 6.3
Where E represents hepatic extraction efficiency, and F 
represents hepatic blood flow, and extrahepatic 
clearance of galactose is assumed to be negligible. 
Hence,
AUC/Q = A.{S + (1-S) (1-E) }/E.F ................. 6.4
In sham operated rats, shunting is zero (S=0), and
AUC/Q = A. (1-E) / E . F ............................. 6.5
Equation 6.5 shows us that with increasing dose, AUC 
should not increase merely in proportion. The ratio 
AUC/Q should also increase if, as a result of the 
higher blood galactose concentration attained, hepatic 
extraction efficiency, E, decreases.
RESULTS
Total area under the galactose appearance curve 
(AUC total), area under the galactose appearance curve 
at 70 minutes (AUC t=70min), blood galactose appearance 
peaks and corresponding appearance peak times, AUC/dose 
total, and AUC/dose t=70min in individual sham operated 
rats are tabulated against oral galactose doses in 
Table 11. A clearly defined blood galactose appearance 
peak was seen in all rats who received at least 50 
mg/kg galactose orally, and in 6 out of 9 rats who 
received an oral dose of 25 mg/kg (Table 11). In all 
but five cases a single blood galactose appearance peak 
was seen. In all but 2 rats a first blood galactose 
appearance peak reached a maximum level between 10 and 
40 minutes, and of these, five showed a second peak to 
occur between 50 and 102 minutes following 
administration of the oral dose. In the case of a 
single blood galactose appearance peak, galactose
levels in most animals returned towards basal level 70 
minutes after administration of the oral dose, but if a 
second peak occurred, basal levels were not reached 
until 110 minutes. In two rats the maximum level of the 
second blood galactose peak exceeded that of the first
peak, and in a third rat both peaks reached the same
maximum level (Table 11).
In three rats who received 25 mg/kg galactose, there
was no well-defined appearance peak, and the maximum 
concentration recorded in blood did not exceed 5 mg/kg 
(Table 11).
In three out of six rats who received 13 0 mg/kg, 1 out 
of 2 who received 50 mg/kg and 2 out of 9 who received 
25 mg/kg, some residual food was found in the stomach 
on completion of the experiment. The expectation of 
delayed absorption and reduced areas under the curve in 
the presence of food was not consistently found, indeed 
absorption of galactose from the stomach and areas 
under the galactose appearance curve were variable 
regardless of whether the stomach contained food or not 
(Table 11).
Descending oral doses of galactose were accompanied 
with decreasing systemic blood concentrations in sham 
operated rats. Areas under the galactose appearance 
curve 7 0 minutes following gavage (AUC t=7 0min) in the 
range 140 to 6375 mg.min/1, 1510 and 3140 mg.min/1, 
196 and 1345 mg.min/1, and -180 to 655 mg.min/1 at 
oral galactose doses of 130, 100, 50, and 25 mg/kg
respectively are shown in Figure 16. The relationship 
between area under the galactose appearance curve 
(AUC) and oral galactose dose (GD) was described by the 
linear regression equation AUC = 28.12GD - 514.35. A
correlation coefficient of 0.698 was found. The mean + 
SD values for AUC t=70min were 228 + 263 mg.min/1, 771 
+ 813 mg.min/1, 2325 + 1153 mg.min/1 and 3159 + 2538
mg.min/1 at oral doses of 25, 50, 100, and 130 mg/kg
respectively (Table 12) .
In Table 12 the mean ± SD for AUC total, AUC t=70min, 
AUC/dose total, AUC/dose t=7 0min are tabulated against 
oral galactose concentrations of 25, 50, 100, 130
mg/kg.
At increasing oral doses, AUC/dose showed an
increasing trend. Individual values of AUC/dose t=70min 
ranged from 1.1 to 49.0, 15.1 and 31.4, 3.6 and 24.5,
and -7.2 to 26.2 kg.min/1 at oral galactose doses of
130, 100, 50, and 25 mg/kg respectively (Table 11). The 
mean + SD for AUC/dose t=70min was 24.3 + 19.5, 23.3 +
11.5, 14.1 + 14.8, and 9.2 + 10.5 kg.min/1 at oral
doses of 130, 100, 50, and 25 mg/kg respectively (Table
12). However, the difference between values was not 
statistically significant. A similar pattern was found 
for total AUC/dose.
The pattern of systemic galactose appearance, and the 
corresponding AUC total and AUC t=70min from different 
rats at the same oral concentration of galactose were 
very variable (Table 11). Figure 17 shows the 
variability between systemic galactose appearance 
curves, and so area under the curve in two sham 
operated rats after orogastric administration of 
galactose at a dose of 130 mg/kg.
At oral galactose doses of 25 mg/kg, systemic galactose 
concentrations approximated basal levels of galactose
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and thus the liver threshold dose for first pass 
clearance of galactose in sham operated rats was 
provisionally taken to be 25 mg/kg.
A well-defined blood galactose appearance peak was seen 
in only three out of seven portal vein ligated rats who 
received an oral dose of galactose of 25 mg/kg (Table
13). In only one rat was a second blood galactose 
appearance peak seen, which exceed the first peak by 3 
mg/1. Blood galactose reached a maximum level 10 to 50 
minutes after administration of the oral dose, 
declining towards basal levels after 60 minutes. The 
maximum concentration in blood did not exceed 70 mg/1 
above baseline, and the minimum was 2 mg/1. In only
one rat was food found in the stomach on completion of
the experiment.
Gavage with 25 mg/kg of galactose in portal vein
ligated rats produced an area under the curve at 
t=70min no greater than 890 mg.min/1 (Table 13), with a 
mean + SD of 257 + 313 mg.min/1 (Table 12) . No
significance difference was found in AUC t=70min values 
between portal vein ligated and sham operated rats at 
an oral galactose dose of 25 mg/kg (p=0.844). 
Similarly, no significant difference in total AUC 
values between portal vein ligated and sham operated 
rats at an oral galactose dose of 25 mg/kg (p=0.927) 
was found.
AUC/dose at 70 minutes ranged from -1.8 to 35.6
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kg.min/1 at an oral dose of 25 mg/kg (Table 13), with a 
mean ± SD of 10.3 ± 12.5 kg.min/1 (Table 12). AUC/dose 
total ranged from 7.6 to 3 5.6 kg.min/1 at an oral dose 
of 25 mg/kg (Table 13), with a mean + SD of 16.9 + 9.1 
kg.min/1 (Table 12). No significant difference was 
found in AUC/dose total, and AUC/dose t=70min between 
portal vein ligated rats and sham operated rats, 
p=0.936 and p=0.850 respectively.
TABLE 11
Dose Duration AUC AUC
(mg/kg)
of
sampling
(mins)
total t=7i 
(mg.min/1)
130 190 2215 1695
130(i) 152 535 140
130(i) 70 2003 2003
130 70 6375 6375
130 140 8305 2590
130(i) 70 6152 6152
100 150 2400 1510
100 150 4405 3140
50 90 334 196
50(i) 150 1930 1345
25 (i) 150 310 50
25 (i) 100 675 465
25 70 475 475
25 150 500 120
25 110 380 200
25 150 1180 655
25 110 340 245
25 110 165 -180
25 110 -115 25
CGmax Tpk AUC/dose AUC/dose
1 2 1 2 total rt II o
(mg/1) (mins) (kg. min/1)
45 28 10 50 17.0 13.0
7 7 22 102 4.1 1.1
64 - 30 - 15.4 5.4
190 - 30 - 49.0 49.0
118 - 90 - 63.9 19.9
131 - 30 - 47 . 3 47.3
47 49 30 70 24 . 0 15.1
90 - 60 - 44 . 5 31.4
5 - 30 - 6.1 3.6
35 - 40 - 35.1 24 . 5
8 5 10 90 12 . 4 2 . 0
10 13 10 60 27 . 0 18. 6
13 - 20 - 19 . 0 19 . 0
5 - (a) - 20.0 4.8
8 - 20 - 15.2 8.0
21 - 10 - 47.2 26.2
10 - 10 - 13.6 10.2
3 - (a) - 6. 6 -7.2
0 - (a) - -4.6 1.0
Individual AUCtotal and other expressions have 
been calculated in sham operated rats at different oral 
galactose doses. The above calculated expressions are 
defined on the following page.
The definitions of the calculated expressions in Table 
11 are shown below;
Auctotal
AUCt=7o
CGmax
Tpk
AUC/dosetotal
AUC/dose^_70
(i)
(a)
Total area under the galactose 
appearance curve
Area under the galactose appearance 
curve from 0 to 7 0 minutes 
Maximum blood galactose concentration 
after oral dose
Time of blood galactose appearance 
peak
Total systemic availability 
of galactose
Total systemic availability of galactose 
from 0 to 7 0 minutes 
Food present in stomach 
No definable peak
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Figure 16
This shows decreasing areas under the 
curve with descending oral doses of galactose 
in sham operated rats. The relationship between 
area under the curve (AUC) and oral galactose 
dose (GD) is described by the linear regression 
equation AUC = 28.12GD-514.35. A correlation 
coefficient of 0.698 was found.
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TABLE 12
Type Dose AUCtotal AUCt=7Q AUC/dosetotal AUC/doset=70
Mean + SD Mean + SD Mean + SD Mean + SD
(mg.min/1) (mg.min/1) (kg.min/1) (kg.min/1)
SO 130 4264 + 3084 3159 + 2538 32.8 ± 23.7 24.3 ± 19.5
(n=6)
SO 100 3403 + 1418 2325 + 1153 34.3 ± 14.5 23.3 ± 11.5
(n=2)
SO 50 1132 + 1129 771 ± 813 20.6 + 20.5 14.1 ± 14.8
(n=2)
SO 25 434 ± 357 228 ± 263 17.4 + 14.3 9.2 + 10.5
(n=9)
PVL 25 420 + 229 257 ± 313 16.9 ± 9.1 10.3 ± 12.5
(n=7)
AUC^_0^a^ = Total area under the galactose 
appearance curve 
AUCt=70 = Area under the galactose appearance 
curve from 0 to 70 minutes 
AUC/dose^.0 .^a^ = Total systemic availability of
galactose after an oral dose 
AUC/dose^_70 = Systemic availability of galactose
from 0 to 70 minutes after an oral 
dose
This table shows the mean and standard deviation 
of the mean of AUCtotal anc  ^ other calculated 
expressions at various oral galactose doses in sham 
operated rats and in portal vein ligated rats at an 
oral dose of 25 mg/kg. No significant difference was 
found between sham operated and portal vein ligated 
rats in AUCtotal (p=0.906), AUCt=70min (P=0.751), 
AUC/dosetotal (p=0.922), and AUC/doset=70min (p=0.757) 
at an orAl galactose dose of 2 5 mg/kg.
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Figure 17
This shows galactose concentration time curves over 
a 2hr 30min time period in two sham operated rats 
following oral administration of a 130 mg/Kg dose 
of galactose.
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TABLE 13
Dose Duration AUC AUC CGmax Tpk AUC/dose AUC/dose
of _ total t=70 1 2  1 2  total t=70
sample
(mg/kg) (mins) (mg.min/1) (mg/1) (min) (kg.min/1)
25 70 380 380 17 — 30 - 15. 2 15.2
25 70 890 890 70 - 10 - 35.6 35.6
25 (i) 150 505 255 12 - 50 - 20.2 10.2
25 150 320 90 5 - (a) 12.8 3.6
25 150 380 190 5 - (a) 15. 2 7.6
25 150 275 -45 2 5 (a) 11. 5 -1.8
25 110 190 40 4 - (a) 7.6 1.6
AUC^.0 .^a  ^ = Total area under the galactose 
appearance curve 
AUCt=70 = Area under the galactose appearance 
curve from 0 to 70 minutes 
CGmax = Maximum blood galactose
concentration after oral dose 
Tpk = Time of blood galactose appearance 
peak
AUC/dose .^0 .^a2 = T°tal systemic availability of
galactose after an oral dose 
AUC/dose^._70 = Systemic availability of galactose
from 0 to 70 minutes after an 
oral dose 
(i) = Food present in stomach 
(a) = No definable appearance peak
Individual values of AUC^0^a -^ and other 
expressions have been calculated in portal vein ligated 
rats after a 25 mg/kg oral dose of galactose.
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DISCUSSION
Experiments in sham operated rats suggest that an 
oral dose of no more than 25 mg/kg is required to be 
sure of avoiding significant systemic breakthrough of 
galactose. However, in contrast to the experiments in 
patients described in Chapter 4, no increase in
systemic availability was observed when the same dose 
was given to portal vein ligated rats. The erratic 
appearance curve seen in some animals suggests that 
absorption of galactose from the gastrointestinal tract 
in rats may be similarly erratic, delayed or 
incomplete, and this source of variability could mask 
differences between portal vein ligated and sham 
operated groups.
It is unlikely that oral galactose would enter the 
portal circulation via a different route from the
microspheres with which the shunting characteristics of 
the model were established. Microspheres enter the 
portal circulation following injection into the 
ileocolic cannula at a point distal to the superior 
mesenteric vein. Galactose, in turn is absorbed from 
the small intestine and enters the portal vein via the 
superior mesenteric vein. The main pattern of 
collateral development in rats with a prehepatic portal 
vein stenosis is through splenorenal collaterals and
retrograde filling of the inferior mesenteric vein
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(Halvorsen and Myking, 1974; Bengmark et al, 1976). 
Both microshperes and galactose should encounter these 
collaterals upon entry into the portal vein and be 
quantitatively diverted into the systemic circulation. 
However, because of the failure to demonstrate a 
significant difference in the systemic availability of 
galactose between portal vein ligated and sham operated 
rats, it would seem possible that galactose may not be 
subjected, for whatever reasons, to the same degree of 
portasystemic shunting as that of the microspheres.
A third possibility for the failure to demonstrate a 
difference in the systemic availability of galactose 
between sham operated and portal vein ligated rats is 
that the galactose concentration threshold established 
in these experiments, above which extraction by the 
normal liver is incomplete, is so low in the rat that 
it gives rise to blood concentrations below the limits 
of sensitivity of the assay even when shunting is 
present. As discussed in chapter 3, resolution at 
blood galactose concentrations of 10 mg/1 and below, is 
reduced as one reaches the limits of assay sensitivity. 
Such blood galactose concentrations are common after an 
oral dose of 25 mg/kg of galactose.
In the final sections of this chapter we examine the 
first two of these possibilities, and in the following 
chapter we address the other one.
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SECTION B. CARBON-14 LABELLED GALACTOSE
INTRODUCTION
This section examines the idea that erratic and/or 
incomplete absorption of galactose from the gut maybe 
part responsible for the non-significant difference in 
systemic availability of oral galactose between sham 
operated and portal vein ligated rats. By measuring 
the amount of radioactivity present in various sections 
of the gastrointestinal tract following oral 
administration of carbon-14 labelled galactose in sham 
operated, and portal vein ligated animals, the percent 
retention of galactose in each section of the 
gastrointestinal tract can be calculated and a picture 
formed of the distribution and retention of galactose 
in the gut. The techniques used and results are 
described in this section.
217
MATERIALS AND METHODS
Animals were prepared as described in Chapter 5.
Animals weighting 354.5 + 46.6 grams (mean + SD) were
used in all experiments. A solution was prepared 
containing 4 mg/ml unlabelled galactose and 0.04 MBq/ml 
carbon-14 labelled galactose, dissolved in distilled 
water. A dose containing 25 mg/kg body weight of 
unlabelled galactose was flushed into the stomach of 
the rat, twenty minutes after a 2ml water gavage. 
Arterial blood samples were collected every 10 minutes, 
and samples analysed, after deproteinisation, as 
described in Chapter 3. Prior to orogastric 
administration of galactose an arterial blood sample 
was collected to determine basal galactose 
concentrations.
At the end of the experimental period, approximately 2 
hours, the rat was sacrificed by opening the chest, an 
incision was then made in the abdomen and the stomach
together with contents and the intestines were removed.
The intestines were divided into the duodenum, the 
remainder of the small bowel, and the large bowel. 
Each section was sliced individually into approximately 
1 cm long segments, the stomach was dealt with 
similarly, after the removal of its contents. Tissue 
samples and stomach contents were then placed in 
previously weighed liquid scintillation counting vials
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and digested by the addition of 10ml 10M concentrated 
sodium hydroxide for two days in an oven at a 
temperature of approximately 60 to 80 degrees C. When 
digestion was complete each vial was weighed once 
again, and 0.5ml of the digested tissue removed for 
counting of radioactivity. The vial was then re-weighed 
again to determine the tissue sample weight.
The 0.5ml digested tissue sample was then bleached by 
the addition of 0.5ml 3 0% hydrogen peroxide for 1 hour. 
10 ml of liquid scintillant, Optiphase "Safe" (LKB) was 
added, and the sample counted in a Packard Tri-Carb 
2660 liquid scintillation counter with automatic quench 
correction. The counter was regularly calibrated with 
a set of quenched carbon-14 standards. A 0.2 5ml sample 
of the 4mg/ml original stock solution was also counted 
for radioactivity and the following calculations made;
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Tissue calculations
1• Total tissue solution weight
The total weight of the digested stomach, duodenum 
and the small and large bowel (including solvent) 
were individually calculated.
Total tissue solution weight (grams)
= Weight of vial after digestion of tissue 
weight of the empty vial (g)
2. Radioactivity in tissue sample
Radioactivity per gram (DPM/g)
= Radioactivity in 0.5ml digested tissue 
sample (DPM)
Weight of 0.5 ml sample (g)
3. Radioactivity in total tissue
Radioactivity in total tissue (DPM)
= Radioactivity in tissue sample (DPM/g) 
multiplied by total tissue weight (g)
4. Radioactivity administered
Radioactivity administered (DPM)
= Radioactivity in 0.25ml stock solution 
(DPM) multiplied by amount of oral 
galactose given (ml) multiplied by 4
5. Percentage radioactivity in tissue
Percentage radioactivity in tissue (%DPM)
= Radioactivity in total tissue (DPM)
------------------------------------------ x 10o
Administered radioactivity (DPM)
Blood samples collected from the right femoral 
artery cannula were also counted for carbon-14 
radioactivity after deproteinization as described in 
Chapter 3. 0.2ml of the resultant supernatant was
counted by placing in a liquid scintillation counting 
vial with 10 ml of liquid scintillant, Optiphase "Safe" 
(LKB), and then counted in a Packard Tri-Carb 2 660 
liquid scintillation counter, as previously described.
Statistical Analysis
The statistical significance of observed 
differences between sham operated and portal vein 
ligated animals was tested by the Student's t-test.
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RESULTS
The percentage of carbon-14 labelled galactose 
retained in various sections of the gastrointestinal 
tract in three sham operated and four portal vein 
ligated animals after orogastric administration of 25 
mg/kg of galactose is shown in Table 14. The extent of 
retention two hours after the initial oral dose in sham 
operated rats ranged from 3.62 to 15.29 percent, with 
a mean of 10.47 + 6.09% (SD), and in portal vein 
ligated rats ranged from 15.15 to 34.64 percent, with a 
mean of 21.06 + 9.16% (SD). This difference was not 
statistically significant (p=0.147).
The greatest individual percent retention of carbon-14 
galactose occurred in the gastric fluid of a portal 
hypertensive rat (28.50%), however in both control and 
portal vein ligated rats the greatest mean percent 
retention of carbon-14 galactose was found in the 
small intestine and the stomach. Overall the percent 
retention in various sections of the gastrointestinal 
tract varied greatly from animal to animal (Table 14). 
In three sham operated rats and one portal vein ligated 
rat systemic blood galactose concentrations were 
measured, and the total area under the galactose 
apparance curve (AUC total), area under the galactose 
appearance curve from 0 to 70 minutes (AUC t=70min), 
AUC/dose total, AUC/dose t=70min calculated and
tabulated against corresponding percent retention of 
carbon-14 galactose in the gastrointestinal tract 
following oral administration of 25 mg/kg of galactose 
(Table 15). The largest area under the curve was 
associated with the smallest amount of percent carbon- 
14 retained in the gastrointestinal tract, and a trend 
towards increasing retention with decreasing area under 
the curve was seen in this small group of rats (Figure 
18). The relationship between total area under the 
galactose appearance curve (AUC) and percent retained 
carbon-14 radioactivity (RR) in the gastrointestinal 
tract is given by the linear regression equation AUC = 
489.2 - 34.3RR . A correlation coefficient of 0.911 was 
found (Figure 18).
In all experiments collected blood samples were 
measured for carbon-14 radioactivity. The measured 
radioactivity was converted into equivalent galactose 
concentration (mg/1) by dividing the concentration of 
carbon-14 (MBq/1) by the specific activity of the 
original galactose solution (MBq/mg). Figure 19 shows a 
galactose concentration time curve and its 
corresponding carbon-14 radioactivity curve translated 
into equivalent mg/1 from a portal vein ligated rat 
following oral administration of 25 mg/kg of galactose. 
Both graphs initially follow a similar pattern as 
systemic blood galactose concentrations increase 
following oral galactose administration. Systemic blood
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galactose concentrations then decline with time as 
galactose is removed from blood by the liver, however 
equivalent galactose concentration remain elevated at 
an almost steady state. This elevate state can be 
attributed to circulating carbon-14 labelled 
metabolites of galactose which are released into blood 
as galactose is metabolised in the liver.
TABLE 14
PERCENT DPM
PROCEDURE GASTRIC INTESTINAL SEGMENTS
GASTRIC STOMACH DUODENUM SMALL LARGE TOTAL 
FLUID INTESTINE AMOUNT
RETAINED
SO (a) 1.28 (b) 1.28 1. 06 3 .62
so (a) 2.29 0.80 4 . 93 4.48 12 . 50
so (a) 7.47 0.78 7 . 00 0. 04 15.29
lean 3 . 68 0.79 4 .40 1.86 10. 47
SD 3 . 32 0.01 2 . 90 2 .32 6. 09
PVL (a) 12 .23 4.78 1. 10 0.33 18.44
PVL 28.50 1.73 3 . 69 0. 62 0. 10 34 . 64
PVL 2.97 2.45 3 . 05 6.59 0. 09 15.15
PVL 1.51 1. 00 0.29 12 . 34 0. 87 16. 01
lean 10.99 4.35 2.95 5.16 0.35 21.06
SD 15.18 5.28 1.91 5.50 0.37 9.16
(a) =
(b) =
Gastric
stomachs
Duodenum
bowel
fluid counts included 
counts included with
with
small
A comparison of the percentage of carbon-
labelled galactose retained in various sections of the 
gastrointestinal tract in both sham operated and portal 
vein ligated rats after orogastric administration. The 
mean percentage retention of galactose in the 
gastrointestinal tract in all 7 animals was 16.52 +
8.07 (± SD).
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TABLE 15
Procedure Dose AUC AUC AUC/dose AUC/dose Total
total rt II o total t=7 0 amount
retain<
(mg/kg)(mg.min/1) (kg.min/1) (%)
SO 25 340 245 13.6 10. 2 3 . 62
SO 25 165 -180 6.6 -7 . 2 12 . 50
SO 25 -■115 25 -4.6 1.0 15.29
PVL 25 190 40 7.6 1.6 18.44
AUC^0 -^a^ = Total area under the galactose 
appearance curve 
AUCt=70 = Area under the galactose appearance 
curve from 0 to 7 0 minutes 
AUC/dose^-0 .^a  ^ = Total systemic availability of
galactose after an oral dose 
AUC/dose^._70 = Systemic availability of galactose
from 0 to 70 minutes after an 
oral dose
This shows the total area under the galactose 
appearance curve from concentration time graphs and 
other calculated expressions together with the 
corresponding percentage of carbon-14 galactose 
retained in the gastrointestinal tract following oral 
administration of 25 mg/kg galactose in control and 
portal hypertensive rats.
c
1
d)
E
LLI
>
X
D
O
HI
X
H
400 n
300 -
200 -
100 -
X
LLI
0
1 0
< 
ui 
x 
<
- 100 -
<
Ho
-200
4 6 8 10 12 14
RETAINED RADIOACTIVITY (%)
— i
1 6
Figure 18
This shows the negative relationship between 
total area under the curve (AUC) and percent 
retained C-14 radioactivity (RR) in the gastro­
intestinal tract in a small group of sham 
operated rats. The relationship is described 
by the linear regression equation AUC = 489.2- 
34.3RR.A correlation coefficient of 0.911 was 
found.
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Figure 19
This shows a galactose concentration time curve and its
corresponding Carbon-14 radioactivity curve translated
into equivalent mg/l galactose concentration after a
25 mg/Kg oral dose of galactose in a portal vein ligated
rat. As blood galactose concentration declines,
equivalent mg/l galactose concentration remains at an
almost constant level. This is attributed to circulating 
14
C-labelled galactose metabolites.
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DISCUSSION
The purpose of these experiments were to examine 
galactose retention in the gastrointestinal tract and 
its possible relationship in the failure to demonstrate 
a significant difference in systemic availability 
between sham operated and portal vein ligated rats as 
shown in the previous section. Experiments in both 
sham operated and portal vein ligated rats have shown 
absorption of galactose from the gastrointestinal tract 
to be incomplete two hours after the initial oral dose. 
Galactose retention also varied widely from animal to 
animal, with a trend towards a reduction in the 
systemic availability of galactose with increasing 
retention. These observations would explain the 
erratic, and delayed galactose appearance curves seen 
in some animals in the previous section, and this 
source of variability could indeed mask differences in 
the systemic availability of galactose between portal 
vein ligated and sham operated groups.
The erratic and incomplete absorption of galactose from 
the gastrointestinal tract could be attributed to the 
presence of food in the gastrointestinal tract, and/or 
the effect of anaesthesia on gastric emptying. It is 
unlikely that galactose retention alone could account 
for the failure to demonstrate a significant difference 
in systemic availability between portal vein ligated
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and control animals; on average less than 2 0 percent of 
an oral galactose dose was retained in the 
gastrointestinal tract. An alternative possibility, as 
discussed in the previous section, is that galactose 
upon entering the portal vein is not subjected to the 
same degree of portasystemic shunting, for reasons that 
are at present unclear, as that of injected 
microspheres with which the characteristics of the 
model were established. In the final part of this 
chapter we infuse galactose directly into the portal 
vein. By this route galactose not only follows the 
same path as injected microspheres, but overcomes the 
problems of gastric retention.
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SECTION C. SINGLE INFUSION OF GALACTOSE INTO THE
PORTAL VEIN
INTRODUCTION
Experiments up to this point have examined the 
systemic availability of galactose following oral 
administration of various doses of galactose, and the 
percent retention of galactose in various sections of 
the gastrointestinal tract in both control and portal 
hypertensive rats. In the previous sections we 
suggested that the failure to demonstrate a significant 
difference in systemic availability of oral galactose 
between portal hypertensive and control rats stemmed 
from erratic and incomplete absorption of galactose 
from the gut and a possibility that galactose was not 
subjected to the same degree of portasystemic shunting 
as microspheres upon entry into the portal vein. In 
order to avoid these problems experiments were 
performed in which galactose was infused directly into 
the portal vein. By this route, the problems associated 
with absorption of galactose from the gut are 
circumvented, and also galactose follows the same path 
as injected microspheres, which in portal vein ligated 
animals are subjected to portasystemic shunting as 
discussed in Chapter 5.
This section describes the technique used and the 
results produced.
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MATERIALS AND METHODS
Animals weighing 255.6 + 29.43 grams (mean + SD) 
were used in all experiments. Portal hypertension was 
produced using the portal vein ligation technique as 
described in Chapter 5. Animals were fasted for 24 
hours before study in wire bottom stainless steel 
cages, and were allowed water ad libitum. Mean arterial 
pressure and arterial blood gases were measured as 
described in Chapter 5. The ileocolic branch of the 
portal vein was cannulated, and mean portal pressure 
measured prior to commencing the experiment as 
described in Chapter 5. Arterial blood samples were 
collected and analysed by galactose dehydrogenase 
enzyme assay as described in Chapter 3. Before 
infusion, an arterial blood sample was collected to 
determine basal galactose concentration.
D-galactose dissolved in distilled water at a 
concentration of 40 mg/ml was infused from a 5 ml glass 
syringe by a Braun infusion pump (B.Braun-Melsungen AG, 
West-Germany) at a rate of 0.9 ml/hr into the portal 
vein, giving galactose infusion rates in the range 128 
mg/kg/hr to 17 6 mg/kg/hr. Timed arterial blood samples 
were collected every ten minutes, until 4 0 minutes when 
the infusion ended, and thereafter every five minutes 
for another seventy minutes.
Once arterial blood sampling was complete approximately
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500,000 Cobalt-labelled microspheres (Co57) were 
injected via the ileocolic cannula into the portal 
vein. Three minutes later the animal sacrificed by 
opening the chest, and the lungs, kidneys and liver 
were removed and placed in vials for counting 
radioactivity. The larger organs were dissected and 
placed in several vials for counting. The tissues were 
counted for radioactivity by a Gamma Scintilation 
counter (Packard Instruments, Auto-gamma 5000) and the 
magnitude of portasystemic shunting calculated as 
described in Chapter 5.
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Analysis of the intraportal infusion
The forty minute intraportal infusion of galactose 
was analysed as if it represented an oral dose, 
completely absorbed from the gut at a uniform rate over 
the same period. The area under the galactose 
appearance curve was calculated as described in Section 
A, and the "oral" dose was equated with total infused 
dose.
Further, the slope of the blood galactose clearance 
curve after the termination of the infusion was used to 
provide additional information about systemic galactose 
clearance. Equation 2.6 of Chapter 2,
Ca(t)/dt = -(F/Vd) .Ca(t) ........................6.6
gives an expression relating the rate of disappearance 
of galactose from the blood to liver blood flow (F) and 
the distribution volume for galactose (Vd) under the 
assumptions that,
(a) the liver is the only organ of extraction
(b) hepatic extraction efficiency is 100 percent
(c) blood galactose is in continuous equilibrium 
with the total body pool and that elimination 
obeys first-order kinetics.
A more generalised form of this equation is,
dCa(t)/dt = -(K/Vd).Ca(t) ......................... 6.7
where k is the systemic clearance, and no assumptions 
are made about the route of clearance. The solution to 
equation 6.7 is,
Ca(t) = C a (0)exp(-Kt/Vd) ........................6.8
Where, Ca(0) = arterial concentration (Ca) at time
zero.
or, taking logarithms,
Log (Ca(t) ) = Log (Ca(0)) - Kt/Vd ............. 6.9
The factor K/Vd was calculated by linear regression 
analysis as the slope of the galactose clearance curve . 
on a logarithmic scale.
AUC.K/dose.Vd calculation and Statistical analysis
The area under the appearance curve divided by its 
corresponding dose (AUC/dose) was calculated as
described in section A. AUC/dose multiplied by
clearance was also calculated. The latter term gives us 
an expression for the systemic availability of
galactose related to the the volume of distribution 
(Vd). With reference to section A, equation 6.1
stated,
AUC/Q = SA/K = S + (l-S) (1“E)/K ................6.1
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Where, SA = Systemic availability
K = Systemic galactose clearance 
Q = Galactose dose
In this section, clearance is derived from the slope of 
the galactose clearance curve, and is described by K/Vd 
(equation 6.9). If equation 6.1 is multipied through by 
the term for systemic clearance (K/Vd), then
AUC.K/Q.Vd = SA/Vd = S + (1-S) (1-E)/Vd ....... 6.10
gives an expression for systemic availability which is 
related to the distribution volume for galactose.
The statistical significance of observed differences 
between sham operated and portal vein ligated animals 
was tested by the Student's t-test.
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RESULTS
Table 16 shows the area under the galactose 
appearance curve (AUC) in 15 individual sham operated 
and portal vein ligated rats at intraportal infusion 
rates ranging from 128 mg/kg/hr to 17 6 mg/kg/hr. The 
mean and standard error of the mean (SEM) was 3731 +
462.24 mg.min/1 and 3225.8 + 359.26 mg.min/1 in portal 
vein ligated and control animals respectively. No 
significant difference was found between both groups (p 
= 0.395).
The mean and standard error of the mean of galactose 
dose, systemic clearance, AUC/dose and AUC.K/dose.Vd in 
both groups of animals following a 40 minute 
intravenous infusion of galactose are shown in Table 
17. The mean galactose dose + SEM, 91.38 + 3.42
mg/kg/hr given to portal vein ligated rats was greater 
than that received by sham operated rats, 81.56 + 2.64 
mg/kg/hr, this difference was statistically significant 
(p = 0.03) .
Mean systemic clearance (K/Vd) ± SEM values of 0.092 + 
0.0091 min”1 and 0.094 + 0.0071 min”1 in portal vein 
ligated and control animals respectively were not 
significantly different from each other (p>0.05). 
Figure 20 shows the galactose concentration time curve 
in a sham operated rat following a 40 minute 
intraportal infusion of galactose at an infusion rate
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of 128 mg/kg/hr. The area under the galactose
appearance curve was 1942 mg.min/1. The slope of the 
above galactose clearance curve (K/Vd) plotted on a 
logarithmic scale with regression line is shown in 
Figure 21. The gradient of the slope by linear
regression analysis was 0.115 min-1. The correlation 
coefficient was 0.99.
Mean AUC/dose and AUC.K/dose.Vd were not significantly 
different for the two groups (p > 0.05). The mean + SEM 
for AUC/dose was 41.10 + 5.14 kg.min/1 and 39.91 + 4.83 
kg.min/1 and for AUC.K/dose.Vd was 3.37 + 0.31
kg/hr/1 and 3.13 + 0.29 kg/hr/1 in portal vein ligated 
and sham operated rats respectively (Table 17).
The mean + SD portasystemic shunting value calculated 
from injected microspheres in portal vein ligated rats 
was 56.38 + 32.48 percent and 0.135 + 0.238 percent in 
sham operated rats. Figure 22 shows the poor
relationship between area under the galactose
appearance curve (AUC) and portasystemic shunting 
(PSS) in portal vein ligated rats. The relationship is 
described by the linear regression equation AUC = 
3155.76 + 3.28PSS, with a correlation coefficient of
0.070.
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TABLE 16
Area under the curve (AUC) 
(mg.min/1)
Procedure PVL SO
(n=15) (n=15)
1828 1942
2442 4202
2393 3054
3978 3061
4948 2422
5396 3159
3716 5293
4828 3946
5129 4567
4399 5580
1778 4401
7408 1683
1142 2345
1639 1688
4941 1044
MEAN 3731 3225.8
SEM 462.24 359.26
This shows individual areas under the galactose 
appearance curve (AUC) in both portal vein ligated 
(PVL) and sham operated (SO) animals after a forty 
minute intraportal infusion of galactose at infusion 
rates ranging from 128 to 17 6 mg/kg/hr. The mean + SEM 
are also shown. No significant difference was found 
between PVL and SO rats (p = 0.395).
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TABLE 17
Procedure
Dose 
(mg/kg)
Clearance
(min"1)
AUC/dose
(kg.min/1)
AUC.K/dose. Vd 
(kg/hr/1)
PSS
microspheres
PVL
(Mean ± SEM)
91.38 ± 3.42 
(n=15)
0.092 ± 0.0091 
(n=12)
41.10 + 5.14 
(n=15)
3.37 ± 0.31 
(n=12)
Mean + SD
56.38 ± 32.48 
(n=13)
SO p value
(Mean ± SEM)
81.56 ± 2.64 = 0.03
(n=15)
0.094 ± 0.0071 > 0.05
(n=10)
39.91 ± 4.83 > 0.05
(n=15)
3.31 ± 0.29 
(n=10) 
Mean + SD 
0.14 ± 0.24 
(n=12)
> 0.05
< 0.05
This shows the mean + SEM of galactose dose, and 
other calculated expressions, as defined in the 
following page, in both control (SO) and portal vein 
ligated animals (PVL) following an intraportal infusion 
of galactose. The difference in dose and percent 
portasystemic shunting between PVL and SO rats were the 
only expressions to be statistically significant (p =
0.03: p < 0.05).
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The definitions of the calculated expressions in Table
17 are shown below;
Dose = Total amount of galactose given 
Clearance = Slope of the galactose clearance 
curve (K/Vd)
AUC/dose = Systemic availability of galactose 
dependent upon clearance after 
intraportal infusion 
AUC.K/dose.Vd = Systemic availability of galactose
dependent upon volume of 
distribution after intraportal 
infusion
PSSln^ croSpjieres = Portasystemic shunting as measured
by injected microspheres
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This shows the galactose concentration time curve 
in a sham operated rat following a 40 minute 
intraportal infusion of galactose at a rate of 128 
mg/kg/hr. The area under the galactose appearance 
curve was 1942 mg.min/1.
242
100 n
o>
E
2 10
<
cc
I-z
LU
O
O
o
UJ
(/>oh
o
<
<
o
1 -
~i------- r~
40 5030
i
60
i
70
i
80
TIME (minutes)
Figure 21
This shows the slope of the galactose clearance 
curve (K/vd) plotted on a logarithmic scale with 
regression line following a 40 minute intraportal 
infusion of galactose at a rate of 128mg/kg/hr in 
a sham operated rat. The gradient of the slope 
by linear regression analysis was 0.115 min-1.
The correlation coefficient was 0.99.
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Figure 22
This shown the poor relationship between area 
under the curve (AUC) and portasystemic shunting 
(PSS) in portal vein ligated rats. The 
relationship is described by the linear regression 
equation AUC = 3155.76 + 3.28PSS. A correlation 
coefficient of 0.070 was found.
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DISCUSSION
In these experiments, galactose was infused into 
the portal vein by the same route as injected 
microspheres, which showed a mean portasystemic 
shunting value of 56% in the portal vein ligated group. 
However, there was no difference in area under the 
galactose appearance curve (AUC) or AUC/dose. The 
failure to detect the expected greater systemic 
availability in portal vein ligated rats relative to 
sham operated rats in these experiments cannot be due 
to the difference in doses administered, as this was on 
average slightly higher in portal vein ligated rats. 
The possibility that differences between groups in 
total systemic galactose clearance (K) is compensating 
for the difference in shunting appears to be 
contradicted by the fact that the calculated parameters 
K/Vd and SA/Vd were similar in both groups. The 
calculation of these parameters is based on the some 
what doubtful assumption of instantaneous equilibration 
of galactose between blood and tissue during the 
disappearance phase of the curve. However it is 
inherently unlikely that K would be higher in the 
portal vein ligated that sham operated groups as would 
be necessary to compensate for differences in shunting. 
Portal vein ligated rats would be expected if anything 
to have lower liver blood flow and K values.
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It is improbable that portal vein ligation caused any 
major alteration in the distribution volume (Vd). The 
most likely explanation for these results is that the 
extraction efficiency of the liver at the galactose 
concentrations achieved in these experiments is very 
low in the sham operated group. Thus a high degree of 
"functional" shunting in this group would have the same 
effect as anatomical and functional shunting combined 
in portal vein ligated rats.
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CONCLUSIONS
Experiments have shown that erratic and incomplete 
absorption of galactose from the gastrointestinal tract 
is in part responsible for the failure to demonstrate 
a significant difference in the systemic availability 
of galactose between portal vein ligated and control 
rats following an oral dose of 25 mg/kg of galactose. 
This oral dose was established as the galactose 
concentration threshold above which extraction by the 
normal liver is incomplete.
The intraportal infusion of galactose further suggested 
that a similar systemic availability of galactose in 
both sham operated and portal vein ligated rats would 
arise if the hepatic extraction efficiency at the 
galactose concentrations encountered in this study, in 
sham operated, rats was very low.
In the following chapter we examine more closely the 
systemic availability of intraportally administered 
galactose in rats, and the dependency of hepatic 
extraction efficiency on circulating blood galactose 
concentrations.
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CHAPTER SEVEN INTRAPORTAL AND INTRAVENOUS
INFUSION OF GALACTOSE IN AN 
EXPERIMENTAL PREHEPATIC MODEL 
OF PORTAL HYPERTENSION
1. Introduction
2. Materials and methods
3 (a). Kinetic model and results
(b). Galactose clearance
(c). Extrahepatic galactose elimination
4. Discussion
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INTRODUCTION
It has been hypothesised that the failure to 
demonstrate a significant difference in systemic 
availability of galactose between portal hypertensive 
and control rats, following oral administration of 
galactose, is a result of erratic and incomplete 
absorption from the gut, and a failure of galactose to 
"see" the major portacaval shunts as a result of its 
site of entry into the portal vein (Chapter 6). The 
results of the last section of chapter 6, however, not 
only suggested that the route of administration of 
galactose is not a factor in the failure to demonstrate 
a significant diference in systemic availablity of 
galactose between portal hypertensive and control rats, 
but also implied that the extraction efficiency of the 
liver was very low in the sham operated group at the 
doses used. This finding thus brought into question 
hepatic extraction efficiency in rats.
In this chapter we examine more closely the systemic 
availability of intraportally administered galactose in 
rats, and the dependence of hepatic extraction 
efficiency on circulating blood galactose
concentrations. It has been shown that hepatic 
uptake of galactose by the hepatocytes follows 
Michaelis-Menten kinetics (Keiding et al, 1976; Keiding 
and Chiarantini, 1978). It has further been shown, by
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Keiding and Bass (1983), that from the Michaelis-Menten 
equation, V = VmaxCm/(Km+Cm) (Chapter 2) a formula for 
extraction efficiency (or rate) (E) can be developed 
where, E = l-exp[1-(Vmax-Inf)/FKm]. In this equation 
the symbols Inf and F represent galactose infusion rate 
and liver blood flow respectively. This equation, 
however, has a relatively large number of unknown 
parameters and a simpler approach in the intact rat is 
to apply the Michaelis-Menten equation not to the 
hepatocyte alone, but to the whole organ. Thus V, and 
Vmax would represent the galactose elimination rate and 
its maximum value for the liver as a whole, and Km the 
concentration of galactose in the systemic circulation 
at which elimination is half maximal. Keiding (1973) 
has shown this to produce Km and Vmax values in 
reasonable approximation to those found for the 
hepatocyte. However, the 'Km' value for galactose in 
systemic blood is higher than 'Km' for hepatocytes 
owing to the decreasing galactose concentration as the 
blood flows through the liver (Keiding, 1973). This 
chapter considers explicitly the Michaelis-Menten 
equation in the context of experimental studies on 
galactose elimination kinetics in portal hypertension 
and focuses on the development of a theoretical model 
through which the kinetic parameters that may be 
influencing galactose clearance are clarified.
In the following experiments, galactose was infused by
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both a portal and intravenous route in portal vein 
ligated and sham operated rats. At various galactose 
infusion concentrations, mean equlibrium blood 
galactose concentrations were measured and from 
resultant graphs the parameters Vmax and Km calculated. 
Expressions of hepatic extraction efficiency were 
derived and extraction efficiencies calculated. Mean 
galactose clearance was also measured at each 
intravenous infusion rate. Further, the magnitude of 
portasystemic shunting was calculated by both 
microsphere injection, as described in Chapter 5, and 
from shunting equations derived from the kinetic model. 
Each method was compared with the other.
Finally, a possible extrahepatic route of galactose 
elimination was examined by collecting and measuring, 
by enzyme assay and fluorescence spectrophotometry 
(Chapter 3), the concentration of galactose appearing 
in urine following completion of an experiement.
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MATERIALS AND METHODS
Animals weighing 289.4 + 41.7 grams were used. 
Portal hypertension was produced using the partial 
portal vein ligation technique as described in Chapter
5. Mean arterial pressure and arterial blood gases were 
measured as described in Chapter 5. Cannulation of the 
left femoral vein, was performed for the intravenous 
infusion, the ileocolic branch of the portal vein was 
cannulated for the portal infusion, and mean portal 
pressure measured prior to commencing the experiment as 
described in Chapter 5. Before the infusion, an 
arterial blood sample was collected to determine basal 
galactose concentration.
D-galactose dissolved, at a range of concentrations, in 
5 ml of distilled water was infused from a 5 ml glass 
syringe by a Braun infusion pump (B .Braun-Melsungen AG, 
West-Germany) at a rate of 0.9 ml/hr into the ileocolic 
cannula and the intravenous cannula • sequentially in 
random order. Each infusion had a duration of one hour, 
and the same concentration of galactose was used for 
both infusions in a given experiment. Arterial blood 
sampling began after infusing for 30 minutes and 
continued thereafter every 10 minutes until 60 minutes. 
All arterial blood samples were analysed as described 
in Chapter 3.
Once arterial blood sampling was complete approximately
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500,000 Cobalt-labelled microspheres (Co57) were 
injected via the ileocolic cannula into the portal 
vein. After sacrifice, three minutes later the lungs, 
kidneys and liver were removed and placed in vials for 
counting radioactivity. The larger organs were 
dissected and placed in several vials for counting. The 
magnitude of portasystemic shunting was calculated as 
described in Chapter 5.
In some experiments, upon their completion, urine was 
was collected by suprapubic puncture of the bladder, 
and the concentration of galactose in the urine 
measured by enzyme assay as described in Chapter 5.
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Design of the study
Portal vein ligated and sham operated animals 
were divided into four infusion groups, receiving a 
galactose infusion rate of either 25, 50, 75, and 100,
mg/kg/hr. Additional experiments were performed with an 
intravenous infusion only at a rate of 125 mg/kg/hr.
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KINETIC MODEL:
THE THEORY BEHIND THE GALACTOSE DUAL INFUSION TECHNIQUE 
AND RESULTS
With reference to the introduction, it has been 
shown that galactose is removed from the blood by the 
liver according to Michaelis-Menten kinetics (Keiding, 
1973) . Whole organ elimination of galactose is thus 
described by the Michaelis-Menten equation,
V = VmaxCm/(Km + Cm) ............................ 7.1
where,
V = galactose elimination rate for liver
Vmax = maximum galactose elimination rate
Km = Michaelis-Menten constant - blood galactose
concentration at half maximum elimination 
rate
Cm = mean concentration of galactose in blood
entering liver by hepatic arterial (ha) and 
portal venous(pv) routes combined
As the model develops the superscripts ip and iv 
will be used when necessary to distinguish blood 
galactose concentrations for the two routes of 
infusion. Equations without these superscripts are 
valid for both infusions. All variables refer to the 
equilibrium state when nothing is changing 
with time.
Further assumptions that are made are,
1). The physiological parameters, i.e. Shunting (S), 
Blood flow (F), Vmax and Km are the same for both i.v
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and i.p infusions. Infusion rate (I) is also the same 
for both the i.v and i.p infusions by design.
2). The liver is assumed to be the only significant 
organ of galactose elimination, so that the hepatic 
galactose elimination rate equals galactose infusion 
rate at equilibrium, V = I. It follows that V is also 
the same for both i.v and i.p infusions.
3). Galactose elimination follows Michaelis-Menten 
kinetics, with a rate that depends only on Cm and not 
arterial galactose concentration (Ca) or portal venous 
galactose concentration (Cp) individually. This is 
equivalent to assuming that arterial and portal blood 
mix before encountering hepatocytes.
The development of the kinetic model which will allow 
us to examine the variability of hepatic extraction 
efficiency stems primarily from equation 7.1 together 
with formulae derived from model definitions which 
will be described later.
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INTRAVENOUS INFUSION OF GALACTOSE IN SHAM OPERATED RATS
Relationship between equilibrium blood galactose 
concentration and infusion rate
If we examine the intravenous infusion of 
galactose and assume that no galactose is extracted 
outside the liver, the concentration of galactose in 
blood entering the portal vein from the gut, and the 
mean concentration in blood supplying the liver (Cm), 
is the same as arterial concentration, ie.:
Cmiv = Caiv = Cpiv ...............................7.2
and so equation 7.1 can be rewritten,
V = VmaxCalv/(Km + Calv) ........................7.3
From Assumption 2 (V = I), equation 7.3 becomes,
I = VmaxCaiv/(Km + Calv) ........................7.4
Experimental studies carried out in which equilibrium 
blood galactose concentrations at various infusion 
doses were measured, produced a hyperbola plot, from 
which, by non-linear regression analysis (Statgraphics 
statistical graphic system), the parameters Vmax and Km 
were estimated. Figure 23 shows equilibrium systemic 
galactose concentrations over 15 minutes following an 
intraportal and intravenous infusion of galactose at an
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infusion rate of 100 mg/kg/hr. The gradient by linear 
regression analysis on data from 45 to 60 minutes of 
the intravenous infusion expressed as percent of the 
mean systemic galactose concentration was 0.17 + 0.41
(SD) percent/min, and the range was -0.77 to +1.70. 
The increasing trend in systemic galactose 
concentrations at an intravenous infusion rate of 100 
mg/kg/hr is due to the fact that at this infusion rate 
we are on that part of the hyperbola curve which is 
approaching the maximum galactose elimination rate 
(Vmax) and saturation kinetics.
Figure 24 shows the hyperbola plot in sham operated 
rats. By curve fitting Vmax was found to equal 177.2 + 
14.2 mg/kg/hr and Km to equal 43.5 + 7.7 mg/1 (mean + 
SEM) .
A more widely used approach to the determination of 
Vmax and Km from data of this kind is to rearrange 
equation 7.4 in linear form. Of the various forms 
introduced, the "Lineweaver-Burk plot" is the more 
frequently applied (Engel, 1981).. Taking reciprocals 
of both sides of equation 7.4,
1/1 = Km + Caiv/Vmax.Caiv
= Km/Vmax.Ca^v + Ca^v/Vmax.Ca^v
= Km/Vmax.Calv + 1/Vmax .................... 7.5
or by rearranging,
1/Ca^v = Vmax/Km.I - 1/Km ...................... 7.6
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Figure 25 shows the plot of l/Calv against 1/1 to be 
linear, with a slope of Vmax/Km and an intercept on the 
ordinate of -1/Km. The estimated values of Km and 
Vmax, derived by linear regression analysis 
(Statgraphics, statistical graphic system) were 89.2 + 
32.7 mg/1 and 280 + 121 mg/kg/hr (mean + SEM). The 
standard errors of these values are much larger than 
those derived from the non-linear curve fitting 
procedure, and they are very heavily weighted by 
systemic galactose concentrations from the 25 mg/kg/hr 
intravenous infusion, which are subject to relatively 
high percent errors of measurement. The Vmax and Km 
values of 177.2 mg/kg/hr and 43.5 mg/1 respectively, 
derived from non-linear regression analysis, are deemed 
more accurate and are thus the preferred values.
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This shows equilibrium systemic galactose 
concentrations over 15 minutes following an 
intraportal and intravenous infusion of 
galactose at a rate of 100 mg/Kg/hr. The 
gradient of the line by linear regression 
analysis on data from the intravenous infusion 
of galactose expressed as % of mean galactose 
concentration was 0.17%/min ± 0.41 (SD). The 
range was -0.77 to +1.7.
260
INFUSION RATE VERSUS MEAN EQUILIBRIUM 
GALACTOSE CONCENTRATION IN SHAM
OPERATED RATS1 5 0  n
120 -
Jz 
D)
o>
E 90 -
UJ + +H
<
DC
60 -z
O
U)
D
U -
Z
30 -
40 80 1 2020 60 1 000
MEAN EQUILIBRIUM GALACTOSE CONCENTRATION (mg/l)
Figure 24
This shows the relationship between mean 
equilibrium blood galactose concentration at 
various intravenous infusion rates in sham 
operated rats. By non-linear regression 
analysis the parameters Vmax and Km of the 
curve can be estimated. In this case Vmax 
was 17 7 .2  ± 14 .2  mg/kg/hr, and Km was 4 3 . 5  
± 7 . 7  mg/l, (Mean ± SE) .
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Figure 25
The "Lineweaver-Burk plot" gives a linear 
relationship between mean equilibrium blood 
galactose concentrations and intravenous 
infusion rates, and allows Vmax, and Km to 
be estimated from the slope of the line and 
its intercept on the ordinate respectively. 
In this case the mean ± SE of Vmax was 
2 80 ± 121 mg/kg/hr and Km was 89.2 ± 32.7 
mg/l in sham operated rats.
Relationship between expressions of hepatic extraction
efficiency
One of the aims of this chapter was to examine the 
variability of hepatic extraction efficiency. With 
knowledge of the values for Vmax and Km, together with 
a number of assumptions and formula derived from model 
definitions, two expressions for extraction efficiency 
of the liver for galactose (E) can be derived. By 
definition, extraction efficiency (E) is the rate of 
hepatic extraction (V) divided by the rate of delivery 
of galactose, the latter being given by the 
concentration of galactose in blood (Cm) multiplied by 
total liver blood flow (F^),
ie. E = V/F1Cm .........................................7.7
or from equation 7.1,
E = Vmax/F^(Km + Cm) ..............................7.8
When Cm is very low (ie. negligible compared with Km),
equation 7.8 becomes;
E = Vmax/F^Km.. ....................................7.9
It is normally assumed at sufficiently low blood 
concentrations, hepatic extraction of galactose is 
complete (ie. E = 1). However this assumption can be 
tested, thus at low Cm, extraction is represented by
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Eo, and equation 7.9 shows that;
Vinax/F^Km = Eo ................................... 7.10
Hence, by rearranging and substituting equation 7.10 
into 7.8,
E = Eo.Km/(Km + Cm) ............................. 7.11
For the intravenous infusion, equation 7.11 becomes,
E = E o .Km/ (Km + Caiv) ........................... 7.12
Another expression can be derived by inserting equation 
7.10 into equation 7.1, and solving for Cm:
Cm = V. Km/ (FI. Eo. Km - V)
= V.Km/(Vmax - V) ............................ 7.13
Inserting equation and 7.13 into equation 7.11,
E = [1 - (V/Vmax) ] . Eo ........................... 7.14
These two expressions for extraction efficiency, which 
for brevity we refer to as E-^  and E2 , are compared in 
Figure 26, ignoring the common unknown factor Eo. Each 
equation is compared as if each rat has the group mean 
values of Km and Vmax. The extraction term in the 
equation E2 = Eo.Km/(Km + Calv) is dependent upon 
individual equilibrium blood galactose concentration 
measurements in rats, whereas in equation E-^  = [1
(V/Vmax)].Eo extraction is independent of any 
individual rat measurements. By linear regression 
analysis the relationship between E2 and E^ is given 
by the equation E2 = 0.040 + 0.923E-L with a
correlation coefficient of 0.970. The standard error 
(SE) of the intercept and the slope were 0.034 and 
0.057 respectively. This result shows that the linear 
relationship is close to the line of identity. This 
reinforces the validity of the theory and our approach 
to applying Michaelis-Menten kinetics to the whole 
organ.
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Figure 26
This shows the good relationship between 
two extraction efficiency expressions,
1- (inf/177.2) , denoted by and 43. 5/(43. 5 + 
Ca1V) denoted by E i n  sham operated rats 
following intravenous infusions of galactose. 
The relationship is described by the linear 
regression equation = 0.040 + 0.923E^. A 
correlation coefficient of 0.970 was found.
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INTRAPORTAL INFUSION IN SHAM OPERATED RATS
If we now examine the intraportal infusion of 
galactose in sham operated rats, we can derive a third 
expression for extraction efficiency (E3). This 
expression can then be compared with the two previous 
expressions of extraction (E-j^ and E2) / derived from the 
intravenous infusion of galactose, in order to test the 
assumptions and self consistency of the theory.
The concentration of recirculating galactose in blood 
entering the portal vein from the gut is equal to 
arterial concentration, as with the i.v. infusion. 
However, this concentration is increased by the 
galactose being directly infused into the portal vein. 
The increase in concentration is given by the rate of 
galactose infusion (I) divided by the volume of blood 
flowing in the portal vein per unit of time (Fpv), ie. 
I/Fpv. Hence, total galactose concentration in the 
portal vein (Cp1^) is given by,
Cp^P = Ca^P + I/Fpv ............................ 7.15
From Assumption 2 (V = I), and by rearranging the 
extraction efficiency equation 7.7,
I = E . F ^ C m  .......................................7.16
When arterial galactose concentration (Ca) and portal 
venous galactose concentration (Cp) are different Cm is
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given by their average weighted according to flow in
artery and portal vein, ie. equation 7.17,
Cm = (FhaCa + FhpCp)/F-L ....................... 7.17
where,
Fhp = hepatic portal flow 
Fha = hepatic arterial flow
Substituting equation 7.17 into equation 7.16,
I = EfFhaCa1? + FhpCpiP).........................7.18
Substituting equation 7.15 into equation 7.18,
I = E(FhaCaiP + FhpCCa^-P + I/Fpv)) ..............7.19
Total liver blood flow equals the sum of hepatic
arterial flow and the hepatic component of portal
venous flow, i.e. F^ = Fha + Fhp and by substituting
into equation 7.19,
I = E(F1Caip + IFhp/Fpv) ........................7.20
In sham operated rats portasystemic shunting is zero
and hepatic portal flow (Fhp) equals portal
venous inflow (Fpv), and equation 7.20 becomes,
I = E(F1CaiP + I)..................................7.21
To eliminate the unknown variable F^ from equation 
7.21, we must draw on the results of the intravenous 
infusion. We first note that E must have the same
value for both infusions. This follows from the fact 
that the derivation of equations 7.10, 7.13, and 7.14
does not depend on the route of administration of 
galactose, and these expressions for E and Cm are 
dependent only on variables which are assumed to remain 
constant. We may express equation 7.7 as,
E = I/F1Caiv ..................................... 7.22
Substituting into equation 7.21 and rearranging,
E = 1 - CaiP/Caiv ................................7.23
This equation gives us our third extraction efficiency 
expression (E3)/ and unlike the other two hepatic 
extraction efficiency expressions it is dependent 
only on data derived from individual animals. By 
comparing this expression of extraction efficiency with 
the two previous derived expressions the relationship 
between the terms can be examined. The expected 
relationships are E3 = Eo.(l - I/Vmax), and E3 = 
Eo.Km/(Km + Calv). E3 is plotted against 1-I/Vmax and 
Km/(Km+Calv) in Figures 27 and 28. The regression line 
in both cases does not differ significantly from the 
line of identity, and from its gradient the estimated 
value for Eo is 1.00 + 0.22 (+SEM) (Figure 27) and 0.96 
+ 0.26 (+SEM) (Figure 28). The results of these
comparisons therefore suggest that the hepatic 
extraction efficiency for galactose at very low
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concentrations is effectively 100%. The extraction 
efficiency expression (Eo) can thus be dropped from 
the equations. The good agreement between mean values 
for extraction efficiency (E) derived from the 
intravenous and intraportal infusions in individual 
animals (E3), and the values derived from the 
collective intravenous data alone (E-l and E2) / shown in 
Table 18, suggests that the assumptions underlying this 
analysis are sound. Thus the relationship between 
infusion rate, Calv, and Ca1^ is consistent with the 
theory. Individual variations in Km and Vmax values 
would account for the scatter of the data points in 
Figures 26, 27 and 28 about the regression line.
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The relationship between the extraction 
efficiency expression 1- (Ca1 >^/Calv) , derived 
from the intraportal infusion of galactose in 
sham operated rats and denoted by E^, and the 
extraction efficiency expression 1-(inf/177.2) 
denoted by is described by the linear 
regression equation E^ = l.OE^ - 0.0657. A 
correlation coefficient of 0.784 was found.
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This shows the relationship between the 
extraction efficiency expression 1-(Caip/Calv) 
denoted by and the extraction efficiency 
expression 43.5/(43.5+Ca1V) denoted by E^. The 
relationship is described by the linear 
regression equation E^ = O.96E2 - 0.036. A 
correlation coefficient of 0.712 was found.
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TABLE 18
Infusion No of Expressions of Extraction
Rate animals Efficiency
(mg/kg/hr)
El E2 E3
[ 1- (V/Vmax) ] .Eo Eo.Km/(Km+Cm) l - C a ^ / C a ^
Mean Mean + SEM Mean + SEM
25 3 0. 859 0 .830 + 0. 008 0.804 ± 0. 09
50 3 0. 718 0. 694 + 0. 039 0.606 ± 0. 078
75 4 0. 577 0. 594 + 0. 028 0.571 ± 0. 038
100 5 0.436 0.442 + 0. 024 0.351 + 0.075
125 3 0.295 0. 304 + 0. 015
This shows the mean + SEM hepatic extraction 
efficiency values for all three extraction efficiency 
expressions at different infusion rates in sham 
operated rats. There was no statistically significant 
difference between E-^ , E2 and E3 at any infusion rate.
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INTRAVENOUS INFUSION OF GALACTOSE IN PORTAL VEIN
LIGATED RATS
Relationship between equilibrium blood galactose 
concentration and infusion rate
Returning to the Michaelis-Menten equation,
V = Vmax.Ca-*-v/ (Km + Ca^v ) .......................7.1
Again the parameters Vmax and Km in portal vein 
ligated rats can be estimated from experimental studies 
carried out in which equilibrium blood galactose 
concentrations at various intravenous infusion rates 
were measured. Equilibrium blood galactose
concentrations were achieved as previously shown in
sham operated rats (Figure 23). Figure 29 shows the
relationship between infusion rates and equilibrum 
concentrations, and by non-linear regression analysis
(Statgraphics, statistical graphics system) of the 
hyperbola, the parameters Vmax and Km were estimated to 
be 180.09 ± 27.44 mg/kg/hr and 56.42 ± 17.48 mg/1 (mean 
+ SEM) respectively. The mean values of Vmax and Km 
are not apparently changed from the values estimated 
from the intravenous infusion in sham operated rats, 
however, there was more scatter in data, and thus
presumably more variability in individual values of 
Vmax and/or Km.
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This shows the relationship between mean 
equilibrium blood galactose concentration at 
various intravenous infusion rates in portal 
vein ligated rats. The parameters Vmax and Km 
of the curve were found, by non-linear regression 
analysis, to be 180.09 ± 27.44 mg/kg/hr and 
56.42 ± 17.48 mg/l (Mean ± SE) respectively.
INTRAPORTAL INFUSION OF GALACTOSE IN PORTAL VEIN
LIGATED RATS
Comparison of systemic availability of intraportal 
galactose in portal vein ligated and sham operated rats
Since portal vein ligated animals undergo 
portasystemic shunting, hepatic portal flow (Fhp) is 
equal to flow in the portal vein (Fpv) multiplied by (1 
S) , where S represents portasystemic shunting 
expressed as a fraction, ie
Fhp = Fpv(1 - S) ................................. 7.24
If we return to equation 7.20:
I = E (F^Ca^P + IFhp/Fpv) ........................7.20
then by inserting equation 7.24 into equation 7.20,
I = E(F1Ca1P + 1(1 - S) )......................... 7.25
by rearranging,
Caip = 1(1 - E + ES)/EF1
Since I/E.F-^ = Calv (equation 7.22), then
Caip = Caiv(l - E + ES) ..........................7.26
Caip/Caiv = 1 - E + ES
= 1 - E (1 - S) .........................7.27
or = S + (1 - S) (1 - E ) ................... 7.28
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Caip/Calv = Systemic availability (SA) as 
defined in Chapter 2.
When S = 0, equation 7.28 becomes equivalent to
equation 7.23 as derived for sham operated rats.
Table 19 shows the mean systemic availability values 
calculated from the expression Calp/Calv at four 
different infusion rates in both sham operated and 
portal vein ligated rats. Systemic availability does 
not vary significantly with infusion in portal vein 
ligated rats: by ANOVA a p value of 0.37 3 was found.
However, in sham operated rats systemic availability 
does vary significantly with infusion, a p value of 
0.0071 was found by ANOVA. The increasing systemic 
availability in sham operated rats reflects the 
increasing saturation of the galactose extraction 
mechanism with concentration. The more constant 
systemic availability in portal vein ligated rats 
reflects the fact that a constant fraction of galactose 
is diverted via shunts irrespective of concentration 
and hepatic extraction efficiency. Figure 30 shows 
mean systemic availability (Caip/Calv) values in sham 
operated and portal vein ligated rats. As infusion 
rates increase systemic availability in sham operated 
rats converges towards the systemic availability in 
portal vein ligated rats. Error bars clearly indicate 
the SEM at each mean value.
TABLE 19
Infusion
Rates
(mg/kg/hr)
Systemic availability
PVL SO
Mean + SEM
25
50
75
100
Overall Mean + SEM
0. 648 + 0. 090 0. 196 + 0. 090
0.762 + 0. 076 0. 394 + 0. 078
0. 763 + 0.064 0.429 + 0.038
0.831 + 0. 038 0. 649 + 0. 075
0.750 + 0. 037 0.449 + 0. 036
PVL = Portal vein ligated 
SO = Sham operated
This shows the mean + SEM values for Ca1P/Calv at 
four different infusion rates in portal vein ligated 
and sham operated rats. Systemic availability did not 
vary significantly with infusion in portal vein ligated 
rats (p=0.373 by ANOVA). In sham operated rats a p 
value of 0.0071 was found (ANOVA) and systemic 
availability varied significantly with infusion rate.
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This shows the systemic availability (Caip/
Ca1V) of galactose at four different infusion 
rates in portal vein ligated (PVL) and sham operated 
rats (SO). In sham operated rats systemic 
availability varied significantly with infusion 
rate (p = 0.007). Error bars indicate the SEM 
at each mean value.
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Relationship between portasystemic shunting calculated
from microspheres and infusion rate
Returning to equation 7.28 and rearranging,
S = [(Caip/Caiv) - (1 - E) ]/E .................. 7.29
If Eo is assumed to be 1, then by inserting equation 
7.14, E = [1 - (V/Vmax)].Eo, into equation 7.29, an 
expression for shunting is derived,
S ± = [ (Caip/Calv) - (I/Vmax) ]/ (1 - I/Vmax) ....7.30
A second expression for shunting is derived if equation 
7.12, E = Eo.Km/(Km + Calv), is inserted into equation 
7.29, and Eo is assumed to be 1,
S2 = (Caip/Caiv - [Caiv/(Km + Caiv)(Km + Caiv/Km)
= Ca^p/Ca^v + Ca-’-P/Km - Ca^v/Km
= Caip/Calv - (Caiv - Caip)/Km ............. 7.31
In all experiments portasystemic shunting was 
also calculated from the injection of microspheres into 
the portal vein as described in chapter 5. The mean + 
SEM values of portasystemic shunting calculated from 
microsphere injection and from the two expressions for 
portasystemic shunting in both sham operated and portal 
vein ligated rats are shown in Table 20. From the 
table it can be seen that there is a tendency, which is
non-significant, for the shunting expressions to 
overestimate portasystemic shunting in sham operated 
rats, and to significantly underestimate, p<0.01, 
portasystemic shunting in portal vein ligated rats.
The relationships between portasystemic shunting 
determined from microspheres and that calculated from 
both of the above expressions of shunting in both sham 
operated and portal vein ligated rats are described in 
Figures 31 and 32, where the mean values of Km and Vmax 
respectively have been used.
The relationship between portasystemic shunting (PSS), 
as measured by microspheres and equation S-^  =
[(Ca^P/Ca^v - I/Vmax)]/(l - I/Vmax) is described by the 
linear regression equation = 13.75 + 0.55PSS. A
correlation coefficient of 0.706 was found (Figure 31). 
The standard error (SEM) of the intercept and slope 
were 6.2 and 0.097 respectively. Figure 32 shows the 
relationship between portasystemic shunting (PSS), as 
measured by microspheres and equation S2 = Ca1P/Calv 
(Calv - Ca-^J/Km. The relationship is described by the 
equation S2 = 11.94 + 0.49PSS. A correlation
coefficient of 0.605 was found. The standard error 
(SEM) of the intercept and slope were 7.32 and 0.11 
respectively.
Individual variations in Km and Vmax values 
presumably account for some of the discrepancies 
between portasystemic shunting, as measured by
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microspheres and that calculated from shunting 
equations and S2 . However, as shown in Table 20
there was also a systematic tendency for galactose 
shunting values in portal vein ligated rats to be lower 
than the microsphere values. This finding will be 
discussed more fully in the following discussion.
TABLE 2 0
Procedure Portasystemic Expressions for
Shunting Portasystemic Shunting
(microspheres) S^ S2
(%) (%) (%)
Mean + SEM Mean + SEM Mean + SEM
SO 1.0 ± 0.00 11.0 ± 6.0 10.0 ± 7.0
* * 
PVL 8 3 . 0 + 5 . 0  6 2 . 0 + 5 . 0  5 5 . 0 + 7 . 0
SO = Sham operated rats 
PVL = Portal vein ligated rats
* p < 0.01 galactose versus microsphere 
measurements (paired t-test)
This shows the mean + SEM portasystemic shunting 
values calculated from injection of microspheres into 
the portal vein, and from the shunting expressions S^  ^
and S2 derived from the kinetic model. Galactose 
shunting values (S-^  and S2) in portal vein ligated rats 
were significantly lower than the microsphere values.
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PORTASYSTEMIC SHUNTING CALCULATED FROM
MICROSPHERES AND GALACTOSE (S1) IN SHAM
150 OPERATED AND PORTAL VEIN LIGATED RATS
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Figure 31
This shows the relationship between 
portasystemic shunting calculated from the 
equation S = (Ca1^/Caiv - I/Vmax)/(I -I/Vmax) 
and portasystemic shunting (PSS), as measured 
by microspheres, in both sham operated and 
portal vein ligated rats. The relationship 
is described by the linear regression equation 
S^ = 13.75 + 0.55PSS. A correlation coefficient 
of 0.706 was found.
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PORTASYSTEMIC SHUNTING CALCULATED FROM
MICROSPHERES AND GALACTOSE (S2) IN SHAM
150 OPERATED AND PORTAL VEIN LIGATED RATS
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Figure 32
This shows the relationship between 
portasystemic shunting calculated from the 
equation = Calp/Ca1V - (Calv - Ca^p )/Km 
and portasystemic shunting (PSS), as measured 
by microspheres, in portal vein ligated and 
control animals. The relationship is described 
by the linear regression equation S£ = 11.94 + 
0.49PSS. A correlation coefficient of 0.605 
was found.
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GALACTOSE CLEARANCE AT DIFFERENT INTRAVENOUS INFUSION
RATES IN SHAM OPERATED AND PORTAL VEIN LIGATED RATS
By definition, hepatic clearance (Cl) is the 
volume of blood from which galactose is completely 
removed by the liver in unit time (Chapter 2). This is 
given by the elimination rate of galactose by the liver 
(V) divided by the mean concentation of galactose in 
blood (Cm),
ie. V/Cm = Cl ......................................... 7.32
Clearance would translate into liver blood flow 
(F-j^) if it was assumed that there was complete 
extraction of galactose from each ml of blood flowing 
through the liver.
Comparing equation 7.32 with equation 7.7 (E=V/F^Cm), 
it can be seen that clearance equals EF^.
ie. Cl = EFX .............  7.33
In these experiments we have measured systemic 
clearance of galactose, given by I/Calv, which we 
equate with hepatic clearance under Assumption 2 (V=I). 
Equation 7.33 can thus be rewritten,
I/Caiv = E.F-l .................................... 7.34
The mean clearance values (I/Calv) of galactose at five 
different infusion rates in sham operated and portal
vein ligated rats are shown in Table 21. Mean hepatic 
clearance values in both groups at each of the five 
infusion rates are not significantly different from 
each other (2-way ANOVA). In both groups clearance 
decreased as infusion rate increased (p<0.05), 
reflecting the decline in hepatic extraction 
efficiency.
When the mean systemic clearance values found 
in this chapter were compared to those found from the 
intraportal infusion of galactose in chapter 6, 
systemic clearance of galactose by both routes proved 
to be very similar. The mean systemic clearance value 
calculated in chapter 6 was derived from the slope of 
the galactose clearance curve and was dependent upon 
the volume of distribution (Vd). The volume of 
distribution found in a study by Keiding (1973) was 41 
percent of body weight. If this value is taken to be 
a reliable estimate, then the mean clearance values in
— imin of chapter 6 translated into 1/hr in sham 
operated and portal vein ligated rats were 0.59 and 
0.58 1/hr respectively. The equivalent translated mean 
clearance values in this chapter were 0.64 and 0.58 
1/hr in sham operated and portal vein ligated rats 
respectively. The similarity in clearance values 
calculated from the two different routes of infusion 
demonstrates the consistency of the model and the 
soundness of the methods applied.
TABLE 21
Clearance (1/kg/hr)
Infusion
Rate
PVL SO
(mg/kg/hr) Mean + SEM
25 2.156 + 0.444 2 . 808 + 0.161
50 2 . 560 + 0. 498 2 .752 + 0. 552
75 1.726 + 0. 273 2 . 582 + 0. 300
100 1. 922 + 0.311 1. 854 + 0. 194
125 1.256 + 0. 227 1.257 + 0.092
Overall Mean + SEM 2 . 005 + 0. 190 2 . 225 + 0.129
PVL = Portal vein ligated 
SO = Sham operated
This shows the mean + SEM clearance (I/Calv) 
values at five different intravenous infusion rates in 
sham operated and portal vein ligated rats. In both 
groups clearance decreases as infusion rate increases 
(p<0.05), but there was no significant difference in 
clearance between portal vein ligated and sham operated 
rats at any infusion rate (2-way ANOVA).
EXTRAHEPATIC ROUTE FOR GALACTOSE ELIMINATION
One of the fundamental assumptions underlying the 
kinetic theory described in this chapter has been the 
assumption that the liver is the major organ of 
galactose elimination. This assumption can be examined 
more fully by quantifying possible extrahepatic 
pathways for galactose elimination. Possible routes 
for extrahepatic elimination of galactose are urinary 
excretion and/or renal metabolism and erythrocyte 
metabolism. Keiding (1985) has shown that galactose 
metabolism in the erythrocytes is of no quantitative 
importance. Urinary excretion, however, proved more 
significant as an extrahepatic pathway for galactose 
removal, but was still quantitatively small, an average 
value of 9 percent of the amount galactose given was 
found by Keiding (1973).
In order to eliminated the possibility that urinary 
excretion may be quantitatively important in the 
context of this study and substantiate to some extent 
the assumption that the liver is the major organ of 
galactose elimination, the percent galactose appearing 
in urine was calculated after a two hour continuous 
infusion of galactose at rates of 75 and 125 mg/kg/hr. 
Table 22 shows the mean ± SEM percent urinary excretion 
of galactose in sham operated and portal vein ligated 
rats. At an infusion rate of 7 5 mg/kg/hr percent
urinary excretion was 1.57 + 0.29 and 0.81 + 0.46 (mean 
+ SEM) in portal vein ligated and control rats 
respectively. A mean + SEM percent urinary excretion of 
5.14 + 0.29 and 3.35 + 0.05 was found at an infusion
rate of 125 mg/kg/hr in both portal vein ligated and 
sham operated rats respectively. The values found in 
this study are quantitatively small, implying that 
extrahepatic elimination of galactose by the kidneys is 
negligible. The possible existence of alternative, as 
yet unidentified pathways for galactose elimination 
cannot be ruled out. However, at present it would 
appear that the original assumption that the liver is 
the major organ of galactose elimination is correct.
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TABLE 22
Procedure
Infusion rates (mg/kg/hr) 
75 125
Urinary excretion (%)
Mean + SEM
SO 0.81 ± 0.46 
(n=4)
3.35 ± 0.05 
(n=2)
PVL 1.57 + 0.29 
(n=5)
5.14 ± 0.29 
(n=5)
PVL = Portal vein ligated 
SO = Sham operated
This shows mean + SEM percent urinary excretion 
in sham operated and portal vein ligated rats at two 
different infusion rates.
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DISCUSSION
The purpose of the study carried out in this 
chapter was to examine whether or not poor extraction 
efficiency in sham operated rats could explain the 
failure to see any differences in systemic availability 
of galactose following oral and intraportal doses of 
galactose, as described in the previous chapter.
It has been shown that hepatic uptake of galactose by 
the hepatocyte follows Michaelis-Menten kinetics 
(Keiding et al, 1976; Keiding and Chiarantini, 1978). 
It has also been shown by Keiding and Bass (1983), that 
from the Michaelis-Menten equation, V = VmaxCm/(Km+Cm), 
a formula for extraction efficiency (E) can be 
developed, where E = l-exp[1-(Vmax-I)]/F.Km. The 
symbols I and F represent galactose infusion rate and 
hepatic liver blood flow respectively. In this 
equation, extraction efficiency of the hepatocyte is 
dependent upon the parameters Vmax, Km, and galactose 
infusion rate, all of which can be readily determined, 
and the unknown, and not readily determined parameter 
hepatic blood flow. This unknown parameter makes the 
solution of the equation rather complicated. An 
alternative and simpler approach in the intact rat is 
to apply the Michaelis-Menten equation to the liver as 
a whole. Thus V, and Vmax would represent the galactose 
elimination rate and its maximum value for the liver as
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a whole, and Km the concentration of galactose in the 
systemic circulation at which elimination is half 
maximal. By applying Michaelis-Menten type kinetics to 
the whole liver expressions of hepatic extraction 
efficiency can be derived which are more readily 
solved. Keiding (1973) has shown this approach to 
produce Km and Vmax values in reasonable agreement to 
those found for the hepatocyte (Keiding et al, 1976). 
However, the Km value for galactose in blood is 
higher, 72 mg/l (Keiding, 1973) than 'Km' calculated on 
the basis of galactose concentration in liver tissue, 
between 21.6 and 54 mg/l (Keiding et al, 1976), owing 
to the decreasing galactose concentration as the blood 
flows through the liver (Keiding, 1973) .
In this study Michaelis-Menten kinetics were applied in 
the intact rat and the self-consistency of the kinetic 
model examined by both intravenous and intraportal 
infusions in sham operated rats.
The continuous-infusion technigue used in this study 
was chosen for the following reasons. First, it 
reduces distribution phenomena of galactose and other 
metabolites in the circulatory system as well as the 
intracellular spaces of the liver. Simultaneous 
steady-state estimates of the galactose elimination 
rate and blood concentrations were ensured, and this 
facilitates the comparison of estimates.
The mathematical kinetic model (equation 7.1) assumes a
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time-independent concentration of galactose, i.e., 
dc/dt = 0 .  In all experiments in both the intraportal 
and intravenous infusions of galactose this equilibrium 
state was achieved. For these reasons the steady-state 
experiments are assumed to provide reliable estimates 
of the kinetic parameters.
The model describes the relation between the galactose 
elimination rate, V, (in this study V equals galactose 
infusion rate, I, at equilibrium), and the mean 
equilibrium systemic blood galactose concentration, Cm, 
by the Michaelis-Menten eguation. The model was tested 
by plotting systemic blood galactose concentrations 
against increasing intravenous infusions of galactose 
in sham operated rats. According to the model, the rate 
should asymptotically approach a maximum, and 
saturation kinetics should be followed. Results from 
the experiments were consistent with Michaelis-Menten 
type kinetics and the hepatic elimination of galactose 
was described kinetically by the parameters Vmax and Km 
of the model. The mean estimates of Km and Vmax in this 
study were determined with relatively small errors but 
the systemic availability of galactose at a given 
infusion rate showed significant individual 
differences. The interindividual variation includes 
probably both individual differences between the 
enzymatic reactions in different livers for galactose 
elimination and variations between experimental factors
which will be discussed later. It should also be 
pointed out that the parametrization of the model by 
Vmax and Km implies that the estimates of the 
parameters become highly correlated, and therefore 
caution should be exercised when the estimates are used 
for testing various hypotheses about the parameters.
The parameters Vmax and Km are themselves thought to 
describe one of the enzymatic steps in the metabolic 
conversion of galactose. The first step in the main 
pathway of the hepatic conversion of galactose involves 
phosphorylation to galactose-l-phosphate with
consumption of ATP by the enzyme galactokinase 
(EC.2.7.1.6). It is this practically irreversible 
galactokinase step which is considered to be rate 
limiting in the elimination of galactose by the liver 
and which the parameters Vmax and Km describe 
(Cuatrecausas and Segal, 1965; Keiding, 1973).
On comparison of the Vmax and Km values found in this 
study, 177.2 mg/kg/hr and 43.5 mg/l repectively, and 
those from studies carried out by Keiding (1973), and 
Salaspuro and Salaspuro (1968), it was found that our 
Km value was smaller and Vmax value greater. Keiding 
(1973) demostrated a Km value of 72 mg/l and both 
Salaspuro and Salaspuro (1968), and Keiding (1973) 
found Vmax values of 13.2 and 12.04 mg/lOOg/hr 
repectively. Our equivalent translated Vmax value was 
17.72 mg/lOOg/hr. The Km value is of particular
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importance since it gives us an insight into the 
dependency of hepatic extraction efficiency on 
circulating blood galactose concentrations. In this 
study the level of Km was such that the extraction 
efficiency term Km/(Km + Cm) was highly concentration 
dependent in the range 0 to 100 mg/l. Such high 
dependency on concentration in this range was not 
entirely expected since previous studies had reported 
Km values of 72 mg/l (Keiding, 1973). This level of 
dependency may in part explain why the oral/intraportal 
doses showed relatively high systemic availability in 
sham operated rats. In this chapter we look at 
equilibrium blood galactose concentrations. It should 
be borne in mind that an oral dose may give rise to 
high transient concentrations in the portal vein, hence 
giving low extraction efficiency. The results also 
suggest high variability in individual Km and Vmax 
values, which would further tend to mask differences 
between groups with respect to the systemic 
availability of oral and intraportal doses when the 
liver is near saturation.
In this kinetic model it would seem that galactose 
elimination* kinetics are independent of liver blood 
flow (F-j^ ) . The apparent absence of explicit dependence 
on liver blood flow is misleading, as galactose 
elimination kinetics depends on hepatic blood flow 
through equation 7.10, Vmax/Km.Fj^ = Eo, where Eo is the
hepatic extraction efficiency of galactose at low 
systemic galactose concentrations. This dependence of 
galactose elimination kinetics on hepatic blood flow is 
described through the sinusoidal perfusion theory 
(Keiding and Chiarantini, 1978). If blood flow varies, 
for example through a change in sinusoidal blood 
velocity without affecting the number of sinusoids 
perfused this is unlikely to affect Vmax and Km will 
vary inversely with flow. Therefore an increasing flow 
rate throught the liver will reduce hepatic transit 
time and so consequently reduce Km, thus systemic blood 
galactose concentration will increase as less galactose 
is extrated by the liver. The reverse will occur if 
liver blood flow is reduced. Alternatively, if flow 
varies through a change in the number of perfused 
sinusoids without changing blood velocity it will be 
Vmax rather than Km that changes.
A possible explanation of differences in Km and Vmax 
values in our study to those found by Keiding (1973) 
and Salaspuro and Salaspuro (1968) can perhaps be 
explained by the effect of anaesthesia and the type of 
anaesthesic used, the type of surgery applied, and 
animals differences, such as animal strain and sex on 
hepatic blood flow. Salaspuro and Salaspuro (1968) 
found that the elimination of galactose was temporarily 
blocked by penthotal anaesthesia, and thus subsequently 
in all experiments used unanesthetised rats. Keiding
(1973), however applying the same anaesthetic did not 
find galactose elimination to be affected. A
systematic influence of anaesthesia on the results 
obtained, however cannot be excluded. Further, it was 
assumed in our study that surgical trauma, such as 
cannulation of the portal vein was of minor importance. 
The self-consistency of the theory was tested by 
comparing the extraction efficieny term Km/(Km+Cm), 
with alternative expressions of extraction efficiency 
derived from the intraportal and intravenous infusions 
of galactose, whose solution did not depend on the 
parameter Km. The relationship found between these 
expressions were linear and close to the line of 
identity. This finding thus reinforces the validity of 
the theory and our approach to applying Michaelis- 
Menten kinetics to the whole organ.
From the intraportal infusion of galactose two 
expressions for shunting were derived (equations 7.30 
and 7.31). Using the mean values of Vmax and Km both 
equations can be solved to give portasystemic shunting 
values for each animal individually, which in turn can 
be compared with the independent assessment of 
portasystemic shunting from injected microspheres. In 
sham operated rats all three methods compared 
favourably. However, in portal vein ligated rats there 
was a tendency towards the shunting expressions derived 
from the kinetic model to underestimate the degree of
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portasystemic shunting as compared to that measured by 
injected microspheres. The reason for this is unclear 
but it may well be that injected microspheres are not
as a reliable indicator of the magnitude of
portasystemic shunting as previously supposed. 
Microspheres enter portal venous blood in the physical 
form of radioactive particles whereas galactose enters 
the circulation as a solution. This difference in the 
physical state between galactose and microspheres may 
in part contribute to the observed differences in their 
assessment of the magnitude of portasystemic shuning. 
Further, a particular source of measurement error which 
is commonly encountered with radioactive microspheres 
is that arising from inadequate mixing of injected
microspheres (Buckberg et al, 1971). If this occurs, 
streamlining of microspheres with blood will prevail 
and produce inaccurate assessment of the magnitude of 
portasystemic shunting. Furthermore, if indeed portal 
vein ligated and sham operated rats are not so 
different in the magnitude of portasystemic shunting as 
suggested by the galactose expressions for 
portasystemic shunting, then the systemic availability 
of galactose would in itself be less differentiated
between control and portal hypertensive rats following 
an oral dose of galactose.
One of the main assumptions in this chapter has been 
that the liver is the major organ of galactose
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extraction. This appears to be a reasonable assumption 
since many investigators have shown this to be the case 
(Roe and Cowgill, 1935; Goresky et al, 1973). Further, 
alternative routes of galactose elimination, such as 
urinary excretion, renal metabolism and erythrocyte 
metabolism have been shown to be negligible (Keiding, 
1973; McNamara and Segal, 1972; Keiding, 1985). In this 
study we examined urinary excretion of galactose, which 
proved to be very low at the concentrations attained. 
However, we cannot rule out the possibility that other 
metabolic pathways for galactose elimination may exist, 
but the good approximation between extraction 
efficiency as calculated from Ca1P/Calv and extraction 
efficiency as calculated from the characteristics of 
the intravenous infusion rate versus concentration 
curve suggests that such extrahepatic extraction is 
small. This is because the former is based on a 
comparison of intraportal and intravenous infusions 
which will clearly depend on hepatic extraction 
(irrespective of other pathways), whereas the latter is 
dependent on systemic clearance which is influenced by 
both hepatic and extrahepatic elimination rates.
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CONCLUSIONS
Oral and intravenous administration of galactose 
is a non-invasive, physiological method of measuring 
the magnitude of portasystemic shunting occuring in 
portal hypertension. The technique applied was a 
considerable improvement on earlier methods for 
assessing the magnitude of portasystemic shunting, 
avoiding invasive and time consuming measurements and 
overcoming measurement inaccuracies. The technique was 
easily comprehensible, readily applicable, safe and 
well accepted by the patients.
The galactose dehydrogenase enzyme assay coupled with 
fluorescence spectrophotometry was well able to measure 
the systemic galactose concentrations encountered in 
this study. The enzyme assay was simple, accurate and 
easy to use.
The assumptions underlying the galactose measurement 
technique were tested independently in control 
volunteers from the University Department of Surgery, 
Glasgow Royal Infirmary. The prerequisite of adherance 
of galactose elimination to first-order kinetics at the 
intravenous infusion rates used in this study was 
followed in all control volunteers studied. The oral 
dose of galactose chosen was consistent with high 
extraction efficiency in the normal liver and thus 
effectively complete clearance from blood on first pass
through the normal liver following absorption from the 
small intestine.
Data from the patient study carried out in this thesis 
showed there was a significant difference in the 
systemic availability of galactose between control 
patients and patients with portal hypertension and/or 
liver disease (p < 0.005). No independent method for 
quantitation of the magnitude of portasystemic shunting 
was performed on patients in this study as alternative 
methods required surgical access to the splanchnic 
blood vessels (Groszmann et al, 1972) and it was not 
considered ethically justified to perform such 
vaildatitory measurements on the patients. However, 
portasystemic shunting values from this study are in 
good agreement with those found in other studies 
(Groszmann et al, 1972; Okuda et al, 1977).
The application of the technique in the prehepatic rat 
model of portal hypertension allowed the measurement of 
the magnitude of portaystemic shunting to be assessed 
objectively, in that independent measurements of 
portasystemic shunting could be performed using a 
radioactive microsphere technique.
The initial failure to show a difference in the 
systemic availability of galactose between control and 
portal hypertensive rats was attributed in the main to 
the erratic and incomplete absorption of galactose from 
the gastrointestinal tract. The retention of
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galactose in the gastrointestinal tract does not appear 
to occur in man, as evidenced by the rapid rise and 
peak of systemic galactose concentrations approximately 
10 to 20 minutes following oral administration of 
galactose and the finding that a systemic availability 
of galactose of close to 100 percent was achieved in 
several portal hypertensive patients. The possibility 
of retention in a minority of patients however, cannot 
be excluded but it is difficult to test definitively. 
The accuracy of the technique in this animal model, in 
contrast to man, was further compromised when a 
more comprehensive study into the kinetics of hepatic 
galactose elimination in the rat model, by direct 
infusion of galactose into the portal vein, showed the 
hepatic extraction efficiency for galactose to be 
highly dependent on circulating blood galactose 
concentrations. Hepatic galactose extraction can be 
described by Michaelis-Menten kinetics in which the 
kinetic parameters Vmax and Km repesent the maximum 
galactose elimination rate and the galactose 
concentration at which hepatic galactose elimination is 
half maximal respectively. In this study the kinetic 
parameter Km, was found to have a value of 43.5 mg/1. 
By contrast in human volunteers, systemic galactose 
clearance was found to be independent of concentration 
up to levels in the region of 42 mg/1. The variation in 
the values of the kinetic parameters between animals
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make quantitation of the magnitude of portasystemic 
shunting by galactose in rats inaccurate at the 
individual level, but despite this finding a highly 
significant correlation between the systemic 
availability of intraportally administered galactose in 
rats and portasystemic shunting, as measured from the 
injection of radiolabelled microspheres was found.
It is unclear why there is a difference between rats 
and humans with respect to both absorption of oral 
galactose from the gastrointestinal tract and hepatic 
elimination of galactose. It is possible that the 
difference is a result of species difference and the 
fact that all animals were anaesthetised throughout the 
galactose experiments. Despite this somewhat 
disappointing contrast, the results obtained in 
patients with liver disease and/or portal hypertension 
are compatible with expectations.
To date there is no fixed quantitative definition of 
portasystemic shunting. Indeed quantitation of 
anatomical shunting varies according to the vascular 
bed studied (Groszmann et al, 1972). The fact that 
both functional and anatomical shunting have been 
examined in this study may further compound the 
problem. Therefore, whether the systemic availability 
of galactose should be regarded as a measure of 
portasystemic shunting is largely a matter of 
definition.
The potential clinical usefulness of the method 
described in this thesis is likely to rest on the 
possibility that other gut-derived agents such as 
hormones, nutrients and drugs behave as, and share 
their fate with galactose. An increasing systemic 
availability of galactose should therefore parallel the 
appearance and progression of clinical problems 
associated with portal hypertension. The most likely 
area for future studies would be in hepatic 
encephalopathy, the aetiology of which has been 
associated with the effects of circulatory changes in 
portal hypertension (Phear et al, 1955). This line of 
future investigation, however, can only be explored 
experimentally.
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